Document:

<PAGE>
                                                                     EXHIBIT 4.2

                     SERIES A REGISTRATION RIGHTS AGREEMENT

         This Registration Rights Agreement (the "Agreement") is executed by
BioNumerik Pharmaceuticals, Inc., a Texas corporation (the "Company").

                                  WITNESSETH:

         WHEREAS, the persons identified on Schedule A hereto (the "Purchasers")
have been granted registration rights in connection with their purchase of
shares of the Company's Preferred Stock (as defined herein).

         WHEREAS, the Company is executing this Agreement to set forth in a
separate document the registration rights granted to the Purchasers as part of
the Preferred Stock Purchase Agreement pursuant to which the Purchasers acquired
the Company's Preferred Stock.

         NOW, THEREFORE, the Company hereby confirms its grant of registration
rights to the Purchasers, on the terms and conditions described herein:

         1. CERTAIN DEFINITIONS. As used in this Agreement, the following terms
shall have the following respective meanings:

         "Commission" means the Securities and Exchange Commission or any other
federal agency at the time administering the Securities Act.

         "Common Stock" means the Common Stock, par value $.01 per share, of the
Company.

         "Conversion Shares" means the shares of Common Stock issued and
issuable upon conversion of the Preferred Stock issued to the Purchasers.

         "Exchange Act" means the Securities Exchange Act of 1934, as amended,
or any similar federal statute and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.

         "Holders" means the Purchasers and any holder of Registrable Securities
to whom the registration rights conferred by this Agreement have been
transferred in compliance with Section 2.10 hereof.

         "Preferred Stock" means the Series A Convertible Preferred Stock, par
value $.01 per share, of the Company.

         "Registrable Securities" means (i) the Conversion Shares and (ii) any
Common Stock issued as a dividend or other distribution with respect to or in
exchange for or in replacement of the Conversion Shares or the Preferred Stock
issued to the Purchasers, provided, however, that Registrable

<PAGE>

Securities shall not include any shares of Common Stock which have previously
been registered or which have been sold pursuant to Rule 144.

         The terms "register," "registered" and "registration" refer to a
registration effected by preparing and filing a registration statement in
compliance with the Securities Act, and the declaration or ordering of the
effectiveness of such registration statement.

         "Rule 144" means Rule 144 as promulgated by the Commission under the
Securities Act, as such Rule may be amended from time to time, or any similar
successor rule that may be promulgated by the Commission.

         "Series B Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
B Convertible Preferred Stock.

         "Series C Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
C Convertible Preferred Stock.

         "Series D Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
D Convertible Preferred Stock.

         "Series E Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
E Convertible Preferred Stock.

         "Series F Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
F Convertible Preferred Stock.

         "Series G Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
G Convertible Preferred Stock.

         "Series H Persons" means those persons entitled to registration rights
pursuant to registration rights granted by the Company to holders of its Series
H Convertible Preferred Stock.

         "Securities Act" means the Securities Act of 1933, as amended, or any
similar federal statute and the rules and regulations of the Commission
thereunder, all as the same shall be in effect at the time.

         For purposes of the definition of "Holder" above, holders of Preferred
Stock shall be deemed to be the holders of Registrable Securities issuable upon
conversion or exercise thereof; and for the purpose of calculating any
percentage of Registrable Securities, the calculation shall be made as if the
Preferred Stock had been fully converted or exercised.

                                       2
<PAGE>

         2. REGISTRATION OF REGISTRABLE SECURITIES.

         2.1 Registration on Request.

         (a) Request. Subject to the limitations provided herein, commencing on
January 31, 1998, or on the first anniversary of the effective date of the
Company's first registration statement under the Securities Act, whichever shall
first occur, until the fifth anniversary of the effective date of the Company's
first registration statement under the Securities Act, upon the written request
(specifying that it is being made pursuant to this Section 2.1) of Holders of an
aggregate of at least 400,000 shares (appropriately adjusted for subdivisions
and combinations of shares of Common Stock and dividends on Common Stock payable
in shares of Common Stock hereafter) of Registrable Securities, requesting that
the Company effect the registration under the Securities Act of at least such
number of Registrable Securities, and specifying (x) the intended method of
disposition thereof, (y) whether or not such requested registration is to be an
underwritten offering, and (z) the price range (net of underwriting discounts
and commissions) acceptable to such Holder or Holders to be received for such
Registrable Securities, the Company will within 10 business days after the
Company receives such written request give written notice of such requested
registration to all other Holders of Registrable Securities and thereupon the
Company will use reasonable efforts to effect the registration under the
Securities Act of:

         (i) the Registrable Securities which the Company has been so requested
    to register by such Holders, and

         (ii) all other Registrable Securities which the Company has been
    requested to register by the other Holders thereof by written request given
    to the Company within 15 days after the giving of such written notice by the
    Company (which request shall specify the same information called for by the
    original request to effect registration described above), all to the extent
    requisite to permit the disposition (in accordance with Section 2.1(b)
    hereof) of the Registrable Securities so to be registered.

         (b) Method of Distribution. The Holders of 51% of the Registrable
Securities to be included in such registration statement shall determine the
method of distribution of the Registrable Securities so included; provided,
however, that if no agreement of Holders of 51% or more of the Registrable
Securities to be included in such registration statement is obtained, then if
Holders of more than 30% of the Registrable Securities to be included in such
registration statement request an underwritten public offering, an underwritten
public offering shall be the method of distribution with other methods permitted
to the extent the managing underwriter for such offering, in its sole
discretion, agrees to other methods of distribution being covered by such
registration statement.

         (c) Registration of Other Securities. Whenever the Company shall effect
a registration pursuant to this Section 2.1 in connection with an underwritten
offering, no securities other than Registrable Securities shall be included
among the securities covered by such registration unless (i) the managing
underwriter of such offering shall have advised each Holder of Registrable
Securities to be covered by such registration in writing that the inclusion of
such other securities would not adversely affect such offering or (ii) the
Holders of more than 51% or more of all

                                       3
<PAGE>

Registrable Securities to be covered by such registration shall have consented
in writing to the inclusion of such other securities. The rights of Holders
hereunder to include the Registrable Securities requested to be registered by
such Holders in such registration shall be prior to the right of Series B
Persons, Series C Persons, Series D Persons, Series E Persons, Series F Persons,
Series G Persons, Series H Persons and persons holding securities obtained
through the exercise of warrants issued to certain placement agents and finders
in connection with the sale of the Company's Series E Convertible Preferred
Stock (the "Series E Warrant Purchasers") requesting registration pursuant to
the registration rights granted by the Company to such Series B Persons, Series
C Persons, Series D Persons, Series E Persons, Series F Persons, Series G
Persons, Series H Persons, and Series E Warrant Purchasers (whether pursuant to
"demand" or "piggyback" registration rights) to include securities in such
registration.

         (d) Registration Statement Form. Registrations under this Section 2.1
shall be on such appropriate registration form of the Commission (i) as shall be
selected by the Company, and (ii) as shall permit the disposition of such
Registrable Securities in accordance with the method or methods of disposition
selected pursuant to Section 2.1(b) hereof.

         (e) Expenses. Except as otherwise provided in this Section 2.1(e) or in
Section 2.1(i), the Company shall bear all expenses incurred in connection with
two effective registrations pursuant to Section 2.1 hereof and each registration
pursuant to Section 2.2 hereof (excluding in each case underwriting discounts
and commissions applicable to Registrable Securities), including, without
limitation, in each case: (i) all registration, filing and National Association
of Securities Dealers fees; (ii) all fees and expenses of complying with
securities or blue sky laws; (iii) all word processing, duplicating and printing
expenses, messenger, delivery and shipping expenses; (iv) the fees and
disbursements of the accountants and counsel for the Company including the
expenses of any special audits or "cold comfort" letters or opinions required by
or incident to such registrations; (v) the fees and disbursements of the
accountants and counsel for the Company for services rendered in connection with
inclusion of Registrable Securities in the registration; provided, however, that
if the accountants or the counsel for the Company refuse or decline to undertake
such representation because of an actual or perceived conflict of interest or
otherwise, then the Company shall bear the reasonable fees and disbursements of
one firm of counsel and one firm of accountants (as appropriate) retained by the
Holders of such Registrable Securities; (vi) premiums and other costs of
policies of insurance maintained for the benefit of the Company against
liabilities arising out of the public offering of the Registrable Securities;
(vii) any fees and disbursements of underwriters customarily paid by issuers or
sellers of securities, but excluding underwriting discounts and commissions, if
any. In all cases, each Holder of Registrable Securities shall pay the
underwriting discounts and commissions applicable to the securities sold by such
Holder.

         (f) Effective Registration Statement. A registration requested pursuant
to this Section 2.1 shall not be deemed to have been effected (i) unless a
registration statement with respect thereto has become effective (unless a
substantial cause of the failure of such registration statement to become
effective shall be attributable to one or more Holders of Registrable Securities
whose securities were to have been included in such registration statement),
(ii) if after it has become effective, such registration is interfered with by
any stop order, injunction or other order or requirement of the Commission or
other governmental agency or court for any reason, resulting in a failure to
consummate the offering of Registrable Securities offered thereby, (iii) if
after a registration statement with respect thereto has become effective, the
offering of Registrable Securities offered

                                       4
<PAGE>

thereby is not consummated due to factors beyond the control of the Holders of
such Registrable Securities, including without limitation in the context of a
proposed firm commitment underwriting, the fact that the underwriters have
advised the Holders of such Registrable Securities that such Registrable
Securities cannot be sold at a net price equal to or above the net price
specified in the notice to the Company at the time of the request, or (iv) if
the conditions to closing specified in the purchase agreement or underwriting
agreement entered into in connection with such registration are not satisfied
(unless a substantial cause of such conditions to closing not being satisfied
shall be attributable to one or more Holders of Registrable Securities whose
Registrable Securities were included in such registration statement).

         (g) Selection of Underwriters. If a requested registration pursuant to
this Section 2.1 involves an underwritten offering, the underwriter or
underwriters thereof shall be selected by the Company with the approval of the
Holders of at least 50% of the Registrable Securities to be so registered, which
approval will not be unreasonably withheld.

         (h) Priority in Requested Registrations. If a requested registration
pursuant to this Section 2.1 involves an underwritten offering, and the managing
underwriter shall advise the Company in writing (with a copy to each Holder
requesting registration) that, in its opinion, the number of securities
requested to be included in such registration exceeds the number which can be
sold in such offering within a price range acceptable to the Holders of more
than 50% of the Registrable Securities requested to be included in such
registration, then the Registrable Securities requested to be registered
pursuant to this Section 2.1 shall be reduced to the number of Registrable
Securities which the Company is so advised can be sold in (or during the time
of) such offering by decreasing the Registrable Securities requested to be
registered (pro rata among the Holders requesting such registration on the basis
of the percentage of the Registrable Securities held by such Holder immediately
prior to the filing of the registration statement with respect to such
registration).

         (i) Form S-3. Notwithstanding the other provisions of this Section 2.1,
until the fifth anniversary of the effective date of the Company's first
registration statement under the Securities Act, the Company shall be required
by this Section 2.1 to effect, and bear all expenses (as determined pursuant to
Section 2.1(e) hereof) incurred in connection with, up to four registrations on
Form S-3 (or any successor similar form) of Registrable Securities during such
period, provided that the Registrable Securities to be registered thereon are
expected to have an aggregate disposition price (before deductions for
underwriting discounts and commissions) of at least $500,000.

         (j) Notwithstanding anything to the contrary contained herein, the
Company shall not be obligated to prepare and file any other Registration
Statement pursuant to this Section 2.1 within 180 days of the consummation of an
underwritten public offering of Common Stock pursuant to a registration
statement filed under the Securities Act.

         2.2 Incidental Registration.

         (a) Right to Include Registrable Securities. If the Company at any time
prior to the fifth anniversary of the effective date of the Company's first
registration statement under the Securities Act proposes to register any of its
securities under the Securities Act (other than by a registration on Form S-8,
S-4 or any successor similar forms or any other form not available for
registering the

                                       5
<PAGE>

Registrable Securities for sale to the public and other than pursuant to Section
2.1 hereof), whether or not for sale for its own account, it will each such
time, at least 15 days prior to filing the registration statement, give written
notice to all Holders of Registrable Securities of its intention to do so. Upon
the written request of Holders of an aggregate of at least 100,000 shares
(appropriately adjusted for subdivisions and combinations of shares of Common
Stock and dividends on Common Stock payable in shares of Common Stock hereafter)
of Registrable Securities, made within 15 days after the receipt of any such
notice (which request shall specify the Registrable Securities intended to be
disposed of by each such Holder and the intended method of disposition thereof),
the Company will use reasonable efforts to effect the registration under the
Securities Act of all Registrable Securities which the Company has been so
requested to register by the Holders of such Registrable Securities, to the
extent requisite to permit the disposition (determined pursuant to the
provisions of Section 2.1(b) hereof) of the Registrable Securities so to be
registered, provided that if, at any time after giving written notice of its
intention to register any securities and prior to the effective date of the
registration statement filed in connection with such registration, the Company
shall determine for any reason not to register or to delay registration of such
securities, the Company may, at its election, give written notice of such
determination to each Holder of Registrable Securities and, thereupon, (i) in
the case of a determination not to register, shall be relieved of its obligation
to register any Registrable Securities in connection with such registration (but
not from its obligation to pay expenses in accordance with Section 2.1(e)
hereof), without prejudice, however, to the rights of any Holder or Holders of
Registrable Securities entitled to do so to request that such registration be
effected as a registration under Section 2.1 hereof, and (ii) in the case of a
determination to delay registering, shall be permitted to delay registering any
Registrable Securities being registered pursuant to this Section 2.2(a), for the
same period as the delay in registering such other securities. No registration
effected under this Section 2.2 shall relieve the Company of its obligation to
effect any registration upon request under Section 2.1 hereof.

         (b) Priority in Incidental Registrations. If (i) a registration
pursuant to this Section 2.2 involves an underwritten offering of the securities
so being registered, whether or not for sale for the account of the Company, to
be distributed (on a firm commitment basis) by or through one or more
underwriters of recognized standing, whether or not the Registrable Securities
so requested to be registered for sale for the account of Holders of Registrable
Securities are also to be included in such underwritten offering, and (ii) the
managing underwriter of such underwritten offering shall inform the Company and
the Holders of the Registrable Securities requesting such registration by letter
of its belief that the number of securities requested to be included in such
registration exceeds the number which can be sold in (or during the time of)
such offering, then the Company may include in such offering all securities
proposed by the Company to be sold for its own account and may decrease the
number of Registrable Securities and other securities of the Company that
persons have requested to be included in such registration by (a) first
decreasing the securities requested to be included in such registration other
than Registrable Securities (pro rata among the persons requesting such
registration on the basis of the number of shares of such securities held by
such person immediately prior to the filing of the registration statement with
respect to such registration) and (b) then, to the extent necessary, decreasing
the Registrable Securities requested to be registered (pro rata among the
Holders requesting such registration on the basis of the percentage of the
Registrable Securities held by such Holders immediately prior to the filing of
the registration statement with respect to such registration).

         2.3 Registration Procedures. If and whenever the Company is required to
use reasonable efforts to effect the registration of any Registrable Securities
under the Securities Act as provided in

                                       6
<PAGE>

Sections 2.1 and 2.2 hereof, the Company will, subject to the limitations
provided herein, as expeditiously as possible:

         (a) prepare and (as soon thereafter as possible or in any event no
    later than 60 days after the end of the period within which requests for
    registration may be given to the Company or such longer period as the
    Company shall in good faith require to produce the financial statements
    required in connection with such registration) file with the Commission the
    requisite registration statement to effect such registration and thereafter
    use reasonable efforts to cause such registration statement to become
    effective, provided that the Company may discontinue any registration of its
    securities which are not Registrable Securities (and, under the
    circumstances specified in Section 2.2(a) hereof, its securities which are
    Registrable Securities) at any time prior to the effective date of the
    registration statement relating thereto;

         (b) prepare and file with the Commission such amendments and
    supplements to such registration statement and the prospectus used in
    connection therewith as may be necessary to keep such registration statement
    effective and to comply with the provisions of the Securities Act with
    respect to the disposition of all securities covered by such registration
    statement until such time as all of such securities have been disposed of in
    accordance with the intended methods of disposition by the seller or sellers
    thereof set forth in such registration statement; provided, however, that
    the Company shall not in any event be required to keep the registration
    statement effective for a period of more than three months after such
    registration statement becomes effective;

         (c) furnish to each seller of Registrable Securities covered by such
    registration statement such number of conformed copies of such registration
    statement and of each such amendment and supplement thereto (in each case
    including all exhibits), such number of copies of the prospectus contained
    in such registration statement (including each preliminary prospectus and
    any summary prospectus) and any other prospectus filed under Rule 424 under
    the Securities Act, and such other documents, as such seller may reasonably
    request;

         (d) use reasonable efforts to register or qualify all Registrable
    Securities and other securities covered by such registration statement under
    such other securities or blue sky laws of such jurisdictions as each seller
    thereof shall reasonably request, to keep such registration or qualification
    in effect for so long as such registration statement remains in effect
    (provided, however, that the Company shall not in any event be required to
    keep such registration or qualification in effect for a period of more than
    three months after such registration or qualification becomes effective),
    and take any other action which may be reasonably necessary or advisable to
    enable such seller to consummate the disposition in such jurisdictions of
    the securities owned by such seller, except that the Company shall not for
    any such purpose be required to qualify generally to do business as a
    foreign corporation in any jurisdiction wherein it would not but for the
    requirements of this subdivision (d) be obligated to be so qualified or to
    consent to general service of process in any such jurisdiction;

         (e) use reasonable efforts to cause all Registrable Securities covered
    by such registration statement to be registered with or approved by such
    other United States federal or state governmental agencies or authorities as
    may be necessary to enable the seller or sellers thereof to consummate the
    disposition of such Registrable Securities;

                                       7
<PAGE>

         (f) furnish to each seller of Registrable Securities a copy, or, upon
    request, a signed counterpart, addressed to such seller (and the
    underwriters, if any) of

                  (i) an opinion of counsel for the Company, dated the effective
         date of such registration statement (or, if such registration includes
         an underwritten public offering, dated the date of the closing under
         the underwriting agreement), and

                  (ii) a "comfort" letter addressed to the underwriters, dated
         the effective date of such registration statement (or, if such
         registration includes an underwritten public offering, dated the date
         of the closing under the underwriting agreement), signed by the
         independent public accountants who have audited the Company's financial
         statements included in such registration statement, covering
         substantially the same matters with respect to such registration
         statement (and the prospectus included therein) and, in the case of the
         accountants' letter, with respect to events subsequent to the date of
         such financial statements, as are customarily covered in opinions of
         issuer's counsel and in accountants' letters delivered to the
         underwriters in underwritten public offerings of securities and, in the
         case of the accountants' letter, such other financial matters, and, in
         the case of the legal opinion such other legal matters, as such seller
         or such Holder (or the underwriters, if any) may reasonably request;

         (g) notify each seller of Registrable Securities covered by such
registration statement, at any time when a prospectus relating thereto is
required to be delivered under the Securities Act, upon discovery that, or upon
the happening of any event as a result of which, the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state any material fact required to be stated therein
or necessary to make the statements therein not misleading in the light of the
circumstances under which they were made, and at the request of any such seller,
prepare and furnish to such seller a reasonable number of copies of a supplement
to or an amendment of such prospectus as may be necessary so that, as thereafter
delivered to the purchasers of such securities, such prospectus shall not
include an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not
misleading in the light of the circumstances under which they were made;

         (h) otherwise use reasonable efforts to comply with all applicable
rules and regulations of the Commission, and make available to its security
holders, as soon as reasonably practicable, an earnings statement covering the
period of at least twelve months beginning with the first full calendar month
after the effective date of such registration statement, which earnings
statement shall satisfy the provisions of Section 11(a) of the Securities Act,
and will furnish to each such seller, upon request of such seller, prior to the
filing thereof a copy of any amendment or supplement to such registration
statement or prospectus and shall not file any such supplement or amendment if
such seller shall have delivered to the Company an opinion of counsel that such
amendment or supplement does not comply in all material respects with the
requirements of the Securities Act or of the rules or regulations thereunder;

                                       8
<PAGE>

         (i) provide and cause to be maintained a transfer agent for all
    Registrable Securities covered by such registration statement from and after
    a date not later than the effective date of such registration statement;

         (j) use reasonable efforts to list all Registrable Securities covered
    by such registration statement on any securities exchange on which the
    Common Stock is then listed; and

         (k) refrain from making any sale or distribution of its equity
    securities, except pursuant to any employee stock option or stock purchase
    plan or other employee benefit plan and any preexisting agreement for the
    sale of such securities, for at least 90 days after the closing of the
    public offering pursuant to such registration.

         It shall be a condition precedent to the obligations of the Company to
take any action with respect to registering a Holder's Registrable Securities
pursuant to this Section 2.3 that such seller of Registrable Securities as to
which any registration is being effected furnish the Company in writing such
information regarding such seller, the Registrable Securities and other
securities of the Company held by such seller, and the distribution of such
securities as the Company may from time to time reasonably request in writing.
If a Holder refuses to provide the Company with any of such information on the
grounds that it is not necessary to include such information in the registration
statement, the Company may exclude such Holder's Registrable Securities from the
registration statement if the Company provides such Holder with an opinion of
counsel to the effect that such information must be included in the registration
statement and such Holder thereafter continues to withhold such information. The
deletion of such Holder's Registrable Securities from a registration statement
shall not affect the registration of the other Registrable Securities to be
included in such registration statement.

         Each Holder of Registrable Securities agrees by acquisition of such
Registrable Securities that upon receipt of any notice from the Company of the
happening of any event of the kind described in Section 2.3(g), such Holder will
forthwith discontinue such Holder's disposition of Registrable Securities
pursuant to the registration statement relating to such Registrable Securities
until such Holder's receipt of the copies of the supplemented or amended
prospectus contemplated by Section 2.3(g) and, if so directed by the Company,
will deliver to the Company (at the Company's expense) all copies, other than
permanent file copies then in such Holder's possession, of the prospectus
relating to such Registrable Securities current at the time of receipt of such
notice.

         2.4 Underwritten Offerings.

         (a) Requested Underwritten Offerings. If requested by the underwriters
for any underwritten offering of Registrable Securities pursuant to a
registration requested under Section 2.1 hereof, the Company will enter into an
underwriting agreement with such underwriters for such offering, the portions of
such agreement that relate to Holders of Registrable Securities being registered
to be reasonably satisfactory in substance and form to each Holder of
Registrable Securities being registered and to contain such representations and
warranties by the Company and such other terms as are generally prevailing in
agreements of this type, including, without limitation, indemnities
substantially to the effect and to the extent provided in Section 2.6 hereof.
Each such Holder of Registrable Securities will cooperate with the Company in
the negotiation of the underwriting agreement and will give consideration to the
reasonable requests of the Company regarding the form

                                       9
<PAGE>

thereof, provided that nothing herein contained shall diminish the foregoing
obligations of the Company. If requested by the underwriters of any underwritten
offering pursuant to a registration under Section 2.1 hereof, each Holder of
Registrable Securities agrees to enter into an agreement with such underwriters
not to sell his or its shares of stock in the Company for a period of time (not
to exceed 180 days) after the effectiveness of a registration statement equal to
the period of time which the sellers of securities in such registration have
agreed not to sell their shares after the effectiveness of such registration
statement. The Holders of Registrable Securities to be distributed by such
underwriters shall be parties to such underwriting agreement. Any such Holder
shall not be required to make any representations or warranties to or agreements
with the Company or the underwriters other than representations, warranties or
agreements regarding such Holder, such Holder's Registrable Securities and other
securities of the Company, such Holder's intended method of distribution, and
any representations, warranties or agreements required by law.

         (b) Incidental Underwritten Offerings. If the Company at any time
proposes to register any of its securities under the Securities Act as
contemplated by Section 2.2 hereof and such securities are to be distributed by
or through one or more underwriters, the Company will, if requested by any
Holder of Registrable Securities as provided in Section 2.2 hereof and subject
to the provisions of Section 2.2(b) hereof, arrange for such underwriters to
include all the Registrable Securities to be offered and sold by such Holder
owning the securities to be distributed by such underwriters. In such event, the
Holders of Registrable Securities to be distributed by such underwriters shall
be parties to the underwriting agreement between the Company and such
underwriters. Any such Holder shall not be required to make any representations
or warranties to or agreements with the Company or the underwriters other than
representations, warranties or agreements regarding such Holder, such Holder's
Registrable Securities or other securities of the Company, such Holder's
intended method of distribution and any representations, warranties or
agreements required by law.

         2.5 Preparation; Reasonable Investigation. In connection with the
preparation and filing of each registration statement under the Securities Act
pursuant to this Agreement, the Company will give the Holders of Registrable
Securities registered under such registration statement, their underwriters, if
any, and one counsel or firm of counsel and one accountant or firm of
accountants representing all the Holders of Registrable Securities to be
registered under such registration statement, the opportunity to participate in
the preparation of such registration statement, each prospectus included therein
or filed with the Commission, and each amendment thereof or supplement thereto,
and will give each of them such access to its books and records and such
opportunities to discuss the business of the Company with its officers and the
independent public accountants who have certified its financial statements as
shall be necessary, in the opinion of such Holders' and such underwriters'
respective counsel, to conduct a reasonable investigation within the meaning of
the Securities Act.

         2.6 Indemnification.

         (a) Indemnification by the Company. In the event any Registrable
Securities are included in a registration statement under this Section 2, to the
extent permitted by law, the Company will, and hereby does, indemnify and hold
harmless the seller of any Registrable Securities covered by such registration
statement, its directors and officers, each other person who participates as an
underwriter in the offering or sale of such securities and each other person, if
any, who controls such seller or any such underwriter within the meaning of the
Securities Act, against any losses, claims,

                                       10
<PAGE>

damages or liabilities, joint or several, to which such seller or any such
director or officer or underwriter or controlling person may become subject
under the Securities Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions or proceedings, whether commenced or threatened, in
respect thereof) arise out of or are based upon any untrue statement or alleged
untrue statement of any material fact contained in any registration statement
under which such securities were registered under the Securities Act, any
preliminary prospectus, final prospectus or summary prospectus contained
therein, or any amendment or supplement thereto, or any omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and the Company will
reimburse such seller and each such director, officer, underwriter and
controlling person for any legal or any other expenses reasonably incurred by
them in connection with investigating or defending any such loss, claim,
liability, action or proceeding; provided that the Company shall not be liable
in any such case to the extent that any such loss, claim, damage, liability (or
action or proceeding in respect thereof) or expense arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged
omission made in such registration statement, any such preliminary prospectus,
final prospectus, summary prospectus, amendment or supplement in reliance upon
and in conformity with written information furnished to the Company by such
seller expressly for use in the preparation thereof, and provided further that
the Company shall not be liable to any person who participates as an underwriter
in the offering or sale of Registrable Securities or any other person, if any,
who controls such underwriter within the meaning of the Securities Act, in any
such case to the extent that any such loss, claim, damage, liability (or action
or proceeding in respect thereof) or expense arises out of such person's failure
to send or give a copy of the final prospectus, as the same may be then
supplemented or amended, to the person asserting an untrue statement or alleged
untrue statement or omission or alleged omission at or prior to the written
confirmation of the sale of the Registrable Securities to such person if such
statement or omission was corrected in such final prospectus. Such indemnity
shall remain in full force and effect regardless of any investigation made by or
on behalf of such seller or any such director, officer, underwriter or
controlling person and shall survive the transfer of such securities by such
seller.

         (b) Indemnification by the Sellers. The Company may require, as a
condition to including any Registrable Securities in any registration statement
filed pursuant to Section 2.3 hereof, that the Company shall have received an
undertaking satisfactory to it from the prospective seller of such securities,
to indemnify and hold harmless (in the same manner and to the same extent as set
forth in subdivision (a) of this Section 2.6) each underwriter, each person who
controls such underwriter within the meaning of the Securities Act, the Company,
each director of the Company, each officer of the Company and each other person,
if any, who controls the Company within the meaning of the Securities Act, with
respect to any statement or alleged statement in or omission or alleged omission
from such registration statement, any preliminary prospectus, final prospectus
or summary prospectus contained therein, or any amendment or supplement thereto,
if such statement or alleged statement or omission or alleged omission was made
in reliance upon and in strict conformity with written information furnished to
the Company by such seller expressly for use in the preparation of such
registration statement, preliminary prospectus, final prospectus, summary
prospectus, amendment or supplement; provided that such prospective seller shall
not be liable to any person who participates as an underwriter in the offering
or sale of Registrable Securities or any other person, if any, who controls such
underwriter within the meaning of the Securities Act, in any such case to the
extent that any such loss, claim, damage, liability (or action or proceeding in
respect thereof) or expense arises out of such person's failure to send or give
a copy of the final prospectus, as the same may be then supplemented or amended,
to the person asserting an untrue statement or alleged untrue

                                       11
<PAGE>

statement or omission or alleged omission at or prior to the written
confirmation of the sale of Registrable Securities to such person if such
statement or omission was corrected in such final prospectus. Such indemnity
shall remain in full force and effect, regardless of any investigation made by
or on behalf of any underwriter, the Company or any such director, officer or
controlling person and shall survive the transfer of such securities by such
seller. In no event shall the liability of any selling holder of Registrable
Securities under this Section 2.6(b) be greater in amount than the dollar amount
of the proceeds received by such holder upon the sale of the Registrable
Securities giving rise to such indemnification obligation.

         (c) Notices of Claims, etc. Promptly after receipt by an indemnified
party of notice of the commencement of any action or proceeding involving a
claim referred to in the preceding subdivisions of this Section 2.6, such
indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party, give written notice to the latter of the commencement of
such action; provided that the failure of any indemnified party to give notice
as provided herein shall not relieve the indemnifying party of its obligations
under the preceding subdivisions of this Section 2.6, except to the extent that
the indemnifying party is actually prejudiced by such failure to give notice. In
case any such action is brought against an indemnified party, the indemnifying
party shall be entitled to participate in and to assume the defense thereof,
jointly with any other indemnifying party similarly notified to the extent that
it may wish, with counsel reasonably satisfactory to such indemnified party, and
after notice from the indemnifying party to such indemnified party of its
election so to assume the defense thereof, the indemnifying party shall not be
liable to such indemnified party for any legal or other expenses subsequently
incurred by the latter in connection with the defense thereof other than
reasonable costs of investigation. No indemnifying party shall, without the
consent of the indemnified party, consent to entry of any judgment or enter into
any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from
all liability in respect to such claim or litigation.

         (d) Other Indemnification. Indemnification similar to that specified in
the preceding subdivisions of this Section 2.6 (with appropriate modifications)
shall be given by the Company and each seller of Registrable Securities with
respect to any required registration or other qualification of securities under
any federal or state law or regulation of any governmental authority other than
the Securities Act.

         (e) Indemnification Payments. The indemnification required by this
Section 2.6 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or
expense, loss, damage or liability is incurred.

         (f) Contribution. If the indemnification provided for in this Section
2.6 from the indemnifying party is unavailable to an indemnified party hereunder
in respect of any losses, claims, damages, liabilities or expenses referred to
therein, then the indemnifying party, in lieu of indemnifying such indemnified
party, shall contribute to the amount paid or payable by such indemnified party
as a result of such loss, claims, damages, liabilities or expenses in such
proportion as is appropriate to reflect the relative fault of the indemnifying
party and indemnified parties in connection with the actions which resulted in
such losses, claims, damages, liabilities or expenses, as well as any other
relevant equitable considerations. The relative fault of such indemnifying party
and indemnified parties shall be determined by reference to, among other things,
whether any action in question, including any untrue statement of material fact
or omission or alleged omission to state a

                                       12
<PAGE>

material fact, has been made by, or relates to information supplied by, such
indemnifying party or indemnified parties, and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses, claims,
damages, liabilities and expenses referred to above shall be deemed to include,
subject to the limitations set forth in Section 2.6(c) hereof, any legal or
other fees or expenses reasonably incurred by such party in connection with any
investigation or proceeding.

         The Company and the Holders agree that it would not be just and
equitable if contribution pursuant to this Section 2.6(f) were determined by pro
rata allocation or by any other method of allocation which does not take account
of the equitable considerations referred to in the immediately preceding
paragraph. Notwithstanding the provisions of this Section 2.6(f), no underwriter
shall be required to contribute any amount in excess of the amount by which the
aggregate total price at which the Registrable Securities underwritten by it and
distributed to the public were offered to the public exceeds the amount of any
damages which such underwriter has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission, and no
selling Holder shall be required to contribute any amount in excess of the
amount by which the aggregate total price at which the Registrable Securities of
such selling Holder were offered to the public exceeds the amount of any damages
which such selling Holder has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation.

         2.7 Reporting Requirements Under Exchange Act. When it is first legally
required to do so, the Company shall register its Common Stock under Section 12
of the Exchange Act (as hereinafter defined) and shall keep effective such
registration and shall timely file such information, documents and reports as
the Commission may require or prescribe under Section 13 of the Exchange Act.
From and after the effective date of the first registration statement filed by
the Company under the Securities Act, the Company shall (whether or not it shall
then be required to do so) timely file such information, documents and reports
which a corporation, partnership or other entity subject to Section 13 or 15(d)
(whichever is applicable) of the Exchange Act is required to file.

         Immediately upon becoming subject to the reporting requirements of
either Section 13 or 15(d) of the Exchange Act, the Company shall forthwith upon
request furnish any Holder of Registrable Securities (i) a written statement by
the Company that it has complied with such reporting requirements, (ii) a copy
of the most recent annual or quarterly report of the Company, and (iii) such
other reports and documents filed by the Company with the Commission as such
Holder may reasonably request in availing itself of an exemption for the sale of
Registrable Securities without registration under the Securities Act. The
Company acknowledges and agrees that the purposes of the requirements contained
in this Section 2.7 are (a) to enable any such Holder to comply with the current
public information requirement contained in Paragraph (c) of Rule 144 should
such Holder ever wish to dispose of any of the securities of the Company
acquired by it without registration under the Securities Act in reliance upon
Rule 144 (or any other similar exemptive provision) and (b) to qualify the
Company for the use of registration statements on Form S-3. In addition, the
Company shall take such other measures and file such other information,
documents and reports, as shall hereafter be required by the Commission as a
condition to the availability of Rule 144 under the Securities Act (or any
similar exemptive provision hereafter in effect) and the use of Form S-3. The
Company also

                                       13
<PAGE>

covenants to use reasonable efforts, to the extent that it is reasonably within
its power to do so, to qualify for the use of Form S-3.

         2.8 Stockholder Information. The Company may require each Holder of
Registrable Securities as to which any registration is to be effected pursuant
to this Section 2 to furnish the Company such information in writing with
respect to such Holder and the distribution of such Registrable Securities as
the Company may from time to time reasonably request in writing and as shall be
required by law or by the Commission in connection therewith.

         2.9 Forms. All references in this Agreement to particular forms of
registration statements are intended to include, and shall be deemed to include,
references to all successor forms which are intended to replace, or to apply to
similar transactions as, the forms herein referenced.

         2.10 Transfer of Registration Rights. The registration rights granted
to the Holders of Registrable Securities under this Section 2 may not be
transferred without the prior written consent of the Company; provided that such
registration rights may be transferred, in whole or in part, without such prior
written consent in connection with the transfer of Registrable Securities to (i)
a partner in or an affiliate (defined as any person that directly or indirectly
controls, is controlled by, or is under common control with such Purchaser) of
one or more of the Purchasers or (ii) to an immediate or remote transferee of a
Purchaser who after such transfer is the Holder of at least 25% of the number of
Registrable Securities originally purchased by such original Purchaser
(appropriately adjusted for subdivisions and combinations of shares of Common
Stock and dividends on Common Stock payable in shares of Common Stock subsequent
to the date of this Agreement).

         3. MISCELLANEOUS.

         3.1 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS BY
THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICT OF LAWS
PRINCIPLES THEREOF.

         3.2 Successors and Assigns. Except as otherwise provided herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the
successors and assigns of the parties hereto.

         3.3. Amendment. Except as expressly provided herein, this Agreement, or
any provision hereof, may be amended, waived, discharged or terminated upon the
written consent of the Company and the Holders holding at least fifty percent
(50%) of the then outstanding Registrable Securities.

         3.4 Notices, etc. All notices and other communications required or
permitted hereunder shall be in writing and shall be mailed by first class mail,
postage prepaid, or otherwise delivered by hand or by messenger including
Federal Express or similar courier service, addressed (a) if to a Holder, at
such Holder's address set forth on Schedule A hereto, or at such other address
as such party shall have furnished to the Company in writing, or (b) if to the
Company at 8122 Datapoint Drive, Suite 1250, San Antonio, Texas 78229, Attn:
Chief Executive Officer, or at such other address as the Company shall have
furnished to the other parties hereto.

                                       14
<PAGE>

         Each such notice or other communication shall for all purposes of this
Agreement be treated as effective upon actual delivery, if delivered personally
or by courier, or, if sent by mail, at the earlier of its receipt or the fourth
calendar day after posting, addressed and mailed as aforesaid.

         3.5 No Implied Waiver. Except as expressly provided in this Agreement,
no course of dealing between the Company and any Holder and no delay in
exercising any such right, power or remedy conferred hereby or now or hereafter
existing at law, in equity, by statute or otherwise, shall operate as a waiver
of, or otherwise prejudice, any such right, power or remedy.

         3.6 Severability. If any provision of this Agreement shall be held to
be illegal, invalid or unenforceable under any applicable law, then such
contravention or invalidity shall not invalidate the entire Agreement. Such
provision shall be deemed to be modified to the extent necessary to render it
legal, valid and enforceable, and if no such modification shall render it legal,
valid and enforceable, then this Agreement shall be construed as if not
containing the provision held to be invalid, and the rights and obligations of
the parties shall be construed and enforced accordingly.

         3.7 Headings. The headings of the Sections and paragraphs of this
Agreement have been inserted for convenience of reference only and do not
constitute a part of this Agreement.

         IN WITNESS WHEREOF, this Registration Rights Agreement has been
executed by the undersigned effective as of October 12, 2004.

                                    "COMPANY"

                                    BIONUMERIK PHARMACEUTICALS, INC.

                                    By: /s/ FREDERICK H. HAUSHEER
                                       -----------------------------------------
                                    Title: Chairman & Chief Executive Officer

                                       15
<PAGE>

                                   SCHEDULE A

                                     HOLDERS
--------------------------------------------------------------------------------

<Table>
<Caption>
PURCHASER                                                                                           NO. OF SHARES
-------------------------------------------------------------------------------------------    ---------------------
<S>                                                                                            <C>
BIOVEN PARTNERS, L.P.                                                                                 454,546
     1235 Royal Oaks Loop
     Fredericksburg, Texas 78624

JAMES R. LEININGER                                                                                    558,182
     8122 Datapoint Drive, Suite 1000
     San Antonio, Texas 78229

GENERAL ROBERT F. MCDERMOTT                                                                           113,636
     200 Concord Plaza, Suite 500
     San Antonio, Texas 78216

VICTORIA CAPITAL CORPORATION                                                                          136,364
     c/o Wells Fargo Bank
     ATTN:  Charlie Roberson, C.P.A.
     MAC:T5611-101
     16414 San Pedro, Suite 1000
     San Antonio, Texas 78232

KAREN J. HIXON                                                                                        113,636
     111 W. Lynwood
     San Antonio, Texas 78212

EJO TRUST DATED 05-20-68 FBO ISSUE ELIZABETH B. MESSICK TRUST                                           6,000
     Inverness Counsel, Inc.
     ATTN:  Philip S. Lawrence
     545 Madison Avenue, Ninth Floor
     New York, New York 10022

GRIFFIN ISSUE LLC                                                                                       4,000
     Inverness Counsel, Inc.
     ATTN:  Philip S. Lawrence
     545 Madison Avenue, Ninth Floor
     New York, New York 10022
</Table>

                                       16<PAGE>

                                                                   EXHIBIT 10.15

CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTION.

                   LICENSE AND DEVELOPMENT ALLIANCE AGREEMENT

                      TAKEDA PHARMACEUTICAL COMPANY LIMITED

                                       AND

                        BIONUMERIK PHARMACEUTICALS, INC.

                                 OCTOBER 5, 2004

                                       1
<PAGE>

                   LICENSE AND DEVELOPMENT ALLIANCE AGREEMENT

         This License and Development Alliance Agreement ("Agreement") is
executed as of October 5, 2004 between Takeda Pharmaceutical Company Limited, a
Japanese corporation located at 4-1-1 Doshomachi, Chuo-ku, Osaka 540-8645, Japan
(hereinafter "Takeda"), and BioNumerik Pharmaceuticals, Inc., a Texas
corporation located at 8122 Datapoint Drive, Suite 1250, San Antonio, TX 78229,
United States of America (hereinafter "BioNumerik"). Takeda and BioNumerik may
be referred to herein individually as a "Party" or collectively as the
"Parties."

         WHEREAS BioNumerik has developed the Product that Takeda desires to
distribute in the Territory, and whereas BioNumerik owns the Licensed Patents
and Licensed Information directed to compositions of the Product, to
formulations containing the Product, to methods of making the Product, and to
methods of using the Product, and whereas BioNumerik owns, or has the right to
license to Takeda on the terms described herein, the Licensed Patents, the
Licensed Information, the Licensed Trademarks, and BioNumerik's Licensees'
Patents and Information, and whereas BioNumerik desires to grant an exclusive
license to Takeda to the Licensed Patents, the Licensed Information, and the
Licensed Trademarks in the Field in the Territory, and a license to use
BioNumerik's Licensees' Patents and Information in the Field in the Territory,
all on the terms described herein, and whereas BioNumerik desires to develop and
prepare the Product in order to seek regulatory approval in the Territory;

         WHEREAS Takeda desires to help BioNumerik develop and prepare the
Product in order to seek regulatory approval in the Territory and to help
BioNumerik manufacture the Product for sale in the Territory and Takeda desires
to sell, offer for sale, promote, distribute and market the Product in the
Territory and to obtain an exclusive license to the Licensed Patents, Licensed
Information, and the Licensed Trademarks in the Field in the Territory, and a
license to use BioNumerik's Licensees' Patents and Information in the Field in
the Territory all on the terms described herein;

         NOW THEREFORE, for the consideration described herein and upon the
terms listed below, the Parties hereby agree as follows:

                                       2
<PAGE>

                                    ARTICLE I

                                   DEFINITIONS

         When used in this Agreement, each of the following defined terms will
have the meanings set forth in this Article. There are other terms defined in
this Agreement parenthetically, and such terms will have the meanings apparent
from the context in which such terms are parenthetically defined.

         1.1 "Affiliate" means, with respect to any Party, any corporation,
entity, or person that directly or indirectly controls, or is controlled by or
is under common control with, such Party, but only for so long as such control
exists. For purposes of this Section 1.1, "control" means (a) in the case of
corporate entities, direct or indirect ownership of fifty percent (50%) or more
of the stock or shares entitled to vote for the election of directors; and (b)
in the case of non-corporate entities, direct or indirect ownership of fifty
percent (50%) or more of the equity interest with the power to direct the
management and policies of such non-corporate entities.

         1.2 "BioNumerik Developments and Improvements" means, any and all
inventions, developments, discoveries and improvements useful in the
development, manufacture or sale of the Product (including, without limitation,
formulae, compounds, specifications, designs, chemical and physical data,
clinical data, information concerning synthesis, processes, formulations,
applications, toxicity, operations, regulatory affairs and marketing) that are
created by, generated by, or owned exclusively by BioNumerik subsequent to the
date of this Agreement and during the term of this Agreement.

         1.3 "BioNumerik's Licensees' Patents and Information" means (a) with
respect to Baxter Oncology GmbH ("Baxter"), any and all inventions (including
patents and patent applications), developments, discoveries, and improvements
useful in the development, manufacture or sale of the Product, including,
without limitation, formulae, compounds, specifications, designs, chemical and
physical data, clinical data, information concerning synthesis, processes,
formulations, applications, toxicity, operations, regulatory affairs and
marketing that were or are developed by or for Baxter or its alliance
predecessor, ASTA Medica Aktiengesellschaft ("ASTA Medica") during the term of
the Strategic Alliance Agreement (the "Baxter Alliance Agreement") between
BioNumerik and Baxter, subject in all cases to any

                                       3
<PAGE>

restrictions that existed or may exist on the ability of Baxter or ASTA Medica
to license such inventions, developments, discoveries or improvements to
BioNumerik in accordance with the Baxter Alliance Agreement, (b) with respect to
Grelan Pharmaceutical Co., Ltd. ("Grelan"), any and all inventions (including
patents and patent applications), developments, discoveries, and improvements
directly relating to the Product, including, without limitation, formulae,
specifications, designs, chemical and physical data, clinical data, and
information concerning synthesis, processes, formulations, applications,
toxicity, operations, regulatory affairs and marketing, that were or are
developed by or for Grelan during the term of the Joint Venture Agreement dated
August 30, 2000, as amended September 22, 2000 to add KI Pharmaceuticals, L.L.C.
as a party (the "KI Pharma Joint Venture Agreement") among BioNumerik, Grelan
and KI Pharmaceuticals, L.L.C., subject in all cases to any restrictions that
existed or may exist on the ability of Grelan to license such inventions,
developments, discoveries or improvements to BioNumerik in accordance with the
KI Pharma Joint Venture Agreement, (c) with respect to third parties other than
Baxter and Grelan, any and all inventions (including patents and patent
applications), developments, discoveries, and improvements, and data and
information, useful in the development, manufacture or sale of the Product,
including, without limitation, formulae, compounds, specifications, designs,
chemical and physical data, non-clinical and clinical data, information
concerning synthesis, processes, formulations, applications, toxicity,
operations, regulatory affairs and marketing invented by, obtained by, or at the
direction of, BioNumerik's direct and indirect licensees and/or collaborators,
such as the National Cancer Institute, in any country, before the Effective Date
of this Agreement and subsequently during the course of this Agreement,
including any divisions, renewals, continuations, continuation-in-parts,
substitutions, additions, registrations, confirmations, re-issues,
re-examinations, extensions, supplementary protection certificates, and patent
term extensions of the patents identified above, and any patent or patent
application derived from the these patents or their original patent
applications, provided that any such patent or patent application covers or
relates to the Product as defined herein, (d) with respect to Baxter, all data
and results obtained by Baxter (or its alliance predecessor, ASTA Medica) from
the non-clinical studies, clinical studies and related testing conducted by
Baxter (or its alliance predecessor, ASTA Medica) on the Product pursuant to the
Baxter Alliance Agreement, (e) with respect to Grelan, all data and developments
which arise from research and development (including nonclinical studies and
clinical studies) carried out on the Product by

                                       4
<PAGE>

Grelan pursuant to the KI Pharma Joint Venture Agreement, and (f) with respect
to parties other than Baxter and Grelan, any and all non-clinical, clinical, and
other data, experiments, results, conclusions, know-how, and the like, relating
to the Product obtained or generated by, or at the direction of, BioNumerik's
direct and indirect licensees in any country before the Effective Date of this
Agreement and subsequently during the course of this Agreement, provided that,
with respect to clauses (c) and (f) above, the intellectual property and
information described are only included to the extent BioNumerik actually has
and is authorized to sublicense such intellectual property and information.

         1.4 "Commercial Milestone Payments" means the payments required to be
made by Takeda to BioNumerik pursuant to Section 8.3.

         1.5 "Commercially Diligent Efforts" means, with respect to the
manufacture, supply, delivery, marketing and promotion of the Product or the
conduct of other activities referred to herein as requiring Commercially
Diligent Efforts, such efforts and resources commonly used by a similarly
situated company in the research-based pharmaceutical industry for a product
owned or licensed by it of similar commercial potential at a similar stage in
its lifecycle, taking into consideration various factors such as its safety and
efficacy, product profile, cost to develop, the time required to complete
development, the competitiveness of alternative products, its proprietary
position, the likelihood of regulatory approval, its profitability, sharing of
revenues, its labeling, the regulatory environment, competitive market
conditions and all other relevant factors, all as measured by the facts and
circumstances at the time such efforts are due. In addition to and
notwithstanding the foregoing, with respect to the obligation of Takeda and its
Affiliates and sublicensees to satisfy the requirement to use Commercially
Diligent Efforts as provided in Section 6.1 hereof, from [**] until [**], the
marketing, promotion and selling of the Product will need to be and remain one
of the two top priority products of the oncology business operations of Takeda
in the Territory for [**], one of the three top priority products of the
oncology business operations of Takeda in the Territory for [**], and thereafter
will receive for the term of the Agreement at least [**] of the resources of the
oncology business operations of Takeda in the Territory, ranked in terms of
priority, resource allocation, efforts, product positioning and relative order
of

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       5
<PAGE>

importance. Upon request from BioNumerik, Takeda agrees to provide BioNumerik
with an explanation and documentation sufficient to demonstrate it is meeting
the requirements described in the previous sentence.

         1.6 "Confidential Information" means any and all non-public and
proprietary information that is disclosed by a Party to another Party in
connection with this Agreement. Notwithstanding the foregoing, Confidential
Information will not include any part of such information that:

                  i.       Was already known to the receiving Party as evidenced
                           by the receiving Party's written records, other than
                           any portion of such information that was under an
                           obligation of confidentiality, at the time of
                           disclosure;

                  ii.      Was generally available to the public or was
                           otherwise part of the public domain at the time of
                           disclosure of such information to the receiving
                           Party;

                  iii.     Became generally available to the public or otherwise
                           becomes part of the public domain after disclosure of
                           such information and other than through any act or
                           omission of the receiving Party in breach of this
                           Agreement;

                  iv.      Was subsequently lawfully disclosed to the receiving
                           Party by a third party other than in contravention of
                           a confidentiality obligation of such third party to
                           the disclosing Party; or

                  v.       Was developed or discovered by employees of the
                           receiving Party or Affiliates of the receiving Party
                           who had no access to the Confidential Information of
                           or enabling disclosure originating from the
                           disclosing Party and did not make use of the
                           Confidential Information of the disclosing Party as
                           evidenced by the written records or communications of
                           either Party.

         1.7 "Delivery Costs" means, with respect to the delivery of the Product
as specified by either Party in the Territory the sum of:

                                       6
<PAGE>

                  (a)      Any reasonable and customary warehouse or storage
                           costs;

                  (b)      Any reasonable and customary transportation or
                           shipping costs;

                  (c)      Import, export and customs fees and/or duties
                           attributable to delivery of the Product as specified
                           by either Party in the Territory; and

                  (d)      Reasonable overhead (fixed and variable) allocated to
                           the delivery of the Product as specified by either
                           Party in the Territory, calculated in accordance with
                           normal accounting practices applied on a basis
                           consistent with such Party's past practices and
                           industry standards.

         Costs included in Delivery Costs will not be counted twice in any other
calculation described herein.

         1.8 "Development Plan" means the mutually agreed development plan for
the Product in the Territory described in Section 4.1.

         1.9 "Distribution, Marketing and Promotion Expenses" means the actual
recorded expenses that are in accordance with Sections 9.2(d) and 9.2(e) or the
Marketing Plan or are otherwise approved by prior mutual consent of the Parties,
for the distribution, marketing, selling and promotion of the Product conducted
in accordance with the Marketing Plan, including, but not limited to [**]. For
clarity, the Distribution, Marketing and Promotion Expenses include, but are not
limited to, expenses incurred by either Party for preparation of the launch of
the Product in the Field in the Territory. The same cost or expense will not be
counted twice in the calculation of the Distribution,

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       7
<PAGE>

Marketing and Promotion Expenses and the Net Sales or Net Profits. Delivery
Costs are not included in the Distribution, Marketing and Promotion Expenses.
The Distribution, Marketing and Promotion Expenses will be within the budgets
set forth in the Marketing Plan for each Fiscal Year and such budgets may be
changed by mutual agreement by both Parties.

         1.10 "Effective Date" means, except for Articles XVIII and XXII of this
Agreement, the next business day after which the following have both occurred:
(1) either (a) the expiration or earlier termination of any notice and waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, and the rules and regulations promulgated thereunder (the "HSR Act") or
(b) the approval of the transactions contemplated herein under the HSR Act,
unless an HSR Act filing is deemed unnecessary by Takeda at its sole discretion,
and (2) BioNumerik's obtaining any necessary approvals by BioNumerik's
shareholders of (x) the issuance of the Preferred Stock and the Common Shares,
and (y) the execution of the Registration Rights Agreement with respect to the
Preferred Stock and the Common Shares, although BioNumerik has represented, in
accordance with Section 21.2(q), that each member of its Board of Directors will
recommend approval of and support approval of and each of BioNumerik's
shareholders owning five percent (5%) or more of the capital stock of BioNumerik
will vote in favor of all aspects of this Agreement with Takeda that require
such shareholder approval, including the issuance of Preferred Stock and Common
Shares as described in this Agreement. BioNumerik will use diligent efforts to
notify and obtain any necessary approvals from BioNumerik's shareholders
referenced in clause 2 of the first sentence of this definition within
twenty-one (21) days following the execution of this Agreement. If BioNumerik
has not obtained such approvals within twenty-eight (28) days following the
execution of this Agreement, then Takeda has the option to terminate this
Agreement at any time before the necessary approvals by BioNumerik's
shareholders are obtained. Further, BioNumerik will inform Takeda in writing
when such necessary approvals by BioNumerik's shareholders have been obtained.
BioNumerik agrees that following execution of this Agreement until thirty (30)
days following execution of this Agreement, BioNumerik will not seek to enter
into another alliance transaction directly concerning the Product in the
Territory and also BioNumerik will not, during such thirty (30) day period
referred to in this sentence, participate in any discussions with a third party
concerning any tender or exchange offer, merger, acquisition or other business
combination involving BioNumerik or any of its subsidiaries. With

                                       8
<PAGE>

respect to the immediately preceding sentence and Sections 8.4(j) and 21.2(q),
the Parties' rights and obligations will begin immediately upon delivery to each
Party of fully executed counterparts of this Agreement. If an HSR Act filing is
deemed unnecessary by Takeda at its sole discretion, then the Effective Date is
the next business day after the BioNumerik shareholder approvals referenced in
clause 2 of the first sentence of this definition have been obtained.

         1.11 "Field" means any and all indications for a human pharmaceutical
product.

         1.12 "Fiscal Year" means the period from April 1st through March 31st
of the following year of the term hereof, or portion of a Fiscal Year if less
than the entire Fiscal Year applies at the beginning or end of the term hereof.

         1.13 "Generic Entry Date" means the first date that a third party who
is not an Affiliate or sublicensee of Takeda or BioNumerik is legally
distributing a generic version of the Product in the Territory, or just in the
United States, and is not being sued by either BioNumerik or Takeda regarding
the Product.

         1.14 "G&A Costs" means allocated costs associated with administrative,
accounting, legal (including patent counsel), human resources and information
systems. These costs would be allocated to the extent of the amount of support
they provide to the Product.

         1.15 "Incurred Costs" means the costs not otherwise deducted from Net
Sales that are actually incurred by either Takeda or BioNumerik relating to the
manufacture, distribution, marketing, promotion, and Third Party Payments in the
Territory. Incurred Costs do not include costs associated with research and
development of the Product, unless expressly stated. Incurred Costs include, but
are not limited to, the following costs:

         (a) [**];

         (b) [**];

         (c) [**];

         (d) [**];

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       9
<PAGE>

         (e) [**];

         (f) [**]; and

         (g) [**].

         However, in the event that BioNumerik licenses any Product
manufacturing rights to Takeda in the future, and Takeda manufactures some or
all of the Product, then Takeda's Manufacturing Costs for the portion of the
Product that it manufactures will be included in the Incurred Costs. Costs for
damaged Product and for recall of the Product will be included in the Incurred
Costs unless such damage or recall arises out of the negligence or willful
misconduct by one Party or by the breach of representations or warranties
contained in this Agreement by one Party or is otherwise allocable to either
Party pursuant to other provisions of this Agreement, including without
limitation Article XVI. Costs included in Incurred Costs will not be counted
twice in any other calculation described herein.

         1.16 "Licensed Information" means any and all non-clinical, clinical,
and other data, experiments, results, conclusions, know-how, and the like,
created by, generated by, or owned exclusively by, BioNumerik before the
Effective Date and subsequently during the course of this Agreement by testing,
studying, using, making, selling, offering for sale, and/or marketing the
Product.

         1.17 "Licensed Patents" means any and all patents, or patent
applications, including utility models and designs and certificates of
inventions, issued or filed in the Territory and owned by or exclusively
licensed to BioNumerik that claim or directly concern the Product, a formulation
containing the Product, a method of making the Product, and/or a method of using
the Product, regardless of when filed or obtained, including, but not limited
to, the following patents and patents derived from the following applications:
[**]. The Licensed Patents also include any divisions,

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       10
<PAGE>

renewals, continuations, continuation-in-parts, substitutions, additions,
registrations, confirmations, reissues, re-examinations, extensions,
supplementary protection certificates, and patent term extensions of the patents
identified above, and any patent or patent application derived from these
patents or their original patent applications, provided that any such patent or
patent application claims or directly concerns the Product as defined herein.
Any other patents issued or filed in the Territory that BioNumerik may have any
control over, and that claims or directly concerns the Product are included in
the definition of Licensed Patents, to the extent that BioNumerik has a right to
exclusively license any such patent to Takeda in the Territory, so as to allow
Takeda the ability to fulfill the purposes of this Agreement.

         1.18 "Licensed Trademarks" means (a) "TAVOCEPT", including any
registrations and any applications therefor issued or filed in the Territory and
owned by BioNumerik, and (b) any back-up trademarks for the Product to which
BioNumerik has or may obtain rights during the term of this Agreement, to the
extent of BioNumerik's rights, including any registrations and any applications
therefor that relate to the Product.

         1.19 "Manufacturing Costs" means the fully allocated cost of
manufacturing the Product in a final packaged form (calculated in accordance
with Generally Accepted Accounting Principles ("GAAP")), including [**]. The
Manufacturing Costs will not include any profit for BioNumerik or, to the extent
it is at any time authorized to manufacture the Product, Takeda, or their
respective Affiliates or sublicensees (excluding third party
contract-manufacturers). Costs included in Manufacturing Costs will not be
counted twice in any other calculation described herein.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       11
<PAGE>

         1.20 "Marketing Plan" means the mutually agreed marketing plan for the
commercialization of the Product in the Territory created by Article XIII,
Section 13.3 and further described in Article VI, Section 6.2.

         1.21 "Material Data" means any and all data, information, or
documentation, that Takeda, or a similarly situated company, would have
reasonably considered important when deciding material conditions of this
Agreement including, but not limited to, its Exhibits and attachments or whether
to purchase a license to certain rights to the Product, to take a license to the
Licensed Patents, Licensed Information, BioNumerik's Licensees' Patents and
Information, or Licensed Trademarks, or to enter into an alliance agreement with
BioNumerik similar in nature to this Agreement, including, but not limited to,
all data, information, and documentation regarding non-clinical, and clinical
studies of the Product, potential efficacy of the Product, recognized and
possible side effects, injuries, toxicities, and sensitivities associated with
the Product, manufacturing of the Product, quality of the Product, compliance
with applicable laws and regulations, communications with Regulatory Agencies,
conflict with third parties' intellectual property rights, and ownership,
validity, and enforceability of the Licensed Patents and Licensed Trademarks,
except in each case where such data, information or documentation would not
reasonably be considered important when deciding material conditions of this
Agreement including, but not limited to, its Exhibits and attachments or whether
to invest in the Product, to take a license to the Licensed Patents, Licensed
Information, BioNumerik's Licensees' Patents and Information, or Licensed
Trademarks, or to enter into an alliance agreement with BioNumerik similar in
nature to this Agreement.

         1.22 "Material Adverse Effect" means an effect that would be materially
adverse to the business, financial condition, and results of operations of the
Party with respect to which such effect is being evaluated.

         1.23 "Milestone Payments" means the payments required to be made by
Takeda to BioNumerik pursuant to Section 8.2.

         1.24 "Net Sales" means the recorded Gross Sales of the Product by
Takeda, its Affiliates, or its sublicensees in the Territory to third parties in
accordance with United States GAAP less the following deductions as determined
in accordance with Takeda's current and

                                       12
<PAGE>

future commercial and accounting policies and practices that are consistently
applied in a manner consistent with GAAP and the Marketing Plan:

                  (a)      [**];

                  (b)      [**];

                  (c)      [**];

                  (d)      [**]; and

                  (e)      [**].

         Deductions used to calculate Net Sales will not be counted twice in any
other calculation described herein. Sales of Product resulting from co-promotion
by BioNumerik, which will be recorded by Takeda, will be included in Net Sales.

         "Gross Sales" means recorded post launch gross sales of the Product in
the Territory by Takeda or its Affiliates or sublicensees to third parties.
Sales between Takeda and its Affiliates and sublicensees are not considered to
be sales to third parties, unless the Affiliate or sublicensee is the end-user
of the Product.

         1.25 "Patent Expiration Date" means the date first following the last
to expire Licensed Patent in the Territory that claims or directly concerns the
Product.

         1.26 "Phase III Studies" means adequate and well-controlled human
clinical studies in any country the results of which could be used to establish
safety and efficacy of the Product, as a basis for any type of New Drug
Application ("NDA") filed with the U.S. Food and Drug

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       13
<PAGE>

Administration or a similar application for the marketing approval of the
Product filed in the Territory, to be conducted before or after the approval of
BioNumerik's NDA for the Product.

         1.27 "Phase IV Costs" means the costs associated with Phase IV Studies,
or Phase III studies that are concluded following receipt of NDA approval for
the Product in the Territory.

         1.28 "Phase IV Studies" means additional clinical studies for the
Product commenced after the receipt of regulatory approval of the Regulatory
Agency for the Product in all or part of the Territory, which studies are
conducted within the parameters of the regulatory approval and other than those
required or requested by the Regulatory Agency as a condition of or in
connection with obtaining full regulatory approval. Phase IV Studies also
include, but are not limited to, studies to gather additional information
regarding the drug's potential risks, medical or pharmacoeconomic benefits,
justifications and descriptions for other indications or comparative data to be
included in United States compendial listings, and optimal use, dose, route, and
schedule of administration, epidemiological studies, modeling and
pharmacoeconomic studies, and investigator sponsored clinical trials, but
specifically excludes PMS (as defined in Section 1.30 below).

         1.29 "PMS Costs" means the costs associated with PMS and related
activities, including, but not limited to, costs for a database of adverse
events relating to the Product in the Territory as well as costs for receiving,
assembling, and reporting to a Regulatory Agency in the Territory of PMS data
from outside of the Territory.

         1.30 "PMS" means post-marketing safety surveillance with respect to the
Product in the Territory which is required by the Regulatory Agency in the
Territory and worldwide by other regulatory agencies where the Product is
undergoing development or is approved.

         1.31 "Product" means any and all formulations, salts and dosage forms,
in the Field, containing BNP7787 with the chemical structure listed below (also
known as "disodium 2,2'dithio-bis-ethane sulfonate", "BNP7787", "Dimesna," and
"TAVOCEPT"), including any salt forms thereof and with or without any
pharmaceutically acceptable carriers, excipients, preservatives, bacteriostatic
components, and adjuvants, and including, but not limited to, any improvements
to which BioNumerik has rights that are made to the Product after the execution

                                       14
<PAGE>

of this Agreement, and any combination products or therapies where BNP7787 is
administered with one or more active ingredients alone or in combination with
other medicaments, regardless of the respective timing and mode of
administration of each active ingredient.

         The Chemical Structure of BNP7787 is set forth below:

                         [CHEMICAL STRUCTURE OF BNP7787]

         1.32 "Profit Share" means the division of profit and loss between the
Parties in accordance with Article IX.

         1.33 "Provisional Margin" means the amount above BioNumerik's
Manufacturing Costs and Delivery Costs that Takeda agrees to pay as part of the
Provisional Price. The maximum Provisional Margin is [**] of the sum of
BioNumerik's Manufacturing Costs and BioNumerik's Delivery Costs.

         1.34 "Provisional Price" means the unit price at which BioNumerik will
sell the final, packaged form of the Product to Takeda. The Provisional Price is
the sum of:

         (a)      BioNumerik's Manufacturing Costs;

         (b)      BioNumerik's Delivery Costs; and

         (c)      the Provisional Margin.

         Under no circumstance will the Provisional Price that Takeda will pay
         BioNumerik be less than the actual Manufacturing Costs and Delivery
         Costs for the Product.

         1.35 "Regulatory Agency" means the United States Food and Drug
Administration ("FDA") and the Canadian Health Authority, and/or such other
similar and appropriate

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       15
<PAGE>

government regulatory authority or agency outside the United States, the
approval of which is required to develop, market or distribute the Product in a
portion of the Territory.

         1.36 "Research and Development Payments" means the payments required to
be made by Takeda to BioNumerik pursuant to Section 8.4.

         1.37 "Supply Conditions" means specifications and testing methods of
the Product which are set forth in Exhibit A attached hereto.

         1.38 "Takeda Developments and Improvements" means any and all
inventions, developments, discoveries and improvements useful in the
development, manufacture or sale of the Product (including, without limitation,
formulae, compounds, specifications, designs, chemical and physical data,
clinical data, information concerning synthesis, processes, formulations,
applications, toxicity, operations, regulatory affairs and marketing) that are
developed by or for Takeda subsequent to the date of this Agreement and during
the term of this Agreement.

         1.39 "Tax" means any and all consumption or value-added taxes and
import or export duties incurred by either Party for sales, manufacture,
importation or distribution of the Product for the Territory, including, but not
limited to, those incurred for any transaction between BioNumerik and Takeda.
Any and all income taxes attributable to the Parties will not be included in the
Tax. Costs included in Tax will not be counted twice in any other calculation
described herein.

         1.40 "Territory" means (a) the United States of America, its
territories and possessions (including Puerto Rico), and (b) Canada.

         1.41 "Third Party Payment" means (i) royalty and other payments to a
third party for alleged or adjudged infringement of such third party's patent
rights relating to manufacturing, distribution, promotion, sales, use, offers
for sale or importation of the Product in the Territory; and (ii) damages and
other payments to a third party for alleged or adjudged product liability claims
other than those allocated to either Party pursuant to other provisions of this
Agreement, including without limitation Article XVI. Royalty, damages or other
payments which

                                       16
<PAGE>

BioNumerik or its licensees pay to a third party relating to the Product not
marketed by Takeda or its Affiliates or sublicensees will not be included in the
Third Party Payment.

         1.42 "BioNumerik IPO" means the public offering by BioNumerik of its
Common Shares pursuant to the first effective registration statement under the
U.S. Securities Act of 1933, as amended, (the "Securities Act") of a firmly
underwritten offering of Common Shares.

         1.43 "IPO Price" means the offering price to the public established for
the BioNumerik IPO.

         1.44 "Pre-Transaction Valuation" means the indicated aggregate
valuation for BioNumerik established by multiplying (i) the IPO Price by (ii)
the aggregate number of Common Shares outstanding or issuable upon the
conversion or exercise of convertible preferred stock, options or warrants of
BioNumerik outstanding as of the date of execution of this Agreement.

                                   ARTICLE II

                                  LICENSE GRANT

         2.1 Exclusive License. Subject to Section 2.4, Section 5.1(a), and
Section 6.3, BioNumerik hereby grants Takeda and its Affiliates: (i) an
exclusive license, with the right to sublicense, under the Licensed Patents and
Licensed Information; and (ii) a non-exclusive license, with the right to
sublicense through BioNumerik as directed by Takeda, under BioNumerik's
Licensees' Patents and Information, such license in the case of each of clauses
(i) and (ii) being to make, have made, use, sell, offer for sale, import and
market the Product in the Territory in the Field. Takeda will be responsible for
the performance of its obligations hereunder by its Affiliates and sublicensees.
The license grant hereunder as it relates to BioNumerik's Licensees' Patents and
Information obtained from Baxter or Grelan are granted for the purpose of
supporting non-clinical studies, clinical trials, regulatory approval for the
Product in the Territory, and development, marketing and sale of the Product in
the Territory and are subject to any retained rights of Baxter or Grelan to
practice such BioNumerik's Licensees' Patents and Information other than in
connection with the Product. BioNumerik agrees not to make, have made, use,
sell, offer for sale, import or market the Product in the Territory, except

                                       17
<PAGE>

as specifically allowed in this Agreement. Under this Section, it is understood
that BioNumerik will license to Takeda all the intellectual property rights
regarding the use of the Product in the Field in the Territory that BioNumerik
itself has.

         2.2 BioNumerik's Licensees. Simultaneously with the execution of this
Agreement, BioNumerik will provide Takeda with a written acknowledgement from
each of Baxter and Grelan that BioNumerik has the right to grant Takeda
according to the terms of this Agreement a license to such party's portion of
BioNumerik's Licensees' Patents and Information in the Territory. Such license
includes, but is not limited to, a license to data and results obtained in (a)
the Phase III non-small cell lung cancer clinical trial conducted by Baxter
and/or ASTA Medica for the Product, and (b) the Phase I advanced ovarian cancer
clinical trial conducted by Baxter and/or ASTA Medica for the Product.

         2.3 Sublicenses. Takeda will have the right to sublicense (or to
require BioNumerik to sublicense) the rights granted under Section 2.1 to third
parties in the Field in the Territory subject to the prior written consent of
BioNumerik, which BioNumerik may withhold in its sole discretion after
exercising good faith. Takeda's use of contract sales organizations or other
sales agents in accordance with the Marketing Plan will not be deemed a
sublicense.

         2.4 Retention of Rights. BioNumerik will retain the right for itself
and its Affiliates, sublicensees and contract-manufacturers to use the Licensed
Patents, Licensed Information and BioNumerik's Licensees' Patents and
Information in the Territory without cost as necessary to carry out the
manufacturing and development of the Product described in this Agreement as
being conducted by BioNumerik, to file the NDA and obtain regulatory approval
for the Product in the Territory, and to perform regulatory operations to
maintain such regulatory approval or additional regulatory approvals for the
Product in the Territory or elsewhere, for internal research purposes, and for
purposes of co-developing and co-promoting the Product in the Territory as
described herein or elsewhere, for purposes of manufacturing the Product in the
Territory in accordance with this Agreement, for purposes of manufacturing the
Product in the Territory for use outside the Territory, and for purposes that do
not relate to the Product or to the Product's use within the Territory. In
addition, BioNumerik, its Affiliates, and other parties previously or hereafter
authorized by BioNumerik will retain the right to conduct and have conducted
research

                                       18
<PAGE>

and development (including studies and clinical trials) of the Product
throughout the world for the purpose of obtaining regulatory approvals and label
expansions or other medical indications for the Product outside the Territory.
In addition, BioNumerik may conduct or sponsor non-clinical research and
clinical research regarding the Product through or in collaboration with
academic parties or research institutions ("Academic/Cooperative Studies"),
provided that (a) within six (6) months after the Effective Date, BioNumerik and
Takeda will adopt mutually agreed to Standard Operating Procedures ("SOP's") for
such Academic/Cooperative Studies that are not described in the Development
Plan, and (b) pending adoption of such SOP's, BioNumerik will regularly inform
and consult with Takeda regarding such Academic/Cooperative Studies. In
addition, subject to Section 6.7, nothing contained herein is intended to limit
the right of Takeda or BioNumerik to discover, develop, market, or sell other
therapeutic products or technologies beside the Product throughout the world.

         2.5 Disclosure of Information. BioNumerik will promptly disclose to
Takeda after the Effective Date of this Agreement both Licensed Information and
BioNumerik's Licensee's Patents and Information that it is aware of; BioNumerik
will first collect both Licensed Information and BioNumerik's Licensee's Patents
and Information and then will provide copies to Takeda. During the term of this
Agreement, BioNumerik will promptly inform Takeda of any new Licensed
Information and of any new BioNumerik's Licensee's Patents and Information that
it is aware of and Takeda will promptly inform BioNumerik of any new Takeda
Developments and Improvements.

                                   ARTICLE III

                             TRADEMARK LICENSE GRANT

         3.1 BioNumerik hereby grants Takeda and its Affiliates an exclusive
license, with the right to sublicense, subject to reasonable quality control
conditions determined by BioNumerik, to use the Licensed Trademarks in
connection with the Product in the Territory in the Field as long as Takeda is
selling the Product in accordance with the terms of this Agreement, including
Article XV as applicable. Any sublicense of the Licensed Trademarks by Takeda
will be granted only together with a sublicense of the rights granted under
Article II, Section 2.1. BioNumerik agrees not to use, or to grant a license to
any third party to use the Licensed Trademarks in the Territory, whether inside
or outside of the Field, provided, however, that

                                       19
<PAGE>

BioNumerik retains the right to describe TAVOCEPT (or any of the other Licensed
Trademarks) in its own documents and publications, and in the manufacture of the
Product, the Product label or Product container or marketing or promotional
materials, for reporting to regulatory agencies, or for making public disclosure
regarding the Product, including reporting to shareholders or the United States
Securities and Exchange Commission ("SEC"), and to use the Licensed Trademarks
as necessary for other territories and the manufacture of the Product in the
Territory for shipment to other territories.

         3.2 BioNumerik will retain any and all goodwill associated with the
Licensed Trademarks and BioNumerik will also retain the benefit of any goodwill
associated with the Licensed Trademarks. BioNumerik will perform periodic
quality control assessments of any Product bearing one or more of the Licensed
Trademarks, whether the Product originated from Takeda or from a Takeda
sublicensee. Quality control assessments will take place at least once per
calendar year, up to as many as two (2) times per calendar year. Procedures and
policies concerning quality control assessments of the Product bearing one or
more of the Licensed Trademarks are subject to reasonable quality control
conditions determined by BioNumerik and will be reasonably set forth and
communicated to Takeda and any of Takeda's Affiliates or sublicensees.

                                   ARTICLE IV

             DEVELOPMENT OF THE PRODUCT AND SUBMISSION TO REGULATORY
                                     AGENCY

         4.1      Development Plan.

                  (a) The Parties will collaborate and use diligent efforts to
develop the Product with the intent of obtaining regulatory approval for
interstate transport, distribution, sale, promotion, labeling and marketing the
Product in the Territory as soon as reasonably practicable. Each Party will
assure that its Product development responsibilities hereunder are carried out
adhering to ethical and safety standards and in compliance with material
provisions of all applicable laws, regulations, standards, and guidelines in
force in the Territory. BioNumerik and Takeda hereby agree that the development
of the Product will be initially focused on the field of oncology.

                                       20
<PAGE>

                  (b) The development of the Product will be conducted pursuant
to a mutually agreed development plan for non-clinical and clinical studies,
including Phase III and IV Studies, which will specify in detail all planned
development activities and priorities, time frames for completion of activities,
which Party or third party is to be responsible for each activity, and any other
items reasonably required by the Parties (the "Development Plan"). The
Development Plan must be approved by both Parties prior to the commencement of
the non-clinical and clinical studies and may be modified at any time by mutual
written agreement of the Parties through the Joint Steering Committee described
in Article XIII, Section 13.1. An outline of the Development Plan is attached to
this Agreement in Exhibit B and includes a summary synopsis, a timeline, and an
annual budget estimate. BioNumerik will prepare and submit a draft of the
Development Plan to Takeda for consultation and approval within two (2) months
after the Effective Date and the draft of the Development Plan will be
substantially the same as set forth in Exhibit B.

                  (c) A Party will have the obligation to promptly inform the
other Party, as soon as the notifying Party becomes aware, of an expected excess
of development costs over the annual budget in the Development Plan by greater
than [**] of such annual budget or of such otherwise agreed upon plan by the
Parties. The Parties will consult with each other regarding the reasons for and
the handling of such expected excess. It is understood, however, that BioNumerik
will use Commercially Diligent Efforts in conducting the activities under the
Development Plan, including monitoring the costs thereof to stay within the
annual budget. Any Party that is responsible for creating an excess or monetary
loss caused by its negligent conduct for a particular project will be
responsible for correcting the loss at its own expense to the extent such cost
was caused by its negligent conduct. Notwithstanding the foregoing, the Parties
are encouraged to regularly consider and discuss activities that would result in
new indications or expand the market opportunity for the Product and to propose
such matters for consideration by the Joint Steering Committee.

                  (d) Unless otherwise agreed upon by the Parties, the
Development Plan will include the following studies, all of which will be
included in the budget set forth in the Development Plan [**]:

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       21
<PAGE>

[**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       22
<PAGE>

         4.2 Development. Without regard to Section 4.1 above, BioNumerik will
continue to conduct clinical and non-clinical studies of the Product necessary
to submit an NDA to the FDA and otherwise necessary for distribution, sale,
promotion, and marketing the Product in the United States in accordance with the
Development Plan.

         BioNumerik will provide Takeda with monthly status reports on such
studies. The content and format of such reports will be determined by a
Development Committee created by Article XIII, Section 13.2, but will, at a
minimum, include such data and information and a description of discoveries,
inventions and patents and other intellectual property rights as have been
acquired by BioNumerik as a result of the studies. BioNumerik will also respond
to such reasonable inquiries as Takeda may from time to time make with respect
to such studies.

         4.3 Phase III Studies and Phase IV Studies. In accordance with the
Development Plan and as otherwise requested by a Regulatory Agency, BioNumerik
will conduct Phase III Studies and Phase IV Studies of the Product, including
studies for expansion of the approved indications and for indications different
from those currently undergoing, or planned to undergo, Phase III Studies in the
Territory.

                                       23
<PAGE>

         4.4 Studies, Papers, and Presentations. Unless otherwise provided
herein or in an agreement between BioNumerik and Takeda, BioNumerik will be
responsible for conducting any non-clinical and clinical study, the publishing
of scientific papers, and organizing and making presentations at medical or
scientific congresses or other academic meetings under the auspices of the
Development Committee. Subject to the decisions of the Development Committee,
BioNumerik will send Takeda relevant documents (protocols, drafts of initial
scientific papers to be published, drafts of initial manuscripts of
presentations to be made at congresses or other meetings) for Takeda's review
and consent fourteen (14) business days in advance of filing, presentation or
publication. The costs associated with such activities will also be considered
to be part of the Distribution, Marketing, and Promotion Expenses after the
Product is approved.

         4.5 Filing and Maintenance of a NDA. BioNumerik will use Commercially
Diligent Efforts to prepare and file a NDA for the Product in the United States,
and subsequently in Canada, in the Field in accordance with the Development Plan
and in consultation with Takeda, and will use Commercially Diligent Efforts to
obtain and maintain NDA approval for the Product in the United States, and
subsequently in Canada, in the Field. Takeda will provide BioNumerik reasonable
assistance in the preparation of application documents for NDA of the Product in
the Territory. BioNumerik will provide Takeda with draft application documents
for the NDA no later than twenty (20) business days before the anticipated
filing thereof for Takeda's review and comment, and BioNumerik will incorporate
Takeda's reasonable comments in the application documents. BioNumerik will
promptly notify Takeda in writing of any communication with the FDA regarding
the Product in the United States and consult with Takeda about such
communication. Takeda may participate in any meeting and other communication
with the FDA, if such participation is permitted by the FDA, or if requested by
BioNumerik.

         4.6 Orange Book Listing. Based on BioNumerik's judgment and
determination, and in consultation with Takeda, BioNumerik will file appropriate
information with the FDA listing any Licensed Patent, patents in the
BioNumerik's Licensees' Patents and Information and patents referred to in
Article XII in the FDA's "Orange Book" as a patent related to the Product.
BioNumerik will use Commercially Diligent Efforts to maintain the listing in the
Orange Book until the expiration, disclamation, withdrawal, cancellation,
surrender, invalidation or holding of unenforceability of all of the Licensed
Patents. If Takeda identifies a Licensed Patent that should

                                       24
<PAGE>

be listed in the Orange Book and which BioNumerik has not listed, Takeda will
notify BioNumerik, in writing, of the Licensed Patent and the reasons it
believes that such Licensed Patent should be listed. Within ten (10) business
days, BioNumerik will respond, in writing, that it will file appropriate papers
with the FDA to list the Licensed Patent in the Orange Book, or BioNumerik will
give reasons why it does not believe that the Patent should or can be listed.
Any dispute will follow the procedures laid out in Article XIX. BioNumerik will
notify in writing Takeda of a Notice of Allowance of the Licensed Patents and
patents in the BioNumerik's Licensees' Patents and Information within ten (10)
business days after its receipt of the Notice of Allowance regarding each
patent. Takeda will notify in writing BioNumerik of a Notice of Allowance of
patents relating to Takeda Developments and Improvements and patents relating to
Jointly Developed Intellectual Property within ten (10) business days after its
receipt of the Notice of Allowance regarding each patent. This provision will
also apply to any Canadian patent regarding Canadian listing similar to the
Orange Book.

         4.7 Other Listings. BioNumerik will use Commercially Diligent Efforts
to register the Product in specified United States compendial listings with
prior consultation from Takeda.

         4.8 New Formulation and Manufacturing Process. Both Parties will
cooperate with each other in developing a new formulation of the Product and/or
improving the manufacturing process for the Product if both Parties agree that
such activities are necessary. The result, regarding the Product, of such
activities will be included in the scope of this Agreement and the cost for the
activities will be shared equally by both Parties unless otherwise agreed.

                                    ARTICLE V

                           MANUFACTURE OF THE PRODUCT

         5.1 Manufacturing Responsibility.

                  (a) BioNumerik will be responsible for all manufacturing
activities of the Product, including the use of existing or mutually agreed upon
contractor-manufacturers for the manufacture and supply of the Product to
Takeda, and Takeda agrees to purchase from BioNumerik, Takeda's entire
requirement of the Product in the Territory under the conditions set forth
herein. BioNumerik agrees to hire only contract-manufacturers that Takeda
approves in

                                       25
<PAGE>

writing before manufacturing by the contract-manufacturer begins, provided that
Takeda will not unreasonably withhold approval of a prospective qualified
contract-manufacturer. A list of potential contract-manufacturers that have
already been approved by Takeda is set forth on Exhibit G hereto.

                  (b) BioNumerik hereby grants Takeda the right to audit
manufacturing related operations for the Product, including but not limited to
audits of the following: sources, procurement and utilization of raw materials,
API production, Final Drug Product production, FDA inspections and reporting,
operations involving importation or exportation of raw materials, API or Final
Drug Product; label production, carton production, final packaged form of
Product production, transportation, quality assurance, and shipping, and inspect
the facilities of BioNumerik and its contract-manufacturers that manufacture the
Product for the Territory for the foregoing purposes, all subject to Takeda
reasonably cooperating with BioNumerik and its contract-manufacturers regarding
the timing and scope of any such audits. BioNumerik agrees to substantially
comply and to use Commercially Diligent Efforts to cause its
contract-manufacturers to substantially comply with (i) Takeda's reasonable
advice on quality assurance and (ii) all applicable laws, regulations,
guidelines and standards governing manufacture of the Product. Both Parties
agree to cooperate with each other in reducing the costs for the manufacture of
the Product and in keeping a high standard of quality and regulatory compliance
regarding the manufacturing process.

                  (c) BioNumerik will, at its cost, assure that appropriate
back-up suppliers are available in the event that BioNumerik or its
contract-manufacturers are unable to supply or are materially delayed in
supplying the Product to Takeda.

         5.2 Supply Conditions. BioNumerik agrees to supply Takeda the Product
in a final packaged form suitable for distribution to wholesalers, distributors,
cooperative purchasing groups, pharmacies or hospitals at the Provisional Price
to Takeda. The conditions for the supply from BioNumerik to Takeda are
prescribed in Exhibit A to this Agreement.

         5.3 Takeda's Manufacture. Upon Takeda's request at any time, BioNumerik
and Takeda will in good faith negotiate regarding the possible manufacture by
Takeda (including Takeda's right to use contract manufacturers) of a part or all
of the entire requirement of the

                                       26
<PAGE>

Product or bulk Active Pharmaceutical Ingredient of the Product for distribution
and sale in the Territory, provided that any such manufacturing would be subject
to BioNumerik's then existing arrangements with contract-manufacturers and other
third parties relating to manufacture of the Product and the decision of whether
or not to allow Takeda to manufacture any of the Product would be in the sole
discretion of BioNumerik. BioNumerik will not enter into future arrangements
with contract manufacturers and other third parties directly concerning
manufacture of the Product for sale (and not routine testing and analysis) in
the Territory without Takeda's prior written consent, which will not be
unreasonably withheld by Takeda.

         5.4 Manufacturing Costs. BioNumerik will use Commercially Diligent
Efforts to attempt to keep the Manufacturing Costs per unit at or below [**] of
Gross Sales per unit; provided that this maximum Manufacturing Costs is
determined based on the assumption that such Gross Sales per unit is more than
[**] in the United States.

                                   ARTICLE VI

                     MARKETING AND PROMOTION OF THE PRODUCT

         6.1 Marketing. Takeda and its Affiliate or its sublicensees will use
their Commercially Diligent Efforts to promote and market the Product in the
Territory in accordance with the Marketing Plan created by Article XIII, Section
13.3. Takeda will be responsible for assuring that its Affiliates and any
sublicensees meet the standards required in this Section.

         6.2 Marketing Plan. Takeda and BioNumerik agree to jointly develop the
Marketing Plan. The Marketing Plan will be developed by the Promotion Committee
as discussed in Article XIII, Section 13.3. The Marketing Plan may be changed by
the Joint Steering Committee referred to in Article XIII, Section 13.1. The
Marketing Plan will include, but is not limited to, the following items:

                  (a)      the strategy and expected outcomes for
                           cost-effectively marketing and promoting the Product
                           in the Territory, including, but not limited to, the
                           number and location of sales representatives and
                           selling and promotional coordination plans;

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       27
<PAGE>

                  (b)      the strategy and expected outcomes for
                           cost-effectively distributing the Product in the
                           Territory;

                  (c)      the strategy and expected outcomes for
                           cost-effectively training medical personnel about the
                           Product in the Territory, including, but not limited
                           to, the number of medical liaisons and their
                           responsibilities;

                  (d)      the strategy and expected outcomes for
                           cost-effectively marketing and promoting the Product
                           in the Territory specifically to potentially larger
                           sales accounts and to persons identified by at least
                           one of the Parties as "opinion leaders" in oncology,
                           including but not limited to the schedule of such
                           visits and the identification of persons who would
                           participate in such visits;

                  (e)      the projected annual budgets for the Distribution,
                           Marketing and Promotion Expenses; the projected
                           annual budgets will be inclusive of three (3) years
                           with the caps set forth in Sections 9.2(d) and
                           9.2(e); and,

                  (f)      the projected budget for preparation of the launch of
                           the Product in the Territory, including caps to be
                           recommended by the Promotion Committee as approved by
                           the Joint Steering Committee.

         6.3 Co-Promotion. BioNumerik has the right to co-promote the Product
with Takeda in the United States in accordance with this Agreement.

         6.4 Preparation of Promotional Materials. Both Parties will have the
responsibility to prepare, in close collaboration with each other through the
Promotion Committee and as approved by the Joint Steering Committee, promotional
materials for their use in the Territory consistent with the Marketing Plan.
Takeda will indicate BioNumerik's corporate name and/or logo on labels,
packages, package inserts, or promotional materials, etc. for the Products in
such reasonable shape, color and size so as to render the indication plainly
discernible, to the extent permitted by applicable law, regulations and
guidelines in the Territory, with prior review and approval by BioNumerik.

                                       28
<PAGE>

         6.5 Preparation of Training Materials. Both Parties will have the
responsibility to prepare, in consultation with each other, training materials
for their use in the Territory consistent with the Marketing Plan.

         6.6 Recall. Voluntary recall of the Product in each country of the
Territory will be determined by mutual agreement of both Parties; provided,
however, Takeda as a distributor and seller of the Product may start procedures
for the recall of the Product in the case of emergency event by Takeda's own
good faith determination, keeping BioNumerik informed of the progress of such
procedures. All costs and liabilities for the recall arising out of negligence
or willful misconduct by one Party or the breach of representations or
warranties by one Party will be borne by such Party to the extent caused by such
Party, and such Party will indemnify the other Party in accordance with Article
XVI.

      6.7 Non-Compete. Neither BioNumerik nor Takeda will market or promote [**]
in competition with the Product in the Territory during the term of this
Agreement, except with prior written consent or agreement by the other Party.
BioNumerik will not cause or encourage third parties to import the Product into
the Territory for sale in the Territory and BioNumerik will use Commercially
Diligent Efforts to oppose the importation by third parties of the Product into
the Territory for marketing and distribution in the Territory. Except as
expressly provided in this Agreement or by a separate written agreement between
the Parties, BioNumerik will not directly or indirectly distribute or sell
Product in the Territory. Except as expressly provided in this Agreement or by a
separate written agreement between the Parties, Takeda will not directly or
indirectly manufacture Product to be sold in the Territory or manufacture,
market, distribute or sell Product outside the Territory.

                                   ARTICLE VII

                                     CANADA

         7.1 Development. Article IV will apply, mutatis mutandis, to
development of the Product in Canada; provided, however, that both Parties agree
that each will conduct its

                                       29

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>

obligations regarding the development of the Product in Canada after
consultation with the other Party.

         7.2 Marketing and Promotion. Notwithstanding Section 6.1, in
consultation with BioNumerik, Takeda will have an option not to start promotion
or marketing of the Product in Canada until the later of (a) two (2) years after
the commercial launch of the Product in the United States, and (b) sixty (60)
days after marketing approval of the Product by the Regulatory Agency in Canada,
provided that if Takeda does not start promotion or marketing of the Product in
Canada by such time, then all rights granted under Section 2.1 regarding Canada
would revert back to BioNumerik. In addition, at any time after commercial
launch of the Product in Canada. Takeda, upon six (6) months written notice to
BioNumerik, may suspend, discontinue, or terminate promotion or marketing of the
Product in Canada, in which event, all rights granted under Section 2.1
regarding Canada would revert back to BioNumerik. In addition, in the event of
reversion to BioNumerik of rights concerning Canada pursuant to this Section
7.2, Takeda will transfer to BioNumerik, with the right to sublicense, all
necessary data and information possessed by Takeda for BioNumerik to develop and
commercialize the Product in Canada. Before or after the time of any such
reversion of Canada rights to BioNumerik, commercial launch and marketing of the
Product in Canada will be subject to Joint Steering Committee approval, which
will not be unreasonably withheld by either Party. Also, if BioNumerik alleges a
breach of the Agreement by Takeda under Section 15.4(a) and the basis for
Takeda's breach is solely a breach of its obligation to use Commercially
Diligent Efforts to promote and market the Product in Canada, then BioNumerik's
remedy will be the reversion of all rights granted under Section 2.1 regarding
Canada to BioNumerik, as well as the transfer by Takeda to BioNumerik of all
necessary data and information possessed by Takeda for BioNumerik to develop and
commercialize the Product in Canada. If Takeda's Canadian license reverts back
to BioNumerik, then BioNumerik, and its sublicensees, may develop and market the
Product in Canada.

                                  ARTICLE VIII

                  PAYMENTS, COSTS, STOCK TRANSFER, AND REPORTS

         8.1 Initial Payment. The Parties agree that Takeda will acquire from
BioNumerik, and BioNumerik will issue to Takeda, shares of (a) Series I
Convertible Preferred Stock, par

                                       30
<PAGE>

value $0.01 per share (the "Series I Preferred Stock"), and (b) Series J
Convertible Preferred Stock, par value $0.01 per share (the "Series J Preferred
Stock" and together with the Series I Preferred Stock, the "Preferred Stock"),
in the respective amounts provided herein, for aggregate cash consideration of
fifty-two million US dollars (US$52,000,000) (the "Aggregate Preferred Stock
Purchase Price"), in accordance with the terms and subject to the conditions of
that Convertible Preferred Stock Purchase Agreement, a copy of which is attached
hereto as Exhibit C and which will be executed by the Parties on the Effective
Date of this Agreement (the "Preferred Stock Purchase Agreement").

         The number of shares of Series I Preferred Stock initially will be
1,123,417 shares at an initial purchase price of US$34.7929 per share (the
aggregate initial Series I Preferred Stock value, i.e., the initial purchase
price per share multiplied by the initial number of shares, the "Initial Series
I Value"), provided that in the event of a BioNumerik IPO within one year after
the Effective Date, the purchase price and number of shares of Series I
Preferred Stock will be adjusted, immediately following the exercise or
expiration of any underwriters' over-allotment option granted in connection with
the BioNumerik IPO (the aggregate adjusted Series I Preferred Stock value, i.e.,
the adjusted purchase price per share multiplied by the adjusted number of
shares, the "Adjusted Series I Value"), so that the adjusted purchase price will
equal the IPO Price and the number of adjusted shares of Series I Preferred
Stock will equal the lesser of (i) that number of shares of Series I Preferred
stock that on an as-converted basis would represent 9.99% of BioNumerik's then
outstanding common stock, par value $ 0.01 (the "Common Shares") and Preferred
Stock (calculated on an as converted basis) (taking such offering into account)
but exclusive of any Common Shares issuable pursuant to options granted but
unexercised pursuant to BioNumerik's stock option or stock purchase plans or
warrants issued but unexercised in connection with certain other preferred stock
issuances or (ii) that number of shares of Series I Preferred Stock determined
by dividing the Aggregate Preferred Stock Purchase Price by the IPO Price;
provided that if the Pre-Transaction Valuation is less than US$400.00 million,
the adjusted number of shares of Series I Preferred Stock will be 1,362,930. The
number of shares of Series J Preferred Stock initially will be 265,101 shares at
a purchase price of US$48.7100 per share, provided that in the event of a
BioNumerik IPO, if completed within one year after the Effective Date, the
purchase price and number of shares of Series J Preferred Stock will be adjusted
so that the adjusted purchase price per share will equal the

                                       31
<PAGE>

product of 1.40 multiplied by the IPO Price (the "Adjusted Series J Price Per
Share") and the adjusted number of shares will be a number equal to (i) the
difference of the Aggregate Preferred Stock Purchase Price less the Adjusted
Series I Value divided by (ii) the Adjusted Series J Price Per Share; provided
that if such difference is zero (0) or negative, then no Series J Preferred
Stock shall remain outstanding.

         The terms and provisions of the Preferred Stock will be substantially
in the form set forth in Exhibit 1 to the Convertible Preferred Stock Purchase
Agreement. Contemporaneous with the execution of the Convertible Preferred Stock
Purchase Agreement, Takeda and BioNumerik will execute a Registration Rights
Agreement substantially in the form set forth in Exhibit 2 to the Convertible
Preferred Stock Purchase Agreement (the "Registration Rights Agreement").

         Immediately following the determination of the Adjusted Series I Value
and related adjustments to the purchase price and number of shares of Series I
Preferred Stock in the event of a BioNumerik IPO, if completed within one year
following the Effective Date, the Series I Preferred Stock will automatically
convert into Common Shares (the Series I Preferred Stock, in accordance with its
terms, will also automatically convert into common stock in the event of a
BioNumerik IPO at any time following the one year anniversary of the Effective
Date). The Series I Preferred Stock will also be convertible, at the election of
Takeda, at any time upon a "Corporate Reorganization" (as defined in Series I
Preferred Stock designation) or after the first anniversary of the Effective
Date.

         The Series J Preferred Stock will be convertible, at the election of
Takeda, at any time upon a "Corporate Reorganization" (as defined in Series J
Preferred Stock designation) or after the first anniversary of the Effective
Date, will not be automatically convertible upon a BioNumerik IPO, and will be
mandatorily convertible at BioNumerik's election and upon written notice to
Takeda at any time following the one year anniversary of the Effective Date
provided that the closing price or last sale price of the Common Shares on each
of the ten (10) business days preceding BioNumerik's delivery of such notice of
conversion shall have equaled or exceeded the then applicable conversion price
of the Series J Preferred Stock. Furthermore, to the extent then outstanding and
provided that a BioNumerik IPO has occurred, shares of Series J

                                       32
<PAGE>
Preferred Stock will automatically convert into Common Shares at the then
applicable conversion price upon the sixth anniversary of the Effective Date.

         Although the Series I Preferred Stock and Series J Preferred Stock will
vote on an as converted basis together with other classes and series of
BioNumerik capital stock on matters submitted to a vote of shareholders, Takeda
hereby agrees with BioNumerik, as set forth in the separately-executed Voting
Agreement Form attached hereto as Exhibit J, to vote all shares of BioNumerik
capital stock held by Takeda or its Affiliates at any time until the earlier of
three years after launch of the Product in the Territory or five years after the
date of execution of this Agreement in accordance, at Takeda's election, with
either (i) the recommendation of the BioNumerik Board of Directors to
shareholders with respect to such matter, or (ii) in a proportionate manner that
allocates Takeda's votes with respect to any such matter in the same relative
percentages as are recorded by BioNumerik with respect to the properly submitted
votes of other shareholders of BioNumerik as to such matter; provided, however,
that in accordance with the terms of the Preferred Stock the holders of Series I
Preferred Stock and Series J Preferred Stock will have separate class voting
rights with respect to any proposed amendments to the terms of such series of
Preferred Stock and the foregoing voting arrangement between Takeda and
BioNumerik will not apply to Takeda's voting on any such proposed amendment to
the terms of such series of Preferred Stock.

         8.2 Milestone Payments. Within [**] after the NDA for the Product has
been filed by BioNumerik and such NDA filing has been accepted by the FDA in the
United States, Takeda will pay to BioNumerik the sum of sixty million US dollars
(US $60,000,000). Takeda will further pay to BioNumerik, within [**] after the
launch of the Product in the United States, the sum of sixty million US dollars
(US $60,000,000). The term "launch" used in this section means the first receipt
of the Product by commercial entities such as wholesalers, distributors,
pharmacies and hospitals in the United States, after the NDA approval of the
Product and not for the purpose of non-clinical or clinical studies.

         8.3 Commercial Milestone Payments. For the first Fiscal Year during
which sales of the Product in the Territory reach each of the following
indicated annual Net Sales levels,

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       33
<PAGE>

Takeda will pay Commercial Milestone Payments to BioNumerik in the amounts and
at the times described below:

<TABLE>
<CAPTION>
ANNUAL NET SALES IN THE TERRITORY                          PAYMENT
         IN A FISCAL YEAR                               TO BIONUMERIK
---------------------------------             ---------------------------------
<S>                                           <C>
  Two hundred million US dollars                Twenty million US dollars (US
        (US $200,000,000)                               $20,000,000)

 Four hundred million US dollars                Twenty million US dollars (US
        (US $400,000,000)                               $20,000,000)

  Six hundred million US dollars                Thirty million US dollars (US
        (US $600,000,000)                               $30,000,000)

 Eight hundred million US dollars             Forty-five million US dollars (US
        (US $800,000,000)                               $45,000,000)
</TABLE>

         In other words, in the first Fiscal Year that annual Net Sales in the
Territory reach US$200,000,000, Takeda will pay BioNumerik US$20,000,000. If, in
the next Fiscal Year, annual Net Sales reach only US$300,000,000, then no
payment is made, and if, in the following Fiscal Year, annual Net Sales reach
US$500,000,000, Takeda will pay BioNumerik an additional US$20,000,000.

         The following example is intended to help clarify the arrangement and
is for clarification purposes only. In the event the actual annual Net Sales for
the Product are US$100,000,000 in 2008, US$300,000,000 in 2009, US$700,000,000
in 2010, US$900,000,000 in 2011 and US$1,100,000,000 in 2012, then each
Commercial Milestone Payment would be as follows: no payment in 2008;
US$20,000,000 in 2009; US$50,000,000 in 2010 (US$20,000,000 for US$400,000,000
sales plus US$30,000,000 for US$600,000,000 sales); US$45,000,000 in 2011; and
no payment in 2012 and thereafter. Thus, each Commercial Milestone Payment
occurs only once during the life of this Agreement and only when the annual Net
Sales reach the particular

                                       34
<PAGE>

amount shown in a given Fiscal Year. At the same time as the accounting is
reported after the end of a quarter, Takeda will pay to BioNumerik the annual
Commercial Milestone Payment if the annual Net Sales reach the particular amount
shown in a given Fiscal Year to date required to achieve such Commercial
Milestone Payment during that preceding quarter.

         8.4 Research and Development Payments.

                  (a) Subject to the terms and conditions set forth in this
Section 8.4, Takeda agrees to pay BioNumerik up to the following maximum annual
Research and Development Payments in the following calendar years to develop the
Product for the Territory:

<TABLE>
<CAPTION>
      2005                     2006                 2007              2008               2009               Total
-----------------      -------------------      -----------      --------------     --------------   ------------------
<S>                    <C>                      <C>              <C>                <C>              <C>
Thirty million US      Thirty-five million      Thirty-five      Thirty million     Eight million        One hundred
   dollars (US              US dollars           million US      US dollars (US     US dollars (US      thirty-eight
  $30,000,000)           (US$35,000,000)        dollars (US       $30,000,000)       $8,000,000)     million US dollars
                                                $35,000,000)                                          (US $138,000,000)
</TABLE>

                  (b) Within [**] after April 1st of each year,
beginning with calendar 2005 and ending with calendar 2009, Takeda will pay
BioNumerik in cash the first one-half of the annual Research and Development
Payments for such year. For clarity and example, Takeda will pay BioNumerik
fifteen million US dollars within [**] after April 1, 2005.

                  (c) Takeda will satisfy its obligation to pay the remaining
one-half of annual Research and Development Payments not otherwise paid pursuant
to subsection (b) above by purchasing for cash, during each such year, Common
Shares as follows:

                           (i)      Takeda will have the right in connection
                                    with any public or private offering of
                                    securities during such year by BioNumerik
                                    primarily for capital-raising purposes (but
                                    excluding, without limitation, shares
                                    issuable pursuant to an acquisition, another
                                    strategic alliance or

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       35
<PAGE>

                                    licensing arrangement and shares issued
                                    pursuant to employee, director or consultant
                                    benefit plans) to acquire the lesser of (i)
                                    20% of the number of Common Shares to be
                                    issued in each such offering; or (ii) the
                                    maximum number of Common Shares which, when
                                    aggregated with Takeda's existing holdings
                                    of Common Shares and Preferred Stock at the
                                    time, will result in Takeda's holdings not
                                    exceeding 9.99% of BioNumerik's outstanding
                                    Common Shares and Preferred Stock
                                    (calculated on an as converted basis)
                                    (taking such offering into account)
                                    exclusive of any Common Shares issuable
                                    pursuant to options or warrants granted but
                                    unexercised pursuant to BioNumerik's stock
                                    option or stock purchase plans or warrants
                                    issued but unexercised in connection with
                                    preferred stock issuances, at a price per
                                    share and otherwise on terms and conditions
                                    made available to other bona fide purchasers
                                    in any such offering, with such purchase by
                                    Takeda to be made concurrently with the
                                    closing of such other offering, and

                           (ii)     at any time during such calendar year as
                                    BioNumerik will elect upon at least one
                                    hundred twenty (120) days advance written
                                    notice to Takeda, (x) Takeda and BioNumerik
                                    will complete a separate sale or sales of
                                    Common Shares to Takeda at a price equal to
                                    the fair market value of such Common Shares
                                    based upon the average closing price or last
                                    sale price over the 10-business day period
                                    immediately preceding the sale, if
                                    BioNumerik is then a reporting company under
                                    the U.S. Securities Exchange Act of 1934, as
                                    amended (the "Exchange Act")), or, (y) if
                                    BioNumerik is not then a reporting company
                                    under the Exchange Act, Takeda and
                                    BioNumerik may agree upon a separate sale or
                                    sales of Common Shares to Takeda at such
                                    fair market value price as may be mutually
                                    agreed by BioNumerik and Takeda. If, within
                                    sixty (60) days after commencement of
                                    efforts by BioNumerik and Takeda to agree
                                    upon a fair market value price for Common
                                    Shares in accordance with the

                                       36
<PAGE>

                                    immediately preceding sentence, the Parties
                                    have been unable to so agree, then either
                                    Party, upon notice to the other Party, may
                                    elect to have the fair market value price
                                    determined as follows:

                                            (A) For a period of twenty (20) days
                                            after receipt of such notice, the
                                            Parties will attempt to agree upon
                                            an investment banking firm to
                                            determine the fair market value
                                            price for Common Shares and, if the
                                            Parties cannot agree upon an
                                            investment banking firm to make such
                                            determination within such period,
                                            then, with forty (40) days after
                                            receipt of the notice referenced
                                            above, each Party, by notice to the
                                            other Party, will name one
                                            internationally recognized
                                            investment banking firm not
                                            otherwise associated or doing
                                            business with such Party and such
                                            two investment banking firms will
                                            mutually select a third
                                            internationally recognized
                                            investment banking firm, which will
                                            then determine the fair market value
                                            price for Common Shares; and

                                            (B) Each Party may provide the
                                            investment banking firm selected to
                                            determine the fair market price
                                            value for Common Shares such
                                            materials and other written
                                            information, with copies to the
                                            other Party, as such Party believes
                                            relevant to such determination
                                            within ten (10) business days after
                                            such firm's selection. The
                                            investment banking firm will
                                            determine a fair market value price
                                            for Common Shares within sixty (60)
                                            days after its selection. Once the
                                            fair market value price for Common
                                            Shares has been determined by the
                                            investment banking firm, as provided
                                            above, the investment banking firm
                                            will notify both Parties of such
                                            value in writing, and the
                                            corresponding

                                       37
<PAGE>

                                            purchase of Common Shares pursuant
                                            to this Section 8.4 will be closed
                                            within thirty (30) days of such
                                            notification. The decision of the
                                            investment banking firm will be
                                            final and binding on the Parties.
                                            All costs and fees incurred by the
                                            investment banking firm(s) in
                                            connection with the procedures
                                            described above will be borne
                                            equally by the Parties.

                  In addition, with respect to purchases of the Common Shares in
private offerings only, as a condition to each such purchase, Takeda and
BioNumerik will execute and deliver, and the purchase and sale of the Common
Shares will be made in accordance with, a Common Stock Purchase Agreement
substantially in the form of attached Exhibit D. All Common Shares purchased by
Takeda under this subsection (c) will be subject to the Registration Rights
Agreement.

                  (d) BioNumerik will have the right, in its sole discretion, in
any particular calendar year, not to sell some or all of the Common Shares
relating to such year to Takeda pursuant to clause (ii) of subsection (c);
provided, however, that BioNumerik will have no such right to the extent that it
initiates the procedures to select an investment banking firm to determine the
fair market value price in accordance with Section 8.4(c) above with respect to
the Common Shares subject to such valuation procedures. If, for any reason,
BioNumerik is unable or unwilling to sell Common Shares to Takeda or Takeda is
otherwise limited under this Section 8.4 from acquiring Common Shares, in either
case in an amount sufficient for Takeda to satisfy its entire Research and
Development funding obligation hereunder for any calendar year, then upon
written notice to Takeda prior to the end of such calendar year, BioNumerik may
elect to carry over such Takeda purchase commitment (to the extent of the
Research and Development Payment amount for such calendar year that is not paid
during such year pursuant to Section 8.4(c), being referred to as the "Carryover
Amount", expressed in U.S. dollars) to the immediately following calendar year
(together with Takeda's other Common Share purchase commitments for such
following year), but if, in such following calendar year, BioNumerik is unable
or unwilling to sell Common Shares to Takeda or if Takeda is otherwise limited
under this Section 8.4 from acquiring Common Shares, in either case in such
following year in an

                                       38
<PAGE>

amount sufficient to satisfy such Carryover Amount (and all shares sold by
BioNumerik to Takeda in such following year will be first allocated to satisfy
the Carryover Amount) then Takeda's obligation to purchase any additional Common
Shares pursuant to subsection (c) for the immediately preceding calendar year to
which such Carryover Amount relates will terminate. BioNumerik, in its
discretion, may sell Common Shares to Takeda to allow the satisfaction of some,
but not all, of Takeda's funding commitment amount, in which event any remaining
unsatisfied commitment amount would be carried over subject to the limitations
described above. Similarly, to the extent a delay in the sale of Common Shares
is agreed to by the Parties pursuant to Section 8.4(f) to enable Takeda to avoid
a potential liability under Section 16(b) of the Exchange Act, the amount of any
such deferred Research and Development Payment will be treated as a Carryover
Amount to such following calendar year. To the extent any unpurchased amount of
Common Shares in any calendar year does not become a Carryover Amount for the
following year in accordance with the terms of the immediately preceding
sentences, then Takeda's obligation to purchase such amount shall terminate. If,
for any reason, BioNumerik is unable or unwilling to sell Common Shares to
Takeda or Takeda is otherwise limited under this Section 8.4 from acquiring
Common Shares, then in either case the costs for the clinical and non-clinical
development of the Product in the Field for the Territory in accordance with the
Development Plan exceeding Takeda's payment of half of the maximum annual
Research and Development Payment pursuant to Section 8.4(b) will be borne solely
by BioNumerik, but subject to the provisions of Section 8.4(h).

                  (e) Anything else in this Agreement to the contrary
notwithstanding, except as otherwise agreed by BioNumerik, Takeda will not
purchase Common Shares pursuant to this Section 8.4 to the extent that Takeda's
ownership of BioNumerik Common Shares and Preferred Stock then actually
outstanding exceeds, or as a result of such purchase would exceed, 9.99% of
BioNumerik's then outstanding Common Shares and Preferred Stock (calculated on
an as converted basis) exclusive of any Common Shares issuable pursuant to
options or warrants granted but unexercised pursuant to BioNumerik's stock
option or stock purchase plans or warrants issued but unexercised in connection
with certain other previous preferred stock issuances; provided however, that
BioNumerik and Takeda will use reasonable efforts to cooperate with one another,
pursuant to the provisions of the Registration Rights Agreement and otherwise,
so that Takeda will be afforded the opportunity not less often than once every
two

                                       39
<PAGE>

years through the calendar year 2010 to effectuate in an orderly fashion sales
of Common Shares held by Takeda in the principal U.S. securities markets, if
any, in which BioNumerik's Common Shares are then traded (including, without
limitation, in an underwritten public offering, which may involve, at Takeda's
election, selling efforts by BioNumerik's management team; in negotiated block
trades arranged by BioNumerik's or Takeda's principal investment banking firms;
or in sales pursuant to Rule 144 of the Securities Act), and in the amount of up
to 50% of Takeda's then-current holdings of Common Shares and Preferred Stock
(calculated on an as converted basis); provided, however, if the Parties
successfully arrange any such sale opportunity and any Common Shares (including
Common Shares issuable upon conversion of any Preferred Stock that can be
converted) can then be sold by Takeda at a price per share in excess of the
acquisition price for such Common Shares (or the acquisition price for the
underlying Preferred Stock), Takeda will at that time sell all of such Common
Shares to the extent that the number of Common Shares to be sold is equal to the
greater of (i) 25% of Takeda's holdings of Common Shares and Preferred Stock
(calculated on an as converted basis) (provided that 18 months or more will have
elapsed since Takeda was last required to sell or dispose of Common Shares based
upon such 25% standard); and (ii) the minimum number of Common Shares which,
when aggregated with reasonably foreseeable Common Share purchase obligations
under Section 8.4(c) for such calendar year, will result in Takeda's holdings
not exceeding 9.99% of BioNumerik's then outstanding Common Shares and Preferred
Stock (calculated on an as converted basis) exclusive of any Common Shares
issuable pursuant to options or warrants granted but unexercised pursuant to
BioNumerik's stock option or stock purchase plans or warrants issued but
unexercised in connection with certain other previous preferred stock issuances.
Takeda, in its discretion, may also sell additional Common Shares in such
transaction up to the 50% limitation described in the prior sentence of this
Section 8.4(e). Anything in this Section 8.4(e) to the contrary notwithstanding,
Takeda will have no restrictions on sale of Common Shares hereunder in the event
of (i) any sale of all or substantially all of the assets of BioNumerik, or any
sale or related series of sales of shares of BioNumerik's capital stock by any
holders thereof or any merger, consolidation or combination to which BioNumerik
is a party and which results in the beneficial owners of BioNumerik's Common
Shares as of the date immediately preceding such transaction or related series
of transactions no longer beneficially owing the capital stock of BioNumerik (or
any new or surviving corporation with which

                                       40
<PAGE>

BioNumerik merges, consolidates or combines) possessing the voting power (under
ordinary circumstances) to elect a majority of the board of directors, (ii) any
sale or other disposition by Dr. Fred Hausheer, in one or a series of related
transactions, of 50% or more of the Common Shares beneficially owned by Dr. Fred
Hausheer over any two-year period, or (iii) the termination of this Agreement.
However, Takeda hereby agrees that Takeda will not sell or otherwise dispose of
any shares of the Preferred Stock (though Takeda may convert the Preferred Stock
and sell the underlying Common Shares in accordance with the provisions hereof)
except (i) upon or following the occurrence of any of the events specified in
clauses (i), (ii) or (iii) of the preceding sentence and (ii) for transfers to
Affiliates of Takeda or to a successor to substantially all of the business or
assets of Takeda in a transfer permitted under Section 11.1 (which in either
case undertakes in connection with such transfer to be similarly bound to comply
with this undertaking).

                  (f) Anything in this Section 8.4 to the contrary
notwithstanding, Takeda will have no obligation to purchase or sell the Common
Shares or otherwise take any other action to the extent that any such purchase,
sale, or other action would violate the Securities Act, the Exchange Act, or any
other applicable federal or state securities law, or result in any liability to
Takeda under the Securities Act, the Exchange Act, or any other applicable
federal or state securities law. To the extent that Takeda is at any time deemed
a holder of 10% or more of the shares of BioNumerik's outstanding common stock
or is otherwise a person subject to the reporting and short-swing profit
provisions of Section 16 of the Exchange Act, both Parties will cooperate, to
the extent reasonably necessary as identified by Takeda, to arrange the timing
of Takeda sales activity pursuant to Section 8.4(e) and Takeda purchases from
BioNumerik pursuant to Sections 8.4(c) and 8.4(d) so as accomplish the
objectives of not creating liability for Takeda under Section 16(b) of the
Exchange Act and positioning Takeda to make purchases contemplated by Section
8.4(c) to fund Research and Development Payments.

                  (g) Research and Development Payments made by Takeda pursuant
to Section 8.4(b) will be allocated solely for the clinical and non-clinical
development of the Product in the Field for the Territory in accordance with the
Development Plan. Any portion of a Research and Development Payment received for
a particular calendar year that is not spent in that particular calendar year
may be deferred, as reasonably determined by BioNumerik, to be used in the

                                       41
<PAGE>

following calendar year. BioNumerik will provide to Takeda a quarterly
accounting regarding the costs for such development within thirty (30) days
following the end of each calendar quarter of the Fiscal Year. BioNumerik will
send Takeda a written report setting forth the reasonable costs that it incurred
for the clinical and non-clinical development. Each cost will be described and
the date on which the cost was paid will be included.

                  (h) Subject to the limitations of this Section 8.4, the total
amount of the Research and Development Payments made solely by Takeda between
the calendar years 2005 and 2009 will be one hundred and thirty eight million US
dollars (US$138,000,000). All additional required clinical and non-clinical
investment in any particular calendar year that is in excess of the Research and
Development Payments made by Takeda as set forth in Section 8.4(a) above will be
borne equally by BioNumerik and Takeda, provided that the Parties mutually agree
to the additional work to be done. Further, all subsequent required clinical and
non-clinical investment over US$138,000,000 for the Product in the Field in the
Territory will be borne equally by BioNumerik and Takeda for the Product, if the
costs are agreed to in writing by both Parties in the Development Plan. Costs
for clinical and non-clinical studies will include actual payments to service
providers such as contract research organizations ("CROs"), consultants,
clinical and non-clinical drug supply and materials, as well as actual payments
and indirect costs for regulatory filing fees, regulatory document preparation
and copying costs, and each Party's internal direct and indirect costs
reasonably allocated to such studies and materials for such studies and
regulatory filings, regarding the Product in the Field for the Territory.

                  (i) BioNumerik agrees that, for the Applicable Period (as
defined below), it will pay to Takeda within thirty (30) days after each
calendar quarter, one-half of all Manufacturing Net Profits (as defined below)
earned by BioNumerik during the preceding calendar quarter with respect to
BioNumerik's manufacturing rights for Venture Products BN (as defined in the KI
Pharma Joint Venture Agreement a copy of which definition is attached hereto as
Exhibit I). For purposes hereof, "Manufacturing Net Profits" means, for any
relevant period, aggregate sales of the Venture Products BN by BioNumerik, as
manufacturer, to the KI Pharma Joint Venture less (i) fully allocated cost of
manufacturing the Venture Products BN in a final packaged form, and (ii)
overhead (fixed and variable costs associated with management and support of the
manufacturing process) allocated to the Venture Products BN, all calculated in

                                       42
<PAGE>

accordance with normal accounting practices applied on a basis consistent with
BioNumerik's past practices and industry standards for all products manufactured
in a fully utilized facility or normal capacity. "Applicable Period" means the
period commencing upon the first receipt of the Venture Products BN by
commercial entities such as wholesalers, distributors, pharmacies and hospitals
in Japan, after receipt of required regulatory approvals in connection therewith
and not for the purpose of non-clinical or clinical studies and ending after a
period thereafter equal to the number of days from the Effective Date to the
date the BioNumerik IPO occurs, provided that if the BioNumerik IPO occurs
within 365 days after the Effective Date the applicable period will be zero (0)
days.

                  (j) From the date of execution of this Agreement until the
Effective Date, BioNumerik agrees that it will not issue or grant any shares of
Common Shares or Preferred Stock (other than in connection with the BioNumerik
IPO and in connection with the exercise of previously granted stock options or
warrants in the ordinary course) or any options or warrants to acquire any such
shares or any other securities or instruments convertible into such shares.

                  (k) BioNumerik covenants and agrees that it will not cause the
BioNumerik IPO to occur until the earlier of (i) BioNumerik's obtaining of all
necessary approvals by BioNumerik's shareholders of the issuance of the
Preferred Stock and the Common Shares and the execution of the Registration
Rights Agreement, as provided in this Agreement, or (ii) BioNumerik's failure,
after full discharge of its obligations under this Agreement to attempt to
obtain shareholder approvals, to obtain all such approvals.

                                   ARTICLE IX

                       PROVISIONAL PRICE AND PROFIT SHARE

         9.1 Provisional Price. Takeda agrees to pay BioNumerik a Provisional
Price for each unit of Product that BioNumerik supplies to Takeda.

         9.2 Profit Share. Net Profits will be determined by the following
equation:

                  Net Profits = Net Sales minus Incurred Costs

                  Net Profits will be shared equally between BioNumerik and
Takeda as follows:

                                       43
<PAGE>

                  (a) If Net Profits are positive, then each Party will receive
fifty percent (50%) of Net Profits; however, the Provisional Margin paid by
Takeda to BioNumerik as part of the Provisional Price will be deducted from
BioNumerik's share of the Net Profits.

                  (b) If Net Profits are negative, then each Party will bear
fifty percent (50%) of the loss of Net Profits. Specifically, in the event that
Net Profits are negative, BioNumerik will give back to Takeda all or part of the
Provisional Margin plus any additional amount necessary to equal fifty percent
(50%) of the loss of Net Profits.

                  (c) All costs for developing and obtaining approval for a new
indication beyond oncology will be borne equally by the Parties. However, in the
case that one Party does not want to make or cannot afford to bear the costs for
the new indication, the other Party has the option to take the responsibility to
bear the necessary costs itself. In such event the other Party will cooperate
with the Party seeking such new indication with the other Party being reasonably
reimbursed for related costs of the cooperation. In the event that (i) the new
indication for the Product is successful, the other Party will have the option
to reimburse the paying Party [**] of the actual costs incurred for the Product
development and approval with respect to the new indication, in which case the
other Party will then receive [**] of the Net Profits as described in this
Section 9.2 (including, without limitation, [**] of the Net Profits for the new
indication), or in the event that (ii) the other Party does not want to pay for
such [**] share of the costs for the new indication, then the non-paying Party
will receive only [**] of the Net Profits from sales of the Product for the new
indication and the paying Party will receive [**] of the Net Profits from sales
of the Product for the new indication.

                  (d) The amount of Takeda's costs included in the calculation
of the Net Profits will not exceed for each of the first three years from the
anniversary date of the "launch" of the Product as defined in Section 8.2 the
amounts in the Table 9.2(d) immediately following this section. When the
Promotion Committee is discussing the budget to be applied for the fourth year
following the launch and thereafter, if the Parties can not agree to the amount
of the maximum expenses for these four categories in each of these later years,
the Parties understand that, until the Parties have reached agreement on such
applicable amount, the default amount of

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       44
<PAGE>

the maximum expenses in the fourth year will be [**] of the actual amount spent
in the third year, and the default amount in any year thereafter will be [**] of
the actual amount spent in the prior year. Both Parties agree that the division
of these four categories are not strict and Takeda may reasonably allocate its
expenses in one category of them to another category within the total annual
maximum amount for each year.

Table 9.2(d)

        Cap on Certain Takeda's Commercialization Costs (in $US Millions)

[**]

         (e) The amount of BioNumerik's costs included in the calculation of the
Net Profits will not exceed for each of the first three years from the
anniversary date of the "launch" of the Product as defined in Section 8.2 the
amounts in the Table 9.2(e) immediately following this section. When the
Promotion Committee is discussing the budget to be applied for the fourth year
following the launch and thereafter, if the Parties can not agree to the amount
of the maximum expenses for these four categories in each of these later years,
the Parties understand that, until the Parties have reached agreement on such
applicable amount, the default amount of the maximum expenses for these four
categories in the fourth year will be [**] of the actual amount spent in the
third year, and the default amount in any year thereafter will be [**] of the
actual amount spent in the prior year. Both Parties agree that the division of
these four categories are not strict and BioNumerik may reasonably allocate its
expenses in one category of them to another category within the total annual
maximum amount for each year.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       45
<PAGE>

Table 9.2(e)

      Cap on Certain BioNumerik's Commercialization Costs (in $US Millions)

[**]

         9.3 Accounting. Calculation and payment/reimbursement of the Profit
Share will be made quarterly, with an adjustment at the end of the Fiscal Year,
with the calculation of the Net Profits to begin after the first full quarter
following the Effective Date. A statement will be provided by BioNumerik to
Takeda of BioNumerik's Incurred Costs within ten (10) business days following
the end of each calendar quarter of the Fiscal Year. BioNumerik will send a
written report to Takeda detailing its Incurred Costs. Within ten (10) business
days of receiving BioNumerik's report, Takeda will send to BioNumerik, a written
report setting forth the calculation of the Profit Share payment. Such report
will be sent to BioNumerik even when no Product was sold during the calendar
quarter. Within thirty (30) days of the date of such Takeda's report, the
balance will be paid by a Party to the other Party so that the Net Profits will
be equally shared between the parties. For illustration, an example calculation
is set forth in Exhibit H hereto.

         After the Product is launched in the Territory, a monthly accounting
will be made by Takeda to BioNumerik within fifteen (15) days following the end
of each month of the Fiscal Year. Specifically, Takeda will send to BioNumerik,
a written report setting forth the amount and a description of the Product sold
during the preceding month and the associated aggregate Net Sales invoiced
during the month. A report will be sent to BioNumerik even if no Product is sold
during the previous month.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       46
<PAGE>

         Such reports by each Party for the last calendar quarter in a Fiscal
Year will include year-end adjustment in accordance with ascertained Net Sales
and Incurred Costs if necessary.

                                    ARTICLE X

                 WITHHOLDING TAX, AUDIT AND CURRENCY CONVERSION.

         10.1 Withholding Tax. In the event that any payment by a Party to the
other Party under this Agreement is subject to withholding tax required by
applicable laws to be paid to the taxing authority of any country, the amount of
such tax may be withheld from the applicable payment. Such Party will promptly
pay such tax on behalf of the other Party, and will furnish the other Party with
a certificate of withholding tax so deducted or its equivalent for the other
Party's avoidance of duplicate taxation. Each Party will cooperate with and
provide reasonable assistance to the other Party to enable them to obtain
necessary documentation and other information necessary to establish any
exemptions from or refund of withholding or other payments under applicable tax
treaties or other tax laws of applicable countries.

         10.2     Maintenance and Auditing of Records.

                  (a) The Parties will keep and will require that their
Affiliates and sublicensees keep true and accurate records and books of account
containing all data necessary for the calculation of costs for non-clinical and
clinical studies undertaken by BioNumerik hereunder, the Commercial Milestone
Payments and the Net Profit, including, but not limited to, the Incurred Costs,
and Net Sales, profit sharing pursuant to Section 8.4(i), and for preparation of
the written reports due hereunder. Those records and books of account will be
kept for three (3) years following the end of each Fiscal Year to which they
relate.

                  (b) Upon twenty (20) business days notice, each Party may have
an independent registered public accounting firm audit the other Party's or
Affiliate's or sublicensee's records and books of account to verify that every
charge and payment is correctly made in accordance with this Agreement. Such
inspections will be no more frequent than once each calendar year during the
term of this Agreement, and once within six (6) months after termination of this
Agreement. Prior to audit implementation, each Party will submit an audit plan,
including audit scope and name(s) of proposed public accounting firm, to the
other Party

                                       47
<PAGE>

for approval, which approval will not be unreasonably withheld. The independent
registered public accounting firm will keep confidential any information
obtained during such inspection and will only report to the requesting Party the
result on whether the item(s) being reviewed is accurate or not and the amount
of any inaccuracy or discrepancy.

                  (c) The cost of the accounting firm will be the responsibility
of the auditing Party unless the certification shows the audited Party to have
underpaid or overcharged the auditing Party by more than five percent (5%) in
which case the cost of the accounting firm will be the responsibility of the
audited Party. If an audit reveals an over or underpayment or over or
undercharge, the Parties will take such steps as necessary to rectify the error.

                  (d) Within ten (10) business days following any such
certification any monies which such certification shows as being due and owing
by one Party to the other (whether because of an underpayment or overpayment)
will be paid by the owing Party.

                  (e) In the conduct of their respective reporting activities
under this Agreement, each Party, its Affiliates, or its sublicensees will
prepare all accounting information in accordance with United States GAAP or as
otherwise directed by the Joint Steering Committee.

         10.3 Payments To BioNumerik. All payments made under this Agreement by
Takeda to BioNumerik will be made in US dollars and will be wired to the
following institution:

                 [**]

         10.4 Payments To Takeda. All payments made under this Agreement by
BioNumerik to Takeda will be made in US dollars and will be wired to the
following institution:

                 [**]

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       48
<PAGE>

         10.5 Conversion. The exchange rate to be used for converting foreign
currencies into US dollars will be as published in [**] for the purchase of US
dollars on the last business day of the calendar quarter for which the Net Sales
and other items are calculated under this Agreement.

                                   ARTICLE XI

            SUBLICENSE AND TRANSFERABILITY OF RIGHTS AND OBLIGATIONS

         11.1 Except as otherwise provided herein, there is no right to
sublicense and this Agreement may not be assigned by either Party without the
prior written consent of the other Party. Each Party may, at its discretion,
assign this Agreement in whole or in part to one or more of its Affiliates as
well as to a party acquiring all or substantially all of the assigning Party's
business or assets, if the assigning Party (if such assigning Party is a
surviving entity) remains liable and responsible for and the assignee will be
liable and responsible for the performance and observation of all of the
Affiliate's obligations hereunder.

                                   ARTICLE XII

          MAINTENANCE OF LICENSED PATENTS AND TRADEMARKS AND OWNERSHIP
              OF JOINTLY DEVELOPED INTELLECTUAL PROPERTY, RESULTING
                     INTELLECTUAL PROPERTY, AND IMPROVEMENTS

         12.1 Maintenance of Licensed Patents and Trademarks. BioNumerik hereby
agrees (a) to use Commercially Diligent Efforts to file, prosecute and maintain
the Licensed Patents and Licensed Trademarks and (b) to proceed to initiate
interference, re-examinations, reissues and oppositions with respect thereto, at
its costs and pay all necessary fees to assure that the Licensed Patents and
Licensed Trademarks do not terminate prematurely. Each calendar quarter,
BioNumerik will provide Takeda with reports in writing with detailed information
on the status of the Licensed Patents and patents and patent applications
constituting BioNumerik's Licensees' Patents and Information.

         Takeda will have a right to request and, promptly after any such
request, receive from BioNumerik reasonable additional information with respect
to any patent application and/or patent in the Licensed Patents and patents and
patent applications in the BioNumerik's

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       49
<PAGE>

Licensees' Patents and Information. BioNumerik will provide Takeda with a
reasonable opportunity to review and provide substantive input to material
decisions relating to the prosecution and maintenance of the Licensed Patents.
BioNumerik will furnish to Takeda copies of documents relevant to any such
prosecution and maintenance reasonably in advance of the expiration of a
response or application deadline in order to provide Takeda a meaningful
opportunity to comment thereon and to participate in all material decision
making regarding such prosecution and maintenance. For purposes of
clarification, BioNumerik will consider all substantive input and comments
provided by Takeda regarding the prosecution of such patent applications and the
maintenance of such patents. BioNumerik may continue to take ministerial and
non-material procedural matters regarding the Licensed Patents without obtaining
prior input from Takeda.

         BioNumerik agrees not to finally abandon any claims of the Licensed
Patents without providing Takeda written notice of BioNumerik's decision not
less than thirty (30) days prior to any deadline or date imposed by an office
with authority and jurisdiction in any country in the Territory where such
patent application is being prosecuted or such patent is being maintained. Upon
receipt of such notice, Takeda may, in its sole discretion, initiate and/or
continue prosecution activities with respect to such patent application and/or
maintenance activities with respect to such patent, and BioNumerik, upon such
Takeda's decision to initiate and/or continue such activities, will assign,
deliver, transfer and set over to Takeda all interest of BioNumerik in, to and
under such patent application and patent. BioNumerik will provide Takeda
reasonable cooperation, and will make available to Takeda, at reasonable times
and under appropriate conditions, access to all relevant personnel, records,
papers, information, samples, specimens, and the like in its possession
necessary to prosecute such patent application and/or maintain such patent
assigned to Takeda.

         The Parties also agree to consult with each other from time to time, at
one Party's request, on patent policies to be implemented with respect to the
Product in the Territory.

         12.2 BioNumerik Developments and Improvements. All BioNumerik
Developments and Improvements made by BioNumerik on the Product will be included
in the scope of the Licensed Information and Licensed Patents to which
BioNumerik grants Takeda an exclusive

                                       50
<PAGE>

license on the terms described herein and subject to Sections 2.4, 5.1(a), 6.3
and 6.7 hereof. However, nothing in this section should be construed to entitle
BioNumerik to additional consideration besides that expressly contained herein.
BioNumerik will be solely responsible for the prosecution of any patents
relating to the BioNumerik Developments and Improvements made to the Product,
without any right of reimbursement from Takeda for the cost of the prosecution.

         12.3 Takeda Developments and Improvements. Takeda grants a
non-exclusive, perpetual, worldwide except the Territory, royalty-free paid-up
license to BioNumerik (and its designated Affiliates and sublicensees) to: (a)
all Takeda Developments and Improvements to make, have made, use, sell, offer
for sale, market and license the Product incorporating such Takeda Developments
and Improvements throughout the world in areas outside the Territory and, (b)
all data and results obtained by Takeda from the non-clinical studies, clinical
trials and related testing conducted by Takeda for the purpose of supporting
non-clinical studies, clinical trials, regulatory approval for the Product
outside of the Territory, and development, marketing and sale of the Product
outside the Territory, and are subject to any retained rights of Takeda to
practice such Takeda Developments and Improvements other than in connection with
the Product.

         12.4 Jointly Developed Intellectual Property. Information,
developments, improvements, and intellectual property that are jointly developed
by the Parties directly concerning the Product ("Jointly Developed Intellectual
Property") will be jointly owned by the Parties. Takeda and its Affiliates will
have the exclusive right (with the right to sublicense) to use all Jointly
Developed Intellectual Property in the Territory and BioNumerik is hereby
granted a non-exclusive, perpetual, worldwide except the Territory, royalty-free
paid-up license to all Jointly Developed Intellectual Property, and BioNumerik
(and its designated Affiliates and sublicensees) may make, have made, use, sell
and license products and technology incorporating such Jointly Developed
Intellectual Property throughout the world in areas outside the Territory. In
addition, BioNumerik may use the Jointly Developed Intellectual Property to
conduct the activities described in Section 2.4. Takeda will be solely
responsible for (a) filing, prosecution and maintaining of any patents relating
to Jointly Developed Intellectual Property and (b) to proceed to initiate
interference, re-examinations, reissues and oppositions with respect thereto,

                                       51
<PAGE>

but each Party agrees to share the cost of the patent prosecution equally for
Jointly Developed Intellectual Property.

         Each party will promptly notify the other Party as to the creation of,
the conception or reduction to practice of any Jointly Developed Intellectual
Property. Takeda will promptly notify BioNumerik as to whether any patent
applications will be prepared. Takeda will have a right to request and, promptly
after any such request, receive from BioNumerik reasonable additional
information with respect to Jointly Developed Intellectual Property. Takeda will
provide BioNumerik with a reasonable opportunity to review and provide
substantive input to material decisions relating to the prosecution and
maintenance of patents for the Jointly Developed Intellectual Property. Takeda
will furnish to BioNumerik copies of documents relevant to any such prosecution
and maintenance reasonably in advance of expiration of response or application
deadline in order to provide BioNumerik a meaningful opportunity to comment
thereon and to participate in all material decision making regarding such
prosecution and maintenance. For purposes of clarification, Takeda will consider
all substantive input and comments provided by BioNumerik regarding the
prosecution of such patent applications and the maintenance of such patents.
Takeda may continue to take ministerial and non-material procedural matters
regarding the Jointly Developed Intellectual Property without obtaining prior
input from BioNumerik.

         Takeda agrees not to finally abandon any claims of the Jointly
Developed Intellectual Property without providing BioNumerik written notice of
Takeda's decision not less than thirty (30) days prior to any deadline or date
imposed by an office with authority and jurisdiction in any country where such
patent application is being prosecuted or such patent is being maintained. Upon
receipt of such notice, BioNumerik may, in its sole discretion, initiate and/or
continue prosecution activities with respect to such patent application and/or
maintenance activities with respect to such patent, and Takeda, upon
BioNumerik's decision to initiate and/or continue such activities, will assign,
deliver, transfer and set over to BioNumerik all interest of Takeda in, to and
under such patent application and patent. Takeda will provide BioNumerik
reasonable cooperation, and will make available to BioNumerik, at reasonable
times and under appropriate conditions, access to all relevant personnel,
records, papers, information, samples, specimens, and the like in its possession
necessary to prosecute such patent application and/or

                                       52
<PAGE>

maintain such patent assigned to BioNumerik. If Takeda determines not to file a
patent application relating to any Jointly Developed Intellectual Property,
BioNumerik can, in its discretion, file and prosecute and will then obtain sole
ownership rights with respect to such Jointly Developed Intellectual Property
and Takeda will provide necessary assistance to allow BioNumerik to file,
including providing data and other reasonably requested inventorship
documentation and assistance.

         Except as otherwise set forth in this Agreement, inventorship of the
Jointly Developed Intellectual Property will be determined in accordance with
the U.S. Patent Law. In the case of disagreements regarding inventorship, such
issue will be determined through the dispute resolution process under Article
XIX.

         12.5 Patent Term Extension. BioNumerik and Takeda will consult with
each other about Patent Term Extension in the Territory and make a joint
decision thereon. A Party that owns the patent which claims or relates to the
Product will promptly file all applications for any extension of patent term for
which it is eligible in accordance with such joint decision, and take all
reasonable actions necessary to obtain patent extension. Each Party will assist
with all reasonable requests made by the other Party in support of any
application for Patent Term Extensions of, or supplementary protection
certificates relating to, the Licensed Patents, and patents on Takeda
Developments and Improvements and Jointly Developed Intellectual Property.

                                  ARTICLE XIII

                                   GOVERNANCE

         13.1 Joint Steering Committee. A Joint Steering Committee will be
created along with at least two sub-committees as described in Sections 13.2 and
13.3 below. The Joint Steering Committee will have an equal number of members
who are qualified by education, training and experience in oncology product
development, distribution, marketing and/or sales, and who are line managers
from each Party or its Affiliates. The Joint Steering Committee will be
accountable for the following: (i) allocation of sufficient qualified personnel
to specific Product operations; (ii) meeting specific objectives for
development, manufacturing needs, marketing, sales, promotion and/or
distribution of the Product for each quarter and for each Fiscal Year; and,
(iii) meeting specified timelines and approved budgets set by the Joint Steering
Committee. The

                                       53
<PAGE>

Joint Steering Committee will regularly review the actual performance of the
meeting of specific objectives concerning the development, marketing, promotion
and manufacturing needs for the Product, and may modify any of the foregoing
should performance targets not be met, as well as review proposed plans
regarding the Product in the Territory. Decisions by the Joint Steering
Committee will be made by unanimous votes by representatives of both Parties.
Should there be an unresolved disagreement on an issue at the Joint Steering
Committee, such issue will be resolved according to Article XIX. The Joint
Steering Committee will be responsible for the following tasks:

                  (a) Allocate and assign accountability of designated personnel
who are qualified by education, training and experience in the development,
distribution, marketing, promotion and/or manufacturing of the Product to all
specific Product operations and objectives in the Territory;

                  (b) Set the direction, objectives and accountabilities which
will be specifically assigned for the designated personnel who are engaged in
the Development Plan, the Marketing Plan and other plans. The Joint Steering
Committee is accountable for assuring that the proper personnel and resources
are assigned to such plans. The Joint Steering Committee has the final authority
to approve and modify the Development Plan or Marketing Plan or other plans, and
any allocated resources or personnel as identified in Article IV;

                  (c) Has the final authority to decide and engage the
appropriate countermeasure(s) in the event that some failure or lack of progress
by each Party or both Parties in meeting specific objectives for Development or
Marketing Plans or other plans that have been previously implemented, or with
regard to specific tasks or accountabilities of either Party in this Agreement
has occurred;

                  (d) Has the final authority to make decisions regarding the
termination of the Agreement;

                  (e) Has the final authority to approve and disapprove
BioNumerik's contract-manufacturers in Section 5.1;

                                       54
<PAGE>

                  (f) Has the final authority to coordinate auditing and
inspecting reviews of the manufacturing facilities of BioNumerik and its
contract-manufacturers;

                  (g) Is accountable for implementing a coordinated quality and
compliance program that assures both Parties are in compliance and achieving
proper quality targets in accordance with all applicable laws, statutes,
regulations, and ordinances applicable to performing its obligations under this
Agreement;

                  (h) Reviewing all communications, notices and reports which
are sent between the Parties and that all such communications, notices and
reports are provided in a timely manner; and,

                  (i) Is accountable for reviewing and approving potential
measures regarding infringement of intellectual property rights by a third party
or of a third party in the Territory.

                  Any Joint Steering Committee member can request of BioNumerik
and Takeda operating reports, data and analyses on the Product as reasonably
necessary, with reasonable time allocation for preparation of such information,
for the Joint Steering Committee to perform its functions.

         13.2 Development Committee. The Development Committee will have an
equal number of qualified members (as specified in Section 13.1 above) from each
Party and will be responsible for preparing and executing the Development Plan
identified in Article IV and for submitting the Development Plan to the Joint
Steering Committee for approval. In addition, the Development Committee will be
responsible for assuring that the Development Plan is implemented by both
Parties, in terms of the allocation of qualified personnel who will have
specific accountabilities to meet Development Plan objectives, and to assure
that each Party performs its obligations under the Development Plan and under
Article IV. The Development Committee will review and approve all clinical and
non-clinical study protocols of all contemplated studies that are conducted for
the Territory pursuant to the Development Plan. Further, the Development
Committee will review BioNumerik's reports on the clinical and non-clinical
studies produced according to Article IV and will review the materials under
Article IV, Section 4.4. Any disagreements or anticipated or actual failures to
meet specific objectives by

                                       55
<PAGE>

the Development Committee should be brought to the prompt attention of the Joint
Steering Committee. Further, the Development Committee will be accountable for
recommending to the Joint Steering Committee any proposed changes to the
Development Plan. In the event that the Parties cannot agree on which additional
clinical or non-clinical studies to conduct, besides those included in the
Development Plan, either Party may conduct such studies at its own expense,
notwithstanding the provisions of Sections 4.1(b) and 8.4(h), provided that such
studies are not intended to result in an improved label, patent position, or
method of use, or expanded indication that is beneficial to the Product
promotion, marketing or sales. The Development Committee will provide regular
progress and status reports to the Joint Steering Committee.

         13.3 Promotion Committee. The Promotion Committee will have an equal
number of qualified members (as specified in Section 13.1) from each Party and
will be accountable for meeting specific objectives as previously agreed to by
the Joint Steering Committee, performing market research on a regular basis as
approved by the Joint Steering Committee, and recommending potential
modifications to the Marketing Plan identified in Article VI, and for submitting
the Marketing Plan to the Joint Steering Committee for approval. In addition,
the Promotion Committee will be accountable for assuring that the Marketing Plan
is properly implemented by both Parties, in terms of the allocation of qualified
personnel who will have specific accountabilities to meet the Marketing Plan
objectives, and assuring that each Party performs its obligations under the
Marketing Plan and under Article VI. Any disagreements or anticipated or actual
failures by the Promotion Committee should be brought to the prompt attention of
the Joint Steering Committee. Further, the Promotion Committee will be
accountable for recommending to the Joint Steering Committee any proposed
changes to the Marketing Plan. The Promotion Committee will provide regular
progress and status reports to the Joint Steering Committee.

                                   ARTICLE XIV

                          ADVERSE EVENT REPORT AND PMS

         14.1 Within six (6) months of the Effective Date, the Parties will
develop a procedure for the reporting of adverse events between the Parties and
to the Regulatory Agency (substantially in the form of the reporting procedure
attached herewith as Exhibit F), which may

                                       56
<PAGE>

be amended from time to time to reflect applicable laws and regulations and the
Parties' pharmacovigilance practices. As part of this procedure, a PMS database
will be shared by the Parties. The plan for the PMS database and the PMS
reporting responsibilities and operations will be established by the Joint
Steering Committee within six (6) months of the Effective Date.

         14.2 BioNumerik will be responsible for preparing and submitting
regulatory reports or inquiries or responses concerning the Product to the FDA
or other Regulatory Agency as well as any other regulatory communication to the
FDA or other Regulatory Agency concerning the Product as well as making such
communications available to Takeda or any Regulatory Agency as required by
applicable laws, regulations, standards and guidelines or in accordance with
then-current ICH guidelines.

         14.3 Each Party will conduct PMS in the Territory in a coordinated
manner with the other Party. Each Party will regularly report PMS results from
the Territory to the other Party. BioNumerik will summarize and analyze such PMS
data for the purpose of reporting to the FDA and other regulatory agencies as
required by law and in accordance with ICH guidelines. BioNumerik will regularly
report PMS results from other territories to Takeda. BioNumerik will be
responsible for reporting the results of the PMS and any adverse events of the
Product to the Regulatory Agency as well as in other territories where the
Product is in development or approved. Takeda and BioNumerik will have direct
access to PMS data at all times, and BioNumerik will have the responsibility and
the right to report such data to all regulatory authorities in accordance with
all applicable laws and contractual obligations for such safety reporting.

         14.4 Each Party will fully cooperate with the other in all respects
necessary to enable each to fulfill its reporting obligations under applicable
laws and regulations.

                                   ARTICLE XV

                              TERM AND TERMINATION

         15.1 Term. The term of this Agreement will begin on the Effective Date
and will remain in effect until and unless this Agreement is terminated pursuant
to a provision of this Agreement.

                                       57
<PAGE>

         15.2 Termination on Patent Expiration or Generic Entry Date. (a) Takeda
may terminate this Agreement effective as of the Patent Expiration Date in the
Territory or just in the United States or at any time after the Patent
Expiration Date in the Territory or just in the United States, provided that
Takeda has provided BioNumerik with [**] prior written notice, or
Takeda may opt to continue the Agreement until the Agreement is otherwise
terminated. If Takeda terminates this Agreement pursuant to this Section
15.2(a), then (1) the licenses granted to Takeda under this Agreement except for
the Licensed Trademarks will become royalty-free, paid-up and perpetual as to
the terminated portion of the Territory, provided that BioNumerik can promote,
market and sell the Product in the terminated portion of the Territory without
any further obligation to Takeda and (2) the licenses granted to Takeda pursuant
to this Agreement except for the Licensed Trademarks will be extended to
encompass the right of Takeda to make and have made the Product in such
terminated portion of the Territory. Further, in the event of such termination,
BioNumerik (and its designated Affiliates and sublicensees) will be granted a
non-exclusive, perpetual, royalty-free paid-up license under Takeda Developments
and Improvements and Jointly Developed Intellectual Property, to make, have
made, use, and sell the Product in such terminated portion of the Territory.

         (b) Takeda may terminate this Agreement on the Generic Entry Date in
the Territory or just in the United States or at any time after the Generic
Entry Date in the Territory or just in the United States with [**] prior written
notice to BioNumerik, or Takeda may opt to continue the Agreement until the
Agreement is otherwise terminated. If Takeda terminates this Agreement pursuant
to this Section 15.2(b), then (1) the licenses granted to Takeda under this
Agreement except for the Licensed Trademarks will become royalty-free, paid-up
and perpetual as to the terminated portion of the Territory, provided that
BioNumerik can promote, market and sell the Product in the terminated portion of
the Territory without any further obligation to Takeda and (2) the licenses
granted to Takeda pursuant to this Agreement will be extended to encompass the
right of Takeda to make and have made the Product in such terminated portion of
the Territory. Further, in the event of such termination, BioNumerik (and its
designated Affiliates and sublicensees) will be granted a non-exclusive,
perpetual, royalty-free paid-up license under Takeda Developments and
Improvements and Jointly Developed Intellectual Property, to make, have made,
use, and sell the Product in such terminated portion of the Territory.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       58
<PAGE>

         (c) If Takeda desires to retain exclusive rights to use of the Licensed
Trademarks for the Product in the terminated portion of the Territory following
termination pursuant to Section 15.2 (a) or Section 15.2(b), Takeda will make an
offer to BioNumerik of a payment amount to retain such rights to the Licensed
Trademarks, within thirty (30) days after Takeda has provided the written notice
of termination. Within thirty (30) days after Takeda makes its offer, BioNumerik
will have the option to either: (i) accept such payment amount and allow Takeda
to retain such rights to the Licensed Trademarks; or (ii) pay Takeda the payment
amount and retain the rights to the Licensed Trademarks for exclusive use by
BioNumerik and its Affiliates and sublicensees in such terminated portion of the
Territory. If BioNumerik accepts such payment amount, the license granted to
Takeda to the Licensed Trademarks will become royalty-free, paid-up and
perpetual as to the terminated portion of the Territory.

         15.3 Termination for Lack of Viability or Profitability. If the Product
is not commercially viable or profitable in either country of the Territory as
measured by the standards described in this Section 15.3 below, as reasonably
applied by Takeda in its sole discretion but after consultation with BioNumerik
for [**], Takeda may eliminate a country from the Territory or terminate this
Agreement by informing BioNumerik of such elimination or termination in writing
thirty (30) days in advance. The Product is not commercially viable or
profitable if (i) the Net Profits are negative for any three (3) out of four (4)
calendar quarters in a Fiscal Year during the second year after the commercial
launch of the Product or any two (2) calendar quarters in any Fiscal Year after
the first two year period following the commercial launch of the Product; (ii)
Takeda determines in good faith that any event of the subsection 15.3(i) above
is more likely than not to occur; or (iii) Takeda determines in good faith that
the NDA filing or NDA approval of the Product in the United States is more
likely than not to be delayed for more than one (1) year compared with the
initial Development Plan attached hereto. In the event of such a termination,
all rights granted to Takeda under this Agreement will revert to BioNumerik, and
BioNumerik will have no obligation to return any amounts paid to BioNumerik by
Takeda prior to such termination. Further, in the event of such termination,
BioNumerik (and its designated Affiliates and sublicensees) will be granted a
non-exclusive, perpetual, royalty-free paid-up license under Takeda Developments
and Improvements and Jointly Developed Intellectual Property, to make, have
made, use, and sell the Product in the Territory.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       59
<PAGE>

         15.4 Termination for Cause. This Agreement may be terminated as
provided for below if any of the following occur:

                  (a) Material Breach of the Agreement. In the event of a
material breach of this Agreement, the nonbreaching Party may terminate this
Agreement by providing written notice to the breaching Party of the breach and
intent to terminate this Agreement; provided, that this Agreement will terminate
[**] following receipt of the notice of breach unless the breaching
Party corrects the breach within such [**] period, and notifies the
nonbreaching Party of the correction.

         However, if the breaching Party does not correct the breach within such
[**] period, then the nonbreaching Party may provide written notice to the
breaching Party that the termination will be delayed to allow the nonbreaching
Party the opportunity to take any actions necessary to try to correct the breach
itself and to seek fair and reasonable damages from the breaching Party to
reimburse any loss caused by the breach, either (a) through negotiations; (b)
through the dispute resolution procedures in Article XIX; or (c) acceptance of
the breach by the nonbreaching Party, provided that if the nonbreaching Party
has not chosen option (b) within six (6) months of the notice of delay, the
nonbreaching Party will be deemed to have chosen option (c) and have accepted
the breach. Further, the nonbreaching Party will not be considered to have
waived any of its other remedies available to it under the law or equity for any
such breach, including but not limited to damages from the breaching Party to
reimburse the nonbreaching Party for any loss caused by the breach.

         If either Party terminates this Agreement pursuant to this Section
15.4(a), then the Parties will resort to the dispute resolution procedure in
Article XIX for resolution. Pending the outcome of such dispute resolution
procedure, (1) the licenses granted to each Party under this Agreement will
continue; (2) the licenses granted to Takeda pursuant to this Agreement will be
extended to encompass the right of Takeda to make and have made the Product in
the Territory; and, (3) the licenses granted to BioNumerik (and its designated
Affiliates and sublicensees) will be extended to encompass the right to Takeda
Developments and Improvements and Jointly Developed Intellectual Property to
make, have made, use, and sell the Product in the Territory. The Parties expect
that the arbitration decision after the outcome of such dispute resolution

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       60
<PAGE>

procedure will determine issues such as the merits of the alleged breach, how
the Parties' relationship may continue following the dispute resolution
procedure, what rights each Party will have under the other Party's intellectual
property following the outcome of the dispute resolution procedure, how the
Product will continue to be marketed in the Territory, and what monetary
damages, if any, will be provided to the Parties as compensation.

         Pending the outcome of such dispute resolution procedure, the amount
and timing of any payments (including payments by Takeda to BioNumerik pursuant
to Articles VIII and IX of this Agreement) that would otherwise be made by
Takeda to BioNumerik will be referred to the International Chamber of Commerce
for determination by Arbitrator(s) ("the Payment Arbitrator(s)") different than
the Arbitrators selected when the dispute resolution procedure of Article XIX is
invoked. The Parties will mutually select a single Payment Arbitrator. If the
Parties are unable to mutually agree on the selection of a single Payment
Arbitrator, then one arbitrator will be appointed by BioNumerik, one arbitrator
will be appointed by Takeda, and the third arbitrator will be appointed by the
two arbitrators. The selection of the Payment Arbitrator(s) will take place
within thirty (30) days after the filing of the Request for Arbitration. The
Payment Arbitrator(s) will be requested to decide the amount and timing of such
payments on an interim and expedited basis with their decision to be rendered no
later than thirty (30) days after the selection of Payment Arbitrator(s); in
addition to the foregoing, both Parties will use best efforts and will
accordingly perform their respective activities necessary to resolve this
payment issue within sixty (60) days after the filing of the Request for
Arbitration. The Payment Arbitrator(s) decision regarding such payments will
govern such payment matters pending the outcome of the arbitration. Before the
Payment Arbitrator(s)'s decision, payments by Takeda to BioNumerik pursuant to
Articles VIII and IX of this Agreement will continue, provided that if Takeda is
the nonbreaching Party, such payments will continue for no longer than [**]
after the filing of the Request, even if the Payment Arbitrator(s) takes longer
to decide the payments issue than the requested thirty (30) day period provided
further, that if Takeda is still requesting BioNumerik to supply it with
manufactured Product, Takeda will continue to pay to BioNumerik the Provisional
Price per unit of Product supplied by BioNumerik to Takeda.

                  (b) Bankruptcy. Either Party may terminate this Agreement by a
registered letter to the other Party with termination to take immediate effect
upon the sending of such letter

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       61
<PAGE>

if the other Party becomes insolvent or a petition in bankruptcy or corporate
reorganization or any similar relief is filed by or against the other Party, or
a receiver is appointed with respect to any substantial portion of the assets of
the other Party, or a liquidation proceeding is commenced against the other
Party. In the case that Takeda terminates this Agreement pursuant to this
Section, subject to Takeda continuing all payment obligations to BioNumerik as
described in this Agreement, BioNumerik will transfer to Takeda any existing NDA
approvals, applications and/or filings and similar approvals for the Product in
the Territory upon request of Takeda and Takeda will have, with the right to
sublicense, (i) an exclusive and perpetual license under the Licensed Patents
and Licensed Information existing at the time of such termination and (ii) a
non-exclusive and perpetual license under the BioNumerik's Licensees' Patents
and Information existing at the time of such termination (subject to the
restrictions and limitations contained in Section 2.1 with respect to the
license of such BioNumerik's Licensees' Patents and Information), such licenses
in the case of each of clauses (i) and (ii) being to develop, market, promote,
sell, distribute, make, have made, use, sell, offer to sell and import the
Product in the Territory, provided that Takeda will indemnify, defend and hold
BioNumerik and each of BioNumerik's Affiliates, agents, employees, officers and
directors harmless from any and all liabilities, damages, loss, costs, or
expense (including reasonable attorney's fees and product liability claims
directly concerning the Product) arising out of activities conducted by Takeda
after the date of Takeda's termination under this Section 15.4(b), and provided
further that BioNumerik will retain the right for itself and its Affiliates,
sublicensees and contract manufacturers to use any of the Licensed Patents,
Licensed Information and BioNumerik's Licensees' Patents and Information without
any payment obligation to Takeda for purposes of manufacturing the Product in
the Territory for use outside the Territory, for internal research, and for
purposes that do not relate to the Product. BioNumerik will, subject to Takeda
continuing all payment obligations to BioNumerik as described in this Agreement,
also grant Takeda an exclusive and perpetual license to use the Licensed
Trademarks for the Product in the Territory, provided that Takeda can provide
reasonably sufficient explanation to BioNumerik that the goodwill associated
with the Licensed Trademarks will not be substantially damaged by the continued
use by Takeda and its Affiliates and sublicensees of such Licensed Trademarks in
the Territory. In the case that BioNumerik terminates this Agreement pursuant to
this Section 15.4(b), BioNumerik (and its designated Affiliates and
sublicensees) will be granted a non-exclusive,

                                       62
<PAGE>

perpetual, royalty-free paid-up license under Takeda Developments and
Improvements and Jointly Developed Intellectual Property, to make, have made,
use, and sell the Product in the Territory. All rights and licenses granted
under or pursuant to this Agreement by each Party as a licensor or sublicensor
are, and will otherwise be deemed to be, for purposes of Section 365(n) of Title
XI, United States Code (the "Bankruptcy Code"), licenses (or, if applicable,
sublicenses) of rights to "intellectual property" as defined under Section
101(35A) of the Bankruptcy Code. Each Party agrees that each licensee (or, if
applicable, sublicensee) of such rights under this Agreement will retain and may
fully exercise all rights and elections it would have in the case of a licensor
(or sublicensor) bankruptcy under the Bankruptcy Code. Each Party agrees during
the term of this Agreement to create or maintain current copies, or if not
amenable to copying, detailed descriptions or other appropriate embodiments, of
all such intellectual property licensed or sublicensed to the other Party.

         15.5 Termination for Failure to Maintain Safety and Quality in Product
Manufacturing Standards. Takeda may terminate this Agreement at any time if it
determines that BioNumerik or any one of its contract-manufacturers fail to
maintain the applicable safety and quality standards when manufacturing the
Product for Takeda, provided that this provision will only apply with respect to
a failure to maintain appropriate safety and quality standards when
manufacturing the Product for Takeda that would have a Material Adverse Effect
on Takeda. In addition, Takeda will, prior to any such termination, provide
BioNumerik with notice and a sixty (60) day opportunity to correct or remedy
such failure, unless allowing for such notice period would have a Material
Adverse Effect on Takeda due to such failure. In the case that Takeda decides to
continue to market the Product in the Territory following such termination,
BioNumerik will transfer to Takeda any existing NDA approvals, applications
and/or filings and similar approvals for the Product in the Territory upon
request of Takeda and Takeda will have, with the right to sublicense, (i) an
exclusive and perpetual license under the Licensed Patents and Licensed
Information existing at the time of such termination and (ii) a non-exclusive
and perpetual license under the BioNumerik's Licensees' Patents and Information
existing at the time of such termination (subject to the restrictions and
limitations contained in Section 2.1 with respect to the license of such
BioNumerik's Licensees' Patents and Information), such licenses in the case of
each of clauses (i) and (ii) being to develop, market, promote, sell,
distribute, make, have made, use, sell, offer to sell and import the Product in
the Territory, provided that Takeda

                                       63
<PAGE>

will indemnify, defend and hold BioNumerik and each of BioNumerik's Affiliates,
agents, employees, officers and directors harmless from any and all liabilities,
damages, loss, costs, or expense (including reasonable attorney's fees and
product liability claims directly concerning the Product) arising out of
activities conducted by Takeda after the date of Takeda's termination under this
Section, and provided further that BioNumerik will retain the right for itself
and its Affiliates, sublicensees and contract manufacturers to use any of the
Licensed Patents, Licensed Information and BioNumerik's Licensees' Patents and
Information without any payment obligation to Takeda for purposes of
manufacturing the Product in the Territory for use outside the Territory, for
internal research, and for purposes that do not relate to the Product.
BioNumerik will also grant Takeda and its Affiliates and sublicensees an
exclusive and perpetual license to use the Licensed Trademarks for the Product
in the Territory, provided that Takeda can provide reasonably sufficient
explanation to BioNumerik that the goodwill associated with the Licensed
Trademarks will not be substantially damaged by the continued use by Takeda of
such Licensed Trademarks in the Territory. Further, Takeda will continue to pay
all payment obligations to BioNumerik as described in this Agreement. In the
case that Takeda decides not to continue to market the Product in the Territory
following such termination, all rights granted to Takeda under this Agreement
will revert to BioNumerik, and BioNumerik (and its designated Affiliates and
sublicensees) will be granted a non-exclusive, perpetual, royalty-free paid-up
license under Takeda Developments and Improvements and Jointly Developed
Intellectual Property, to make, have made, use, and sell the Product in the
Territory.

         15.6 Suspension or Termination Due to Serious Adverse Event. Either
Party may suspend development, marketing, and sales activities or immediately
terminate this Agreement at its choice at any time upon notice to the other
Party if such Party becomes aware of a "serious adverse drug experience" as
defined in 21 CFR 312 that is associated with the administration of the Product,
provided that this provision will only apply with respect to a serious adverse
drug experience that would have a material adverse effect on the ability to
obtain and/or maintain regulatory approvals in the Territory or only in the
United States and/or to continue to profitably market the Product in the
Territory or only in the United States or would be materially adverse to the
terminating Party's reputation, and provided further that any such suspension
will continue for no more than [**] (unless otherwise agreed upon by the
Parties). If BioNumerik terminates this Agreement pursuant to this section and
Takeda desires to continue to develop and

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       64
<PAGE>

commercialize the Product, BioNumerik will transfer to Takeda any existing NDA
approvals, applications and/or filings and similar approvals for the Product in
the Territory upon request of Takeda and Takeda will have, with the right to
sublicense, (i) an exclusive royalty-free, paid-up and perpetual license under
the Licensed Patents and Licensed Information existing at the time of such
termination and (ii) a non-exclusive royalty-free, paid-up and perpetual license
under the BioNumerik's Licensees' Patents and Information existing at the time
of such termination (subject to the restrictions and limitations contained in
Section 2.1 with respect to the license of such BioNumerik's Licensees' Patents
and Information), such licenses in the case of each of clauses (i) and (ii)
being to develop, market, promote, sell, distribute, make, have made, use, sell,
offer to sell and import the Product in the Territory, provided that Takeda will
indemnify, defend and hold BioNumerik and each of BioNumerik's Affiliates,
agents, employees, officers and directors harmless from any and all liabilities,
damages, loss, costs, or expense (including reasonable attorney's fees and
product liability claims directly concerning the Product) arising out of
activities conducted by Takeda after the date of BioNumerik's termination under
this Section, and provided further that BioNumerik will retain the right for
itself and its Affiliates, sublicensees and contract manufacturers to use any of
the Licensed Patents, Licensed Information and BioNumerik's Licensees' Patents
and Information without any payment obligation to Takeda for purposes of
manufacturing the Product in the Territory for use outside the Territory, for
internal research, and for purposes that do not relate to the Product.
BioNumerik will also grant Takeda and its Affiliates and sublicensees an
exclusive royalty-free, paid-up and perpetual license to use the Licensed
Trademarks for the Product in the Territory, provided that Takeda can provide
reasonably sufficient explanation to BioNumerik that the goodwill associated
with the Licensed Trademarks will not be substantially damaged by the continued
use by Takeda of such Licensed Trademarks in the Territory. If Takeda terminates
this Agreement pursuant to this section and BioNumerik desires to continue to
develop and commercialize the Product, BioNumerik (and its designated Affiliates
and sublicensees) will be granted a non-exclusive, perpetual, royalty-free
paid-up license under Takeda Developments and Improvements and Jointly Developed
Intellectual Property, to make, have made, use, and sell the Product in the
Territory.

                                       65
<PAGE>

         15.7 Termination by Mutual Agreement. The Parties may terminate this
Agreement at any time upon mutual agreement expressed in a writing signed by
authorized representatives of both Parties.

         15.8 Suspension or Termination for Impossibility. In the event that any
act, regulation, or law of government in the Territory, including departments,
agencies, and courts, make impossible or prohibit, modify, or limit any act or
obligation of the Parties, either Party may suspend or terminate the Agreement
or make modifications as necessary and reasonably agreed to by the Parties,
provided that this provision will only apply with respect to a situation that
would permanently prohibit or permanently halt the development or marketing of
the Product in the Territory. In addition, the terminating Party will, prior to
any such termination, provide the non-terminating party with notice and a sixty
(60) day opportunity to correct or remedy such situation. If BioNumerik
terminates this Agreement pursuant to this section and Takeda desires to
continue to develop and commercialize the Product, BioNumerik will transfer to
Takeda any existing NDA approvals, applications and/or filings and similar
approvals for the Product in the Territory upon request of Takeda and Takeda
will have, with the right to sublicense, (i) an exclusive royalty-free, paid-up
and perpetual license under the Licensed Patents and Licensed Information
existing at the time of such termination and (ii) a non-exclusive royalty-free,
paid-up and perpetual license under the BioNumerik's Licensees' Patents and
Information existing at the time of such termination (subject to the
restrictions and limitations contained in Section 2.1 with respect to the
license of such BioNumerik's Licensees' Patents and Information), such licenses
in the case of each of clauses (i) and (ii) being to develop, market, promote,
sell, distribute, make, have made, use, sell, offer to sell and import the
Product in the Territory, provided that Takeda will indemnify, defend and hold
BioNumerik and each of BioNumerik's Affiliates, agents, employees, officers and
directors harmless from any and all liabilities, damages, loss, costs, or
expense (including reasonable attorney's fees and product liability claims
directly concerning the Product) arising out of activities conducted by Takeda
after the date of BioNumerik's termination under this Section, and provided
further that BioNumerik will retain the right for itself and its Affiliates,
sublicensees and contract manufacturers to use any of the Licensed Patents,
Licensed Information and BioNumerik's Licensees' Patents and Information without
any payment obligation to Takeda for purposes of manufacturing the Product in
the Territory for use outside the Territory, for internal research, and for
purposes that do not relate to the Product.

                                       66
<PAGE>

BioNumerik will also grant Takeda an exclusive royalty-free, paid-up and
perpetual license to use the Licensed Trademarks for the Product in the
Territory, provided that Takeda can provide reasonably sufficient explanation to
BioNumerik that the goodwill associated with the Licensed Trademarks will not be
substantially damaged by the continued use by Takeda of such Licensed Trademarks
in the Territory. If Takeda terminates this Agreement pursuant to this section
and BioNumerik desires to continue to develop and/or market the Product,
BioNumerik (and its designated Affiliates and sublicensees) will be granted a
non-exclusive, perpetual, royalty-free paid-up license under Takeda Developments
and Improvements and Jointly Developed Intellectual Property, to make, have
made, use, and sell the Product in the Territory.

         15.9 Right to Complete Contracted Sales. In the event of termination of
this Agreement, Takeda will have the right to complete all contracts for the
sale of the Product under which Takeda is obligated on the date of termination,
provided Takeda pays all Commercial Milestone Payments and Profit Share on such
sales as required herein and provided all such sales are completed within [**]
after the date of termination.

         15.10 Obligations to Make Milestone Payments, Commercial Milestone
Payments and Profit Share. In the event of termination of this Agreement, Takeda
will pay BioNumerik and BioNumerik will pay Takeda all outstanding obligations,
due and payable as of the date of such termination, which will include Milestone
Payments and also include Commercial Milestone Payments and Profit Share
payments for sales of the Product since the last quarter for which Commercial
Milestone Payments and Profit Share have been made, including the sales of the
Product after termination permitted in Section 15.9 herein. The final Commercial
Milestone Payment and Profit Share payment is due ninety (90) days after the
date of termination, or ninety (90) days after the last sale made pursuant to
Section 15.9. For clarity, after the termination of this Agreement, Takeda will
be relieved from payment of the Milestone Payments, Commercial Milestone
Payments and Research and Development Payments, other than as provided in this
Section 15.10, which were not otherwise due at the time of the termination of
this Agreement. In the event of termination of this Agreement, BioNumerik will
have no obligation to return to Takeda any amounts previously paid by Takeda to
BioNumerik.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
                                       67
<PAGE>

         15.11 Termination Report. In the event of termination of this
Agreement, BioNumerik will send to Takeda a termination report identifying the
research and development costs, and the Incurred Costs that it incurred since
the last quarterly report through termination. The termination report will be
transmitted to Takeda within ninety (90) days following termination. Takeda will
send to BioNumerik a termination report identifying the Net Sales of the Product
since the last quarterly report through termination, and the anticipated Net
Sales of the Product for which the deliveries will take place after termination
as provided for in Section 15.9. Takeda's termination report will be transmitted
to BioNumerik within ninety (90) days following termination. The monthly reports
under Section 9.3 will continue until the termination report is sent.

         15.12 Surviving Provisions. The rights and obligations of the Parties
specified in Articles XV, XVI, XVIII, XIX, XX and XXII, and Section 10.2,
Section 12.3, Section 12.4 and Section 21.1(h) (on the terms described in such
Section 21.1(h)) of this Agreement will survive termination of this Agreement
and remain enforceable.

                                   ARTICLE XVI

                                 INDEMNIFICATION

         16.1 Liability. In accordance with Article XX, liability arising from
infringement of a third party's intellectual property rights relating to the
Product being sold in the Territory or from product liabilities relating to the
Product being sold in the Territory will be shared equally by the Parties even
if such liabilities are caused by performance by only one Party; provided,
however, that any liability arising out of the negligence or willful misconduct
of one Party or the breach of representations or warranties by one Party will
not be shared by the other Party.

         16.2 Indemnification by BioNumerik. BioNumerik will indemnify, defend
and hold Takeda and its Affiliates, agents, employees, officers and directors
(the "Takeda Indemnitees") harmless from and against any and all liability,
damage, loss, cost or expense (including reasonable attorneys' fees) arising out
of or relating to claims or suits by third parties arising from: (i)
BioNumerik's failure to perform its obligations under this Agreement or
BioNumerik's negligence or willful misconduct, including, but not limited to,
negligence or willful misconduct of a contract-manufacturer of the Product; or
(ii) breach by BioNumerik of its representations

                                       68
<PAGE>

and warranties under this Agreement; provided, however, that BioNumerik's
obligations pursuant to this Section 16.2 will not apply to the extent such
claims or suits result from the negligence or willful misconduct of any of the
Takeda Indemnitees.

         16.3 Indemnification by Takeda. Takeda will indemnify, defend and hold
BioNumerik and its Affiliates, agents, employees, officers and directors (the
"BioNumerik Indemnitees") harmless from and against any and all liability,
damage, loss, cost or expense (including reasonable attorneys' fees) arising out
of or relating to claims or suits by third parties arising from: (i) Takeda's
failure to perform its obligations under this Agreement or Takeda's negligence
or willful misconduct; or (ii) breach by Takeda of its representations and
warranties under this Agreement; provided, however, that Takeda's obligations
pursuant to this Section 16.3 will not apply to the extent such claims or suits
result from the negligence or willful misconduct of any of the BioNumerik
Indemnitees.

         16.4 Notification of Claim; Conditions to Indemnification Obligations.
As a condition to a Party's right to receive indemnification under this Article
XVI, it will: (i) promptly provide written notice (a "Claim Notice") to the
other Party as soon as it becomes aware of a claim or suit for which
indemnification may be sought pursuant hereto (provided that the failure to give
a Claim Notice promptly will not prejudice the rights of an indemnified Party
except to the extent that the failure to give such prompt notice materially
adversely affects the ability of the indemnifying Party to defend the claim or
suit); (ii) cooperate with the indemnifying Party in the defense of such claim
or suit, at the expense of the indemnifying Party; and (iii) if the indemnifying
Party confirms in writing to the indemnified Party its intention to defend such
claim or suit within ten (10) days of receipt of the Claim Notice, permit the
indemnifying Party to control the defense of such claim or suit, including
without limitation the right to select defense counsel; provided that if the
indemnifying Party fails to (x) provide such confirmation in writing within the
ten (10) day period; or (y) diligently and reasonably defend such suit or claim
at any time, its right to defend the claim or suit will terminate immediately in
the case of (x) and otherwise upon twenty (20) days' written notice to the
indemnifying Party and the indemnified Party may assume the defense of such
claim or suit at the sole expense of the indemnifying Party and may settle or
compromise such claim or suit without the consent of the indemnifying Party. The
indemnifying Party will pay the costs of separate counsel for the indemnified
parties if there

                                       69
<PAGE>

is a conflict of interest involving the counsel selected by the indemnifying
Party. In no event, however, may any indemnifying Party compromise or settle any
claim or suit in a manner which admits fault or negligence on the part of any
indemnified party or that otherwise materially affects any such indemnified
party's rights under this Agreement or requires any payment by an indemnified
party without the prior written consent of each such indemnified party. Except
as expressly provided above, the indemnifying Party will have no liability under
this Article XVI with respect to claims or suits settled or compromised by an
indemnified party without the indemnifying Party's prior written consent.

                                  ARTICLE XVII

                             ENFORCEMENT OF PATENTS

         17.1 Reporting. Each Party will promptly report in writing to the other
Party during the term of this Agreement any known infringement or suspected
infringement of any of the Licensed Patents, patents in the BioNumerik's
Licensees' Patents and Information, patents relating to Takeda Developments and
Improvements described in Section 12.3, and patents relating to Jointly
Developed Intellectual Property described in Section 12.4, or the Licensed
Trademarks by a third party or on account of the manufacture, use, offer for
sale, importation, or sale by a third party of the Product of which it becomes
aware, and will provide the other Party with all available evidence supporting
said infringement or suspected infringement.

         17.2 Filing Suit. BioNumerik will be solely responsible for enforcing
the Licensed Patents or the Licensed Trademarks by filing suit against suspected
infringers of which it becomes aware or whom Takeda brings to its attention and
will have discretion in determining to file suit. BioNumerik will keep Takeda
promptly informed and will from time to time consult with Takeda regarding the
status of any such suit and will provide Takeda with copies of all documents
filed in, and all written communications relating to, such suit. Payments by
Takeda to BioNumerik pursuant to Articles VIII and IX will continue during any
patent litigation unless and until this Agreement is otherwise terminated in
accordance with the terms of this Agreement.

         17.3     BioNumerik Suit.

                                       70
<PAGE>

                  (a) BioNumerik will have the right to select counsel,
witnesses and experts for any suit referred to in Section 17.2 above after
consultation with Takeda and will, except as provided below, pay all expenses of
the suit, including without limitation attorneys' fees and court costs. Takeda
will join as a party to the suit if requested by BioNumerik but otherwise will
be under no obligation to participate except to the extent that such
participation is required or requested by BioNumerik. Takeda will join in any
such suit if required by law and will offer reasonable assistance to BioNumerik
therewith at no charge to BioNumerik. Takeda will have the right to participate
and be represented in any such suit by its own counsel at its own expense. In
the event there are any damages, royalties, settlement fees or other
consideration as a result of such litigation solely conducted by BioNumerik, any
and all of these forms of such consideration will be solely received by
BioNumerik.

                  (b) Takeda, in its sole discretion, may elect, within sixty
(60) days after the commencement of such litigation, to contribute to the costs
incurred by BioNumerik in connection with such litigation, and, if it so elects,
any damages, royalties, settlement fees or other consideration received by
BioNumerik as a result of such litigation will be shared by Takeda and
BioNumerik [**] based on [**] the costs of such litigation provided that such
[**] share will not exceed [**] unless BioNumerik has consented to a higher
share in writing.

         17.4     Takeda Suit.

                  (a) In the event that BioNumerik elects not to initiate an
infringement or other appropriate suit pursuant to Section 17.2 above,
BioNumerik will promptly advise Takeda of its intent not to initiate such a
suit. Takeda will have the right, at the sole expense of Takeda, to initiate an
infringement or other appropriate suit against the party or parties. In
exercising its rights pursuant to this section, Takeda have the sole and
exclusive right to select counsel and will, except as provided below, pay all
expenses of the suit including without limitation attorneys' fees and court
costs. If necessary, BioNumerik will join as a party to the suit but will be
under no obligation to participate except to the extent that such participation
is required as a result of being named a party to the suit. Further, BioNumerik
will join as a party to the suit if requested by Takeda but otherwise will be
under no obligation to participate except to the extent

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       71
<PAGE>

that such participation is required or requested by Takeda. At Takeda's request,
BioNumerik will offer reasonable assistance to Takeda in connection therewith at
no charge to Takeda. Takeda and its litigation counsel will attempt to run the
litigation as effectively as possible to minimize the impact on BioNumerik's
senior management's participation. BioNumerik will have the right to participate
and be represented in any such suit by its own counsel at its own expense. In
the event there are any damages, royalties, settlement fees or other
consideration as a result of such litigation solely conducted by Takeda, any and
all of these forms of such consideration will be solely received by Takeda.

                  (b) BioNumerik, in its sole discretion, may elect, within
sixty (60) days after the commencement of such litigation, to contribute to the
costs incurred by Takeda in connection with such litigation, and, if it so
elects, any damages, royalties, settlement fees or other consideration received
by Takeda as a result of such litigation will be shared by BioNumerik and Takeda
[**] based on [**] the costs of such litigation provided that such [**] share
will not exceed [**] unless Takeda has consented to a higher share in writing.

         17.5 Settlement. Neither Party will settle any such suit under this
Article XVII on terms which grant any license to any other party in derogation
of the rights granted to or retained by either Party hereunder without obtaining
the prior written consent of the other Party, which consent will not be
unreasonably withheld.

                                  ARTICLE XVIII

                          CONFIDENTIALITY AND PUBLICITY

         18.1 Confidentiality. Each Party (including its Affiliates) will keep
the Confidential Information of the other Party in strict confidence and will
not disclose such Confidential Information to any third party nor use such
Confidential Information for any purpose other than pursuant to this Agreement
without the prior written consent of the disclosing Party, each for [**] from
the disclosure of such Confidential Information by the disclosing Party to the
other Party; provided, however, that each Party may disclose and use the
Confidential Information to the extent necessary for its performance of the
obligations hereunder. The terms and conditions of this Agreement will also be
kept confidential by Takeda and BioNumerik. The

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       72
<PAGE>

Parties agree that they may acknowledge and disclose the existence of this
Agreement without disclosing any terms or conditions of this Agreement. Further,
the Parties will mutually agree to the wording of any press release or other
public disclosure concerning either this Agreement or the relationship between
the Parties, such proposed disclosure to be provided to the nondisclosing Party
no later than seven (7) days before the intended disclosure. Additionally,
promptly after the signing of this Agreement, the Parties will develop a
mutually agreed to SOP's and policy to provide intended disclosure to the
nondisclosing Party much quicker than seven (7) days before the intended
disclosure and to receive a response from the nondisclosing Party to the
disclosing Party, including expedited disclosures that must be done almost
immediately. However, any Party may disclose the terms of this Agreement to the
extent required, in the reasonable opinion of such Party's legal counsel, to
comply with applicable laws, including without limitation the rules and
regulations promulgated by the SEC or by the stock exchange on which a Party's
stock is listed or by any stock exchange or similar body on which BioNumerik's
stock may be listed in the future. Notwithstanding the foregoing, before
disclosing this Agreement or any of the terms hereof pursuant to this section,
the Parties will consult with each other on the terms of this Agreement to be
redacted before making any such disclosure.

         18.2 Publicity. Without limitation, the prohibition under Section 18.1
will apply to press releases, governmental filings, and discussions with
lenders, investment bankers, public officials and the media. However, the
prohibition does not apply to any disclosures required by an applicable law
(including Sarbanes-Oxley requirements), disclosures to legal, investment
banking, accounting, financial and tax advisors, shareholders, and including
requests for a copy of related information by tax authorities in the case of an
audit or by any stock exchange on which a Party's stock is listed, provided,
however, that if any copy of this Agreement or any Confidential Information is
to be filed with or to be disclosed to the SEC and such filing or disclosure is
required by an applicable law, the Party intending to make such filing or
disclosure will first consult with the other Party regarding the extent of
disclosure required and use its best efforts to request confidential treatment
of such information, and provided, further that if any Party is required by an
applicable law to disclose any of the Confidential Information, that Party will
notify the other Party as soon as practicable and give as much detail as
possible in relation to

                                       73
<PAGE>

the disclosure required. The Parties will then cooperate with respect to
obtaining an appropriate protective order and/or to determining what information
should actually be released.

                                   ARTICLE XIX

                               DISPUTE RESOLUTION

         19.1 Disputes. Any disputes arising between the Parties relating to,
arising out of or in any way connected with this Agreement or any term or
condition hereof, or the performance by any Party of its obligations hereunder,
whether before or after termination of this Agreement (a "Dispute"), which is
not settled by the Parties within thirty (30) days after notice of such Dispute
is given by one Party to the other in writing will be referred to a senior
executive designated by BioNumerik and a senior executive designated by Takeda
who are authorized to settle such disputes on behalf of their respective
companies ("Senior Executives"). The Senior Executives will meet for
negotiations within thirty (30) days of the end of the initial 30-day
negotiation period referred to above, at a time and place mutually acceptable to
both Senior Executives. If the Dispute has not been resolved within thirty (30)
days after the end of the initial 30-day negotiation period referred to above
(which period may be extended by mutual agreement), the Dispute will be
forwarded to a neutral consultant agreed upon by both Parties. The neutral
consultant will, within twenty (20) days, issue a non-binding comment with
suggestions for resolving the dispute. If the Parties cannot reach agreement on
the Dispute within thirty (30) days of receiving the non-binding comment, the
Dispute will be finally resolved by resorting to arbitration according to
Section 19.2.

         19.2 Arbitration. If a Dispute is not resolved, the Parties hereby
agree to resolve such Dispute by final and binding arbitration administered
under the most recent rules of arbitration of the International Chamber of
Commerce ("ICC"). The arbitration will be conducted in English by one arbitrator
appointed in accordance with the ICC Rules, provided that upon request of either
Party, three arbitrators will be appointed. Although the arbitration will be
conducted in English, the only documents that would need to be translated from a
foreign language by the

                                       74
<PAGE>

Party producing such documents will be those documents that the Party intends to
rely on at the arbitration hearing. If the Parties are unable to mutually select
the arbitrators, one arbitrator will be appointed by BioNumerik, one arbitrator
will be appointed by Takeda, and the third arbitrator will be appointed by the
two arbitrators.

         In any such arbitration, the arbitrator(s) will not have the right to
modify the terms and conditions of this Agreement. As a result, the rights and
obligations of the Parties will be determined in accordance with the terms and
conditions of this Agreement and any decision or award will be only in
accordance with the terms and conditions of this Agreement. The Parties will
exert reasonable efforts to have the decision and award rendered within six (6)
months after the first to occur of (i) notice of breach of this Agreement or
disagreement regarding a term of the Agreement, a right of a Party to the
Agreement, or an obligation of a Party to the Agreement, which breach or
disagreement is a subject of the arbitration, and (ii) a notice invoking this
arbitration provision.

         Judgment upon the award may be entered in any court having jurisdiction
thereof. Any arbitration pursuant to this section will be held in [**], or such
other place as may be mutually agreed upon in writing by the Parties.

         Notwithstanding the provisions of this Section 19.2, either Party will
have the right to seek temporary or permanent injunctive relief in any court of
competent jurisdiction as may be available to such Party under the laws and
rules applicable in such jurisdiction.

                                   ARTICLE XX

                              THIRD PARTY LIABILITY

         20.1 Reporting. Each Party will promptly report in writing to the other
Party during the term of this Agreement any cease and desist letters, lawsuits
that are filed against the Party, and any agency actions instituted against the
Party relating to the Product, the Licensed Patents, the Licensed Trademarks,
the Licensed Information and BioNumerik's Licensees' Patents and Information. At
each Party's request, the other Party will offer reasonable assistance in
connection therewith.

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       75
<PAGE>

         20.2 Settlement. In the event referred to in Section 20.1, each Party
will consult with the other Party about selection of counsels, defense plan and
settlement. Neither Party will settle any such suit on terms which adversely
affect the rights granted to the other Party hereunder without obtaining the
prior written consent of the other Party, which consent will not be unreasonably
withheld.

         20.3 Shared Liability. Liability arising from infringement of a third
party's patent rights relating to the Product being sold in the Territory or
from product liabilities relating to the Product being sold in the Territory
will be shared equally by the Parties as the Third Party Payment even if such
liabilities are caused by performance of only one Party; provided, however, that
any liability arising out of the negligence or willful misconduct of one Party
or the breach of representations or warranties by one Party will not be shared
by the other Party, in which case the responsible Party is liable for bearing
the damages and other payments.

         20.4 Insurance.

      (a) During the term of this Agreement and continuing for a period of [**]
after the termination of this Agreement, each Party agrees to obtain and
maintain, at its sole cost and expense, product liability insurance in the
Territory, in amounts which are reasonable and customary in the pharmaceutical
industry in the United States and Canada for companies of comparable size and
activities at its place of business. Subject to reasonable insurance policy
limitation and exclusions, such product liability insurance will insure against
all liability, including personal injury, physical injury, or property damage
arising out of the manufacture, sale, offer for sale, use, distribution,
marketing and promotion of the Product in the Territory and will include the
other Party as an additional insured.

                  (b) During the term of this Agreement, each Party will carry
insurance in amounts not less than the following for each type specified or as
otherwise might be required by applicable law or regulation:

                           (i)      commercial general liability insurance,
                                    including coverage for bodily injury and
                                    property damage, with limits of not less
                                    than [**] per occurrence and [**] in
                                    the aggregate;

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       76
<PAGE>

                           (ii)     automobile liability insurance with coverage
                                    of not less than [**] per occurrence; and

                           (iii)    worker's compensation with limits in
                                    accordance with statutory requirements,
                                    including employer's liability coverage of
                                    not less than [**].

                  (c) Each Party will provide written proof of the existence of
such insurance to the other Party upon request.

                                   ARTICLE XXI

                         REPRESENTATIONS AND WARRANTIES

         21.1 Takeda's Representations and Warranties. Takeda represents and
warrants to BioNumerik as follows as of the date of execution of this Agreement:

                  (a) Corporate Organization. (i) It is a duly organized and
validly existing corporation under the laws of Japan; (ii) it has full corporate
power and authority to enter into and perform this Agreement; and (iii) it has
taken, or will take prior to the Effective Date, all action necessary or
required for the lawful execution, delivery, and performance of this Agreement.
This Agreement is a legal, valid, and binding obligation, enforceable in
accordance with the terms and conditions hereof.

                  (b) Non-contravention. The execution and delivery of this
Agreement, the performance of this Agreement, the purchase of the Preferred
Stock and Common Shares by Takeda under this Agreement, and the consummation of
the purchase of the Preferred Stock and Common Shares according to this
Agreement do not violate, conflict with, or constitute a default under (i) any
material bond, debenture, note or other evidence of indebtedness, any material
lease, contract, indenture, mortgage, deed of trust, loan agreement, or joint
venture, or any other agreement or instrument to which Takeda is a party or by
which it or its property is bound, where such conflict, violation or default is
likely to result in a Material Adverse Effect to Takeda, (ii) its charter or
similar documents, its by-laws, or other organizational documents of Takeda, or
(iii) any law, administrative regulation, ordinance or order of any court or
governmental agency,

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                       77
<PAGE>

arbitration panel or authority binding upon Takeda or its property, where such
conflict, violation or default is likely to result in a Material Adverse Effect
to Takeda.

                  (c) Governmental Consent. No consent from any governmental
entity is required for the execution and delivery of this Agreement or the
consummation by Takeda of the equity investment, except for the consent, if any,
relating to the HSR Act and any securities filings required to be made under
federal, state or foreign securities laws, which filings, if any, will be made
and approved prior to the Effective Date.

                  (d) Court Order. It is not subject to any order, decree or
injunction by a court of competent jurisdiction which prevents or delays the
consummation of the transactions contemplated by this Agreement.

                  (e) Encumbrances. It has no outstanding encumbrances or
agreements, either written, oral or implied which will prevent the grant of
rights by Takeda herein.

                  (f) Conflicting Agreements. Neither Takeda nor any of its
Affiliates is a party to, or are otherwise bound by, any oral or written
contract that will result in any person or entity obtaining any interest in, or
that would give to any third party any right to assert any claim in or with
respect to, any of BioNumerik's or Takeda's rights under this Agreement nor will
it undertake any such obligation during the term of this Agreement.

                  (g) No Debarment. Takeda has never, to its knowledge, employed
and will not, to its knowledge, employ, or use, a person or entity debarred
under Section 306(a) or (b) of the Federal Food, Drug, and Cosmetic Act.
Further, Takeda, to its knowledge, has not employed and, to its knowledge, has
not used a contractor or consultant that has employed, any individual or entity
debarred by the FDA, or, to the knowledge of Takeda, any individual who or
entity which is the subject of an FDA debarment investigation or proceeding.

                  (h) Standstill Agreement. Takeda agrees that, until the
earlier of three (3) years after launch of the Product in the Territory or five
(5) years after the date of execution of this Agreement, unless otherwise
approved by BioNumerik, neither Takeda nor any of its "Affiliates" (as such term
is defined under the Securities Exchange Act) or representatives will (1)
directly participate in or assist any third party to affect or participate in
any tender or

                                       78
<PAGE>

exchange offer, merger or other business combination involving BioNumerik or any
of its subsidiaries, or (2) acquire BioNumerik's securities through purchases on
the open market that, when added to all other BioNumerik securities owned by
Takeda and its Affiliates would exceed 9.99% of BioNumerik's outstanding capital
stock. This Section 21.1(h) will survive termination of this Agreement unless
this Agreement is terminated by Takeda pursuant to Section 15.4(a) or Section
15.4(b).

         21.2 BioNumerik's Representations and Warranties. BioNumerik represents
and warrants to Takeda as follows as of the date of execution of this Agreement:

                  (a) Corporate Organization. (i) It is a duly organized and
validly existing corporation under the laws of the State of Texas; (ii) it has
full corporate power and authority to enter into and perform this Agreement; and
(iii) it has taken, or will take prior to the Effective Date, all action
necessary or required for the lawful execution, delivery, and performance of
this Agreement. Upon the Effective Date, this Agreement will be a legal, valid,
and binding obligation, enforceable in accordance with the terms and conditions
hereof.

                  (b) Non-contravention. The execution and delivery of this
Agreement, the performance of this Agreement, the transfer of the Preferred
Stock and Common Shares by BioNumerik under this Agreement, and the consummation
of the purchase of the Preferred Stock and Common Shares according to this
Agreement do not violate, conflict with, or constitute a default under (i) any
material bond, debenture, note or other evidence of indebtedness, any material
lease, contract, indenture, mortgage, deed of trust, loan agreement, or joint
venture, or any other agreement or instrument to which BioNumerik is a party or
by which it or its property is bound, where such conflict, violation or default
is likely to result in a Material Adverse Effect to BioNumerik, (ii) its charter
or similar documents, its by-laws, or other organizational documents of
BioNumerik, or (iii) any law, administrative regulation, ordinance or order of
any court or governmental agency, arbitration panel or authority binding upon
BioNumerik or its property, where such conflict, violation or default is likely
to result in a Material Adverse Effect to BioNumerik.

                  (c) Governmental Consent. No consent from any governmental
entity is required for the execution and delivery of this Agreement or the
consummation by BioNumerik

                                       79
<PAGE>

of the equity investment, except for the consent, if any, relating to the HSR
Act and any securities filings required to be made under federal, state or
foreign securities laws, which filings, if any, will be made and approved prior
to the Effective Date.

                  (d) Court Order. BioNumerik is not subject to any order,
decree or injunction by a court of competent jurisdiction which prevents or
delays the consummation of the transactions contemplated by this Agreement.

                  (e) Encumbrances. Except for such shareholder approvals or
waivers as will be obtained prior to the Effective Date, BioNumerik has no
outstanding encumbrances or agreements, either written, oral or implied which
will prevent the grant of rights by BioNumerik herein.

                  (f) Conflicting Agreements. Neither BioNumerik nor any of its
Affiliates is a party to, or are otherwise bound by, any oral or written
contract that will result in any person or entity obtaining any interest in, or
that would give to any third party any right to assert any claim in or with
respect to, any of BioNumerik's or Takeda's rights under this Agreement nor will
BioNumerik undertake any such obligation during the term of this Agreement.

                  (g) Ownership, Validity, and Enforceability. BioNumerik is the
sole, legal, and true owner or exclusive licensee of the Licensed Patents, the
Licensed Trademarks, and its rights in the Licensed Information and it has full
right and authority to grant Takeda and its licensees the licenses and rights
under this Agreement. No third party has any right, title or interest in the
Territory with respect to the Licensed Patents and Licensed Trademarks and
BioNumerik's rights in the Licensed Information. BioNumerik further represents
and warrants that Exhibit E accurately and completely identifies all patents and
patent applications that as of the date of execution of this Agreement are
within the Licensed Patents and BioNumerik's Licensees' Patents and Information
in the Territory. To its knowledge, as of the date of execution of this
Agreement, BioNumerik represents and warrants that there are no disputes or
controversies regarding ownership, validity, or enforceability of the Licensed
Patents, related patent applications, or Licensed Trademarks.

                                       80
<PAGE>

                  (h) BioNumerik's Licensees' Patents and Information.
BioNumerik has the full right and authority to grant Takeda and its licensees
the right to use all clinical, non-clinical, and other data in the Territory as
provided in this Agreement, which BioNumerik's licensees, including Baxter and
Grelan, have and will have, including BioNumerik's Licensees' Patents and
Information.

                  (i) Infringement. To BioNumerik's knowledge, by researching,
developing, making, using, selling, offering to sell, and/or importing the
Product into the Territory, Takeda and its Affiliates and sublicensees and
BioNumerik will not infringe any patents, known patent applications, or
trademarks of any third parties, and there is no pending or threatened
litigation relating to such infringement.

                  (j) Transferred Rights. BioNumerik has not previously
assigned, transferred, conveyed or otherwise encumbered its right, title and
interest in the Licensed Patents as related to the Product in the Territory, in
the Licensed Trademarks or in the Licensed Information, except that:

                           (i)      BioNumerik has granted Baxter an exclusive
                                    license in order to pursue the clinical
                                    development and registration of the Product
                                    in territories outside the United States,
                                    Canada and Japan, where Baxter has exclusive
                                    marketing and sales rights to the Product in
                                    those territories in accordance with the
                                    alliance agreement between BioNumerik and
                                    Baxter; and BioNumerik previously granted to
                                    Baxter a Canada Right of First Offer that
                                    has previously expired; and

                           (ii)     As part of the KI Pharma Joint Venture
                                    Agreement, BioNumerik has granted Grelan and
                                    the KI Pharma Joint Venture an exclusive
                                    license in order to pursue the clinical
                                    development and registration of the Product
                                    in Japan, where Grelan and the KI Pharma
                                    Joint Venture have exclusive marketing and
                                    sales rights to the Product in Japan in
                                    accordance with the KI Pharma Joint Venture
                                    Agreement.

                                       81
<PAGE>

                  (k) Claim Assignment. BioNumerik has not made any assignments,
nor will it make any assignments, of any claim, right of action or any right of
any kind whatsoever, embodied in or arising out of the Licensed Patents or
Licensed Trademarks as related to the Product in the Territory.

                  (l) Lawsuits. No one has filed a lawsuit against BioNumerik,
including a declaratory judgment lawsuit, nor threatened to file a lawsuit
against BioNumerik, including sending a cease and desist letter, relating to the
Product, the Licensed Patents, the Licensed Trademarks or the Licensed
Information in the Territory.

                  (m) Full Disclosure. As of the date of execution of this
Agreement, BioNumerik has provided Takeda and/or Takeda's legal, accounting,
financial, or other advisors with the opportunity to review all Material Data in
BioNumerik's possession, and has not concealed from Takeda any Material Data.
Notwithstanding the foregoing, BioNumerik has provided Takeda and/or Takeda's
advisors with the opportunity to review all human subject safety data
(Life-threatening adverse drug experience, Serious adverse drug experience,
Unexpected adverse drug experience, Adverse Event, Serious Adverse Event,
Adverse Drug Reaction, Expectedness of Adverse Drug Reaction, as defined in 21
CFR 312 and/or ICH Guideline E2A) regarding the Product and all non-clinical
safety data that is in its possession as of the date of execution of this
Agreement regarding the Product.

                  (n) Regulations. BioNumerik is not aware of any safety,
efficacy, or regulatory issues, other than the information that has previously
been made available to Takeda, that would preclude Takeda or BioNumerik, their
licensees and contract service organizations, from researching, developing,
manufacturing, marketing, using, selling, offering for sale, and importing the
Product in the Territory in compliance with the laws and regulations of the
Territory.

                  (o) Research, Development, and Manufacturing. BioNumerik, its
contractors, and its consultants have conducted, and will continue to conduct,
all research and development, including non-clinical studies and clinical
studies of the Product, and all manufacturing of the Product or components
thereof in accordance with (i) all material provisions of applicable laws,
regulations, guidelines, or standards of the Territory, and other countries in
which such activities

                                       82
<PAGE>

are conducted, (ii) the known or published standards of the applicable
Regulatory Agency in the Territory and such other countries, and (iii) the
scientific standards applicable to the conduct of such studies and activities in
the Territory and such other countries. BioNumerik believes it has conducted
appropriate audits of its contract-manufacturers and appropriate diligence
regarding Baxter, Grelan and their contract research organizations (CROs)
relating to compliance with applicable laws and regulations, and has found no
circumstances that BioNumerik believes would be likely to have a Material
Adverse Effect on the development and marketing of the Product in the Territory
as contemplated by this Agreement. Neither BioNumerik, nor, to BioNumerik's
knowledge, any officer, employee or agent of BioNumerik, has made an untrue
statement of a material fact to any Regulatory Agency with respect to the
Product (whether in any submission to such Regulatory Agency or otherwise), or
knowingly failed to disclose a material fact required to be disclosed to any
Regulatory Agency with respect to the Product.

                  (p) No Debarment. BioNumerik has never, to its knowledge,
employed and will not, to its knowledge, employ, or use, a person or entity
debarred under Section 306(a) or (b) of the Federal Food, Drug, and Cosmetic
Act. Further, BioNumerik, to its knowledge, has not employed and, to its
knowledge, has not used a contractor or consultant that has employed, any
individual or entity debarred by the FDA, or, to the knowledge of BioNumerik,
any individual who or entity which is the subject of an FDA debarment
investigation or proceeding.

                  (q) Each member of BioNumerik's Board of Directors will
recommend approval of and support approval of and each of BioNumerik's
shareholders owning five percent (5%) or more of the capital stock of BioNumerik
will vote for all aspects of this Agreement with Takeda that require such
shareholder approval, including the issuance of Preferred Stock and Common
Shares as described in this Agreement. BioNumerik agrees that following
execution of this Agreement until thirty (30) days following execution of this
Agreement, BioNumerik will not seek to enter into another alliance transaction
directly concerning the Product in the Territory and also BioNumerik will not,
during such thirty (30) day period referred to in this sentence, participate in
any discussions with a third party concerning any tender or exchange offer,
merger, acquisition or other business combination involving BioNumerik or any of
its subsidiaries. If BioNumerik breaches this warranty by BioNumerik seeking to
enter into another alliance transaction directly concerning the Product in the
Territory or by BioNumerik participating in

                                       83
<PAGE>

any discussions with a third party concerning any tender or exchange offer,
merger, acquisition or other business combination involving BioNumerik or any of
its subsidiaries, then Takeda has the right to terminate this Agreement.

         21.3 Disclaimer of Consequential and Punitive Damages. UNDER NO
CIRCUMSTANCES WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR CONSEQUENTIAL
OR PUNITIVE DAMAGES ARISING FROM THE USE OF OR INABILITY TO USE THE PRODUCT OR
FROM ANY OTHER PROVISION OF THIS AGREEMENT, SUCH AS, BUT NOT LIMITED TO, LOST
PROFITS, LOST BUSINESS OR OPPORTUNITIES, BUSINESS INTERRUPTION, OR LOSS OF
BUSINESS REPUTATION. THESE DAMAGES ARE HEREBY DISCLAIMED BY BOTH PARTIES.

         21.4 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT AND ITS
EXHIBITS AND ATTACHMENTS, NEITHER PARTY MAKES OR HAS MADE ANY OTHER
REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED.

                                  ARTICLE XXII

                                 HSR ACT REPORTS

         22.1 Within thirty (30) days of the date of execution of this
Agreement, if deemed legally necessary by Takeda in consultation with BioNumerik
but at Takeda's sole discretion, Takeda will file with the Federal Trade
Commission ("FTC") and the Antitrust Division of the United Stated Department of
Justice ("Antitrust Division") the notification and report form (the "Report")
required under the HSR Act, with respect to the transactions contemplated herein
and BioNumerik will reasonably cooperate with Takeda to the extent necessary to
assist Takeda in the preparation of its Report and to proceed to obtain
necessary approvals under the HSR Act, including, but not limited to, the
expiration or earlier termination of any and all applicable waiting periods
required by the HSR Act. Takeda will, within ten (10) days of the date of
execution of this Agreement, determine whether filing of the Report is legally
necessary. In addition, Takeda will make the determination regarding the filing
of the Report as soon as reasonably possible after the execution date of this
Agreement and, if Takeda determines that such filing is legally required, Takeda
will endeavor to file such Report as soon as reasonably possible after the
execution date of this Agreement. If Takeda determines that such filing is not

                                       84
<PAGE>

legally necessary, it will so notify BioNumerik within the above-referenced
thirty (30) day period and the Effective Date will occur upon such notification,
subject to obtaining the BioNumerik shareholder approvals described in the
definition of the Effective Date. Unless Takeda determines that a filing is not
legally necessary, Takeda and BioNumerik will equally split any fees required to
be paid to any governmental agency in connection with making such filings. Each
Party will bear its own expenses, including, without limitation, legal fees and
attorneys' fees, incurred in connection with preparing such filings.

         BioNumerik and Takeda will use respectively their good faith efforts to
eliminate any concern on the part of any court or government authority regarding
the legality of the proposed transaction, including, if required by federal or
state antitrust authorities, promptly taking all steps to secure government
antitrust clearance, including, without limitation, cooperating in good faith
with any government investigation including the prompt production of documents
and information required by a second request for documents and of witnesses if
requested.

         BioNumerik and Takeda will cooperate and use respectively all
reasonable efforts to make all other registrations, filings and applications, to
give all notices and to obtain as soon as practicable all governmental or other
consents, transfers, approvals, orders, qualification authorizations, permits
and waivers, if any, and to do all other things necessary or desirable for the
consummation of the transactions as contemplated hereby. Neither Party will be
required, however, to divest products or assets or to change its business if
doing so is a condition of obtaining approval under the HSR Act or other
governmental approvals of the transactions contemplated by this Agreement. In
addition, neither Party will be required to agree to any limit on the
contemplated agreement.

         In the event that (i) within thirty (30) days of the date of execution
of this Agreement, Takeda fails to file a notification under the HSR Act or (ii)
notification of this Agreement is filed under the HSR Act and the expiration or
earlier termination of any notice and waiting period under the HSR Act has not
occurred within ninety (90) days, then either Party will have the right (but
will not be obligated) to terminate this Agreement by providing the other Party
with written notice to such effect. Upon receipt of such written notice, this
Agreement will be null, void and of no effect and neither Party will have any
further rights or obligations hereunder.

                                       85
<PAGE>

         22.2 Before Takeda acquires a holding of US$50,000,000 or more in
Common Shares (or other voting securities) of BioNumerik, Takeda and BioNumerik
will file with the FTC and the Antitrust Division the Notification Report
required under the HSR Act with respect to the stock acquisitions contemplated
by the Parties. Takeda will also receive HSR approval prior to making any
acquisition that would result in Takeda holding US$50,000,000 or more Common
Shares (or other voting securities) in BioNumerik. All acquisitions of Common
Shares in BioNumerik by Takeda are subject to, and contingent upon, HSR approval
at the time of acquisition, if such approval is required under the HSR Act.
Takeda and BioNumerik agree to cooperate as necessary to prepare and file their
respective HSR Notification Forms and otherwise obtain any required HSR
approvals. Takeda will bear all expenses and fees related to any required HSR
approvals pursuant to this section.

                                  ARTICLE XXIII

                                  MISCELLANEOUS

         23.1 Addresses. All notices, reports, and audit requests with respect
to this Agreement will be made in writing and will be given by certified mail,
return receipt requested, by recognized international courier service, or by
personal delivery, properly addressed to the Party for whom it is intended as
follows:

         If to Takeda:

                  [**]

with a  copy to:

                  [**]

If to BioNumerik:

                  [**]

                                       86

[**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>
         All notices are deemed effective on the date of receipt or, if delivery
is not accepted, five (5) days after placement with a post office for delivery
by certified mail, return receipt requested as described above and five (5) days
after placement with a recognized international courier service for delivery as
described above.

         23.2 Compliance. Each of BioNumerik and Takeda will conduct its
respective obligations and activities under this Agreement, including, but not
limited to, research, development, manufacture, distribution, sale and promotion
of the Product, in compliance with material provisions of all applicable laws,
regulations, guidelines, or standards of the Territory, and other countries in
which such obligations or activities are conducted.

         23.3 Execution. This Agreement will be executed in two (2)
counterparts, each of which will be deemed as original.

         23.4 Choice of Law. This Agreement and the performance of the Parties
hereunder will be construed in accordance with and governed by the laws of the
State of New York, United States of America, without reference to choice of law.

         23.5 Severability. In the event that any term, provision, or covenant
of this Agreement is determined by a court of competent jurisdiction to be
invalid, illegal or unenforceable, that term will be curtailed, limited or
deleted, but only to the extent necessary to remove such invalidity, illegality
or unenforceability, and the remaining terms, provisions and covenants will not
in any way be affected or impaired thereby.

         23.6 Waiver. No waiver by either Party of any breach of this Agreement,
no matter how long continuing or how often repeated, will be deemed a waiver of
any subsequent breach thereof, nor will any delay or omission on the part of
either Party to exercise any right, power, or privilege hereunder be deemed a
waiver of such right, power or privilege, except as stated herein.

         23.7 No Agency Relationship. The relationship between the Parties is
that of independent contractor and contractee. Neither Party will be deemed to
be an agent of the other

                                       87
<PAGE>

in connection with the exercise of any rights hereunder, and neither will have
any right or authority to assume or create any obligation or responsibility on
behalf of the other.

         23.8 Article Headings. The Article and Section headings herein are for
purposes of convenient reference only and will not be used to construe or modify
the terms written in the text of this Agreement.

         23.9 Force Majeure. Neither Party hereto will be deemed to be in
default of any provision of this Agreement, or for any failure in performance,
resulting from acts or events beyond the reasonable control of such Party, such
as Acts of God, acts of civil or military authority, civil disturbance, war,
strikes, fires, power failures, natural catastrophes or other "force majeure"
events.

         23.10 No Solicitation. Neither BioNumerik nor Takeda will directly
solicit any current or future employees of the other Party during the term of
this Agreement to leave the other Party's employment for any reason.

         23.11 Final Agreement. This Agreement and its Exhibits and attachments
contain the entire agreement and understanding of the Parties with respect to
the matters contained herein, superceding all prior understandings, whether
written or oral, concerning the subject matter hereof. The Parties may, from
time to time during the continuance of this Agreement, modify, vary or alter any
of the provisions of this Agreement, but only by a written instrument duly
executed by authorized officials of both Parties hereto.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       88
<PAGE>

         IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed and delivered by their duly authorized representatives as of the date
first written above. The undersigned represent that they are authorized to sign
this Agreement on behalf of the Parties hereto.

Takeda Pharmaceutical Company Limited    BioNumerik Pharmaceuticals, Inc.

By: /s/ Saburo Hamanaka                  By: /s/ Frederick H. Hausheer
    ---------------------------------        --------------------------------

Printed Name: Saburo Hamanaka            Printed Name: Frederick H. Hausheer,
                                                       M.D.

Title: Corporate Officer                 Title: Chairman, CEO & President

  General Manager, Division of Americas

Date: October 4, 2004                    Date: October 5, 2004

                                       89

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]